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Cardiopulmonary impairments are the leading cause of morbidity and mortality in 
advanced stages of Parkinson’s. Although there is some evidence of pulmonary 
impairments in the earlier stages, symptoms remain asymptomatic until advanced 
stages. Aerobic exercise and lung function in people living with Parkinson’s (PLwP) 
has not yet been investigated. This thesis aims to:  
• Review prevalence of pulmonary function, cardiovascular response to 
exercise, and effects of aerobic exercise on cardiopulmonary function, in 
PLwP.  
• Pilot and investigate feasibility of a trial of aerobic exercise to improve 
cardiopulmonary function in PLwP.  
• Survey the effects of COVID-19 pandemic on physical activity in PLwP.  
Methods  
• Reviews of published literature with systematic search, quality assessment 
and narrative synthesis of findings   
• Mixed-methods, single-blind feasibility study exploring: recruitment, attrition, 
intervention, outcome measures, inclusion and exclusion criteria. Pulmonary 
function, cardiac fitness, and physical activity were assessed at baseline, 8-
weeks and 12-weeks. Participants’ experiences and acceptability of 
intervention and outcome measures were explored in focus groups.  
• Online questionnaire to explore effects of COVID-19 pandemic on physical 
activities in PLwP.  
Results  
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• PLwP suffer from obstructive and/or restrictive pulmonary disease; cardiac 
fitness in PLwP is variable; aerobic exercise improves cardiac fitness but no 
studies have assessed effects of aerobic exercise on pulmonary function in 
Parkinson’s.  
• Twenty-four PLwP were recruited and 15 completed the EXoCARP trial, with 
low attrition (n=7), five due to the COVID-19 pandemic. Feasibility and 
acceptability of outcomes and intervention was confirmed. 
• Outdoor and gym-based physical activity decreased in PLwP during the 
COVID-19 pandemic; many PLwP accessed online resources to exercise at 
home.  
Conclusions 
People with early stages of Parkinson’s should be screened for asymptomatic 
pulmonary impairments that could be managed, to prevent late-stage complications. 
Feasibility of a larger trial of aerobic exercise and cardiopulmonary function in 
Parkinson’s was confirmed. Considering remote/online or home-based exercises is 
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Chapter 1: Introduction and Background 
1.1. Overview 
This introductory chapter will describe the general aspects of Parkinson’s. The 
pathophysiology of Parkinson’s will be explained, followed by a description of the 
major clinical features and the stages of Parkinson’s, and then an overview of 
human pulmonary function and cardiovascular response to exercise. This will lead 
to an explanation of the aims of the thesis at the end of the chapter. 
 
1.2. Parkinson’s: epidemiology and general overview 
Parkinson's is the most common age-related motor, neurodegenerative disorder, 
with unknown specific cause (Jankovic, 2008). Its incidence is 160 persons per 
100,000 people in the UK per annum, with an incidence of 15 to 20 per 100,000 
annually (National Institute for Health and Care Excellence, 2018). The prevalence 
of Parkinson’s is 1.5% of people over 60 years old and increases with age up to 
4.3% in people above 85 years old, and is expected to increase considerably within 
the next decades, leading to increases in health demands and, subsequently, costs 
(de Rijk et al., 1995).  
 
1.3. Aetiology and pathophysiology  
Parkinson’s results from unknown (idiopathic) causes that lead to loss of neurons 
from the substantia nigra of the brain basal ganglia, which is responsible for 
producing dopamine, a neurotransmitter essential for controlling body movement 
and balance (Sethi, 2002). These neurons project to the striatum and their loss 
leads to a decrease in the activity of neural circuits within the basal ganglia and an 
increase in inhibitory signals leading to decrease in movement.  
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The main cause of mortality and morbidity in the advanced stages of Parkinson’s is 
respiratory impairment including type 1 respiratory failure, type 2 respiratory failure, 
or both types together (Torsney, 2017). Hart (2008) categorises respiratory failure 
into either lung failure leading to type 1 respiratory failure (PaO2 ≤ 8KPa), or pump 
failure leading to type 2 respiratory failure (PaO2 ≤ 8KPa concurrent with a PaCO2 
of ≥ 6PKa).  
 
Type 1 respiratory failure: Impaired diffusion might occur due to pulmonary oedema 
(West 2008), low partial pressure of inspired oxygen, or a pulmonary disease such 
as emphysema (Hari and Mackenzie 2007). Low partial pressure of inspired oxygen 
occurs in high altitudes, and alveolar hypoventilation occurs in atelectasis or 
pneumonia. PLwP may also suffer from aspiration pneumonia due to the swallowing 
problems they may have (Lanspa et al. 2013). When aspiration pneumonia is 
accompanied by weak cough, type 1 respiratory failure might occur (Ebihara et al. 
2003). Additionally, PLwP generally have low levels of physical activity, which might 
lead to decreased lung volumes and, over time, development of atelectasis and 
subsequently type 1 respiratory failure (Torsney, 2017). If atelectasis happened 
frequently, this could increase the load on respiratory muscles and lead to type 2 
respiratory failure over time (Torsney, 2017).  
 
Type 2 respiratory failure results from an impairment in one or more of the following: 
central respiratory drive; load placed on the respiratory muscles; and the capacity of 
the respiratory muscles (Jones et al., 2016). It was reported previously that PLwP 
have an abnormal ventilatory response to hypercapnia, suggesting that their 
respiratory control is compromised (Seccombe et al., 2011).  
 
PLwP have a kyphoscoliotic posture that, together with a swallowing impairment, 
might decrease the strength of the respiratory muscles (Torsney, 2017). The 
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decrease in the respiratory muscle strength together with the impairment in 
coordination of movements will affect the mechanics of ventilation (Torsney, 2017), 
specifically the “Bucket Handle Movement” (movement that happens due to the 
vertical arrangement of the lumbar and costal segments of the diaphragm) 
(Gatzoulis, 2008). Furthermore, rigidity of the chest wall muscles in PLwP might 
lead to ankylosis of the costosternal and thoracovertebral joints, and subsequently 
affect the mechanics of ventilation (Shill and Stacy, 2002). Moreover, 
kyphoscoliosis, together with chest wall muscle rigidity, might lead to decrease in 
the physical size of the thorax, and subsequently a decrease in lung volumes 
(O'Callaghan, 2018). All these factors might lead to the development of type 2 
respiratory failure in PLwP. Figure 1 represents a summary of the main factors that 
might lead to type 1 and type 2 respiratory failure in PLwP. 
 
Hypercapnic ventilatory response is mediated by the retrotrapezoid nucleus, located 
in the ventral medullary surface, and is expressed as the change in minute 
ventilation (the volume of gas inhaled or exhaled from a person's lungs per minute) 
per change in CO2 at the end of exhalation (Goldberg et al., 2017). The central 
respiratory drive including the medullary surface might be affected in PLwP. 
Seccombe et al. (2011) reported that PLwP are unable to maintain an adequate 
seal to complete the hypercapnic ventilatory response (reported as abnormal in 
47% of their sample) due to medullary impairment. In a healthy population, 
respiratory drive is influenced by hypercapnia, but in PLwP reduced response to 
carbon dioxide was reported (Seccombe et al, 2011), due to medullary surface 
impairment. Findings of Seccombe and colleagues demonstrate impairments of the 
respiratory drive in response to hypercapnia. The impairment of the respiratory drive 
may also be explained by the Braak hypothesis, which suggests that Parkinson’s 
pathology is related to an unknown pathogen (virus or bacterium) that enters the 
body through the nasal cavity, and subsequently is swallowed and reaches the gut, 
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initiating Lewy pathology, and might spread via the olfactory tract and the vagal 
nerve, toward and within the central nervous system (CNS) (Braak et al., 2011). The 
Braak hypothesis suggests early brainstem involvement in PLwP with selective 
degeneration of the neurons in the pons and medulla oblongata in the brainstem, 
and subsequently, respiratory impairment (Braak et al., 2011). However, the Braak 
hypothesis is limited because not all PLwP have Lewy pathology (Rietdijk et al., 
2017).  
 
Another factor that might lead to respiratory impairment in PLwP is the diminished 
dopamine level. Dopamine is an important neurotransmitter not only in the brain but 
also in the carotid body. Dopamine plays an important role in the ventilatory 
response to hypoxia, as it has an inhibitory modulatory effect on the carotid body 
(Hovestadt et al., 1989). For example, dopamine infusion inhibits carotid body 
response to hypoxia and dopamine D2 receptor blockage causes an increased 
response of the carotid body to hypoxia (Bisgard et al., 2001). Onodera et al. (2000) 
studied the peripheral chemosensitivity to hypoxemia and hypercapnia in PLwP, 
and reported a blunted response to both oxygen and carbon dioxide changes, 
suggesting an impairment in the function of the carotid chemoreceptors.  
 
In summary, swallowing impairment, weak cough, low level of physical activity, 
respiratory drive impairment, kyphoscoliosis, decreased strength of the respiratory 
muscles, impaired mechanics of ventilation, rigidity of chest wall muscles, and 
diminished dopamine levels, are the main factors related to the respiratory 




Figure 1: Summary for the main factors that affect respiratory function and lead to respiratory failure in people living with Parkinson's.
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1.4. Disease severity  
The Hoehn and Yahr scale is the main screening test for Parkinson’s severity, 
based on motor function only (Hoehn and Yahr, 1967). Figure 2 represents the five 
stages of the Hoehn and Yahr scale, and shows that the scale ranges from no 
signs, stage 0, to wheelchair bound or bedridden, stage 5. PLwP commonly suffer 
from both motor and non-motor symptoms (Jankovic, 2008). In this thesis, the 
classification of PLwP into people at early stages of Parkinson’s (I-III in Hoehn and 
Yahr), and advanced stages (IV-V in Hoehn and Yahr) will be used.  
 
1.5. Clinical features of Parkinson’s: motor symptoms 
Usually, diagnosis of Parkinson’s is made if a patient presents with bradykinesia, 
accompanied by at least one of the following symptoms: muscle rigidity, resting 
tremor or balance impairments that are not caused by primary visual, vestibular, 
cerebellar or proprioceptive dysfunction (Gelb et al., 1999).   
 
Bradykinesia means slowness of movement, and is responsible for the slowness of 
motor activities, shuffling gait, masked face, and absence of arm swing; it is often 
associated with akinesia (lack of movement) and hypokinesia (reduced amplitude of 
movement) (Jankovic, 2008). It is caused by decreased ability or failure of the basal 
ganglia to reinforce the motor cortex, leading to elongation in reaction time and 
slowness of movement (Berardelli et al., 2001).  
 
Rigidity leads the individual to feel stiffness in joints and muscles, and may 
contribute to the discomfort and pain reported in PLwP. Cogwheel rigidity is 
clinically characterized by increased resistance to passive movement in the limbs 
(flexion, extension and rotation), even in low velocity stretching (Quinn, 1997). In 
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most cases, cogwheel rigidity is present, even in early stages of Parkinson’s. PLwP 
may complain of pain as result of rigidity, specifically in the shoulders, trunk and 
neck, also called axial rigidity, and leading to postural abnormalities; those 
abnormalities include flexed neck, trunk, elbows and knees (Jankovic, 2008). Chest 
wall rigidity is the main cause for the weak respiratory muscles in PLwP (Torsney, 
2017). 
 
Resting tremor is the most common and recognized clinical feature in Parkinson’s, 
at around 4-6 Hz (Jankovic, 2008). As its name implies, resting tremor disappears 
or decreases during movement. Also, resting tremor was found to disappear when 
sleeping and usually occurs in the distal part of the limb (hands and/or ankles) 
(Jankovic, 2008). Tremor in the hand usually occurs as a rapid alternation between 
supination and pronation and is described as “pill-rolling” (Jankovic, 2008). 
Additionally, resting tremor may occur in the lips, chin, jaw and legs (Jankovic, 
2008).  
 
The generic terms of balance and postural stability describe the dynamics of body 
posture required to prevent a fall (Winter, 1995). Balance requires maintenance of 
the body’s centre of mass within the limits of the base of support during sitting or 
standing or controlling the body while moving to a new base of support while 
walking or running (Jankovic, 2008). Balance and postural instability usually occur 
in the late stages of Parkinson’s, after the other main clinical features have 
appeared (Jankovic, 2008).  
 
Freezing is a sudden and transient inability to move that usually lasts for less than 
10 seconds (Jankovic, 2008). Freezing does not occur in all PLwP, reportedly 




Figure 2: Stages of Hoehn and Yahr Scale
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1.6. Clinical features of Parkinson’s: non-motor symptoms 
Non-motor symptoms appear throughout the course of Parkinson’s, comprising a 
variety of symptoms, including respiratory deficits, neuropsychiatric symptoms, 
sleep disorders and cognitive impairments (Park and Stacy, 2009).  
 
A review of pulmonary function highlighted the presence of abnormal pulmonary 
function associated with Parkinson’s (O’Callaghan & Walker, 2018). These include: 
resting dyspnoea(shortness of breath), exertional dyspnoea, and daytime 
somnolence due to nocturnal hypoxia (Brown, 1994). The majority, however, remain 
asymptomatic due to the motor manifestations limiting their exercise tolerance 
(Brown, 1994). This might be due to the low levels of physical activity caused by 
motor symptoms, during which respiratory function is unchallenged and, 
consequently, respiratory complaints are not manifest (Polatli et al., 2001). 
 
Dyspnoea is defined as an “unpleasant or uncomfortable awareness of breathing ” 
(American Thoracic Society, 1999). Dyspnoea is a symptom that is usually 
attributed to impairment in the respiratory system, due to damage or stimulation of 
peripheral structures (lung parenchyma, upper airways, chest wall, respiratory 
muscles and vasculature) and central structures (brainstem ventilatory centres 
response to chemoreceptors in the carotid and aortic bodies) (Vijayan et al., 2020). 
The mechanisms that may lead to dyspnoea in PLwP is not yet fully known (Vijayan 
et al., 2020). However, given the widespread pathology of Parkinson’s, a 
combination of effects of the disease on the respiratory system as a whole, sensory 
and perceptual changes, psychological factors, effects of the medications and/or 
other comorbidities, could contribute to the development of dyspnoea (Vijayan et al., 
2020). As described earlier in this chapter, and according to the Braak hypothesis, 
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neurodegenerative processes in Parkinson’s target the medulla in the brainstem  
which might affect the respiratory centres leading to the development of dyspnoea 
(Braak et al., 2011). Additionally, biomechanical factors (specifically diaphragmatic 
impairment, kyphoscoliosis and chest rigidity) might contribute to inability to expand 
the lungs in inhalation leading to the stimulation of the stretch receptors of the lungs 
and to the perception of dyspnoea. The decreased levels of dopamine affect the 
carotid bodies and subsequently contribute to the perception of dyspnoea in 
Parkinson’s (Braak et al., 2011). 
 
Neuropsychiatric symptoms include: depression; anxiety; fatigue; and psychosis, 
which includes visual hallucinations followed by auditory hallucinations (Park and 
Stacy, 2009). Psychosis is mainly caused by both disease progression and 
levodopa therapy (Poewe, 2003). Around 40% of PLwP are reported to experience 
depression (Cummings, 1992) and anxiety (Richard et al., 1996). Depression 
symptoms include lack of energy, sleep disorders, and poor concentration, as well 
as sadness, suicidal ideation and pessimism depression (Cummings, 1992), 
whereas anxiety symptoms include generalised anxiety, panic, social phobia, 
breathlessness, sweating, chest discomfort and restlessness (Richard et al., 1996). 
Respiratory impairments in PLwP are often mistakenly diagnosed as anxiety or 
depression (Torsney, 2017).   
 
Sleep  disorders affect 60% to 98% of PLwP, and include excessive daytime 
sleepiness, sleep attacks, early morning awakenings, and rapid eye movement 
sleep behaviour disorder (Stacy, 2002). Excessive daytime sleepiness was found to 
be three times more common in PLwP than in the healthy older population, and 
sleep attacks or sudden sleepiness, either with or without warning, are experienced 
by around 7% of PLwP (Abbott et al., 2005). Sleep apnoea and sleep disordered 
breathing, predominantly obstructive was reported in a study of 15 PLwP (Maria, 
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2003). However, it is not known if respiratory impairment is the main cause of 
sleeping impairment in Parkinson’s.  
 
Cognition impairments are common in PLwP, with a reported 30% diagnosed with 
dementia; that is, six times higher than the age-matched general population 
(Aarsland et al., 2001). In a multicentre study, 84% of PLwP showed a decline in 
cognitive function, and 48% met the diagnostic criteria for dementia (Hely et al., 
2005). Cognitive impairment affects quality of life of PLwP and increases the health-
economic requirements by increasing the need for nursing home care (Schrag et 
al., 2000b). Cognitive function is classified into four main domains: executive 
function, visuospatial impairment, attention, and memory. Executive function is a 
higher order function including planning, decision making, initiation, organizing, 
problem solving and evaluation (Lezak, 2004). It has been suggested that the 
decrease in dopamine level in Parkinson’s leads to the disruption of communication 
between the basal ganglia and the frontostriatal circuits which, in turn, affect the 
frontal lobes and lead to deficits in higher level functioning (Lezak, 2004). Although 
PLwP have cognitive impairment because of the pathophysiology of Parkinson’s 
disease itself, respiratory impairment (if found) might contribute to further 
impairment in cognitive function. This is evidenced in people with chronic 
obstructive respiratory disease (COPD) (Andrianopoulos, 2017) and acute 
respiratory distress syndrome (ARDS) (Sasannejad, 2019), but not yet investigated 
in PLwP. 
 
Visuospatial impairment is the ability to receive, interpret, and apply meaning to 
shapes, angles and images and to be able to make sense of orientation of an object 
or image in space (Lezak, 2004). Visuospatial impairment has been reported in 
PLwP (Levin et al., 1991; Montse et al., 2001; Uc et al., 2005) and is associated 
with frontal-executive dysfunction in addition to deficit in temporal and parietal 
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cortices (Pereira et al., 2009). Attention is the ability to focus on an object or 
stimulus, to maintain concentration for an extended period of time and to resist 
distraction (Lezak, 2004). Attentional impairment in Parkinson’s is associated with 
executive function impairment, increased risk of falls and gait problems (Allcock et 
al., 2009). Both visuospatial impairment and attention loss were found to be 
associated with physical activity level in PLwP (Maeshima, 1997). A decrease in 
physical activity level might lead over time to a reduction in lung volumes, and 
subsequently, development of atelectasis (Torsney, 2017).   
 
Memory function is defined as assimilating, storing and retrieving information when 
needed (Lezak, 2004). PLwP have been found to have impairments in recalling past 
experience, people, events, objects and recognition of recently stimuli (Breen, 1993; 
Edelstyn et al., 2007; Edelstyn et al., 2010; Flowers et al., 1984; Higginson et al., 
2005). Figure 3 represents the main motor and non-motor impairment in PLwP. 
Memory loss was found to be affected in people who have sleep disordered 
breathing and sleep apnoea (Lau, 2015), but was not assessed in PLwP. 
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Figure 3: Main motor and non-motor impairment in people with Parkinson’s. 
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1.7. Memory  
This section seeks to explain memory classification and the terminology that is used 
in some chapters within the thesis. The simplest classification of memory is long-
term memory (to save information for a long time) and short-term memory (the 
ability to temporarily save information; also called working memory) (Baddeley, 
2007). Long-term memory is often divided into two further main types: declarative 
(or explicit) memory and implicit (or procedural) memory (Baddeley, 2007). 
 
Implicit memory is the unconscious memory of skills and how to do things such as 
riding a bicycle or swimming (Baddeley, 2007). Declarative memory is memory of 
facts and events, and refers to memories that can be consciously recalled 
(Baddeley, 2007). It consists of information that is explicitly stored and retrieved 
(Baddeley, 2007). 
 
Declarative memory can be further sub-divided into episodic memory and semantic 
memory. Semantic memory describes the acts and general knowledge about the 
world (Collins and Quillian, 1969), whereas episodic memory is defined as the 
memory of autobiographical events including times, places, people and emotions as 
a collection of past personal experiences that occurred in a specific time and place 
(Tulving and Donaldson, 1972). Tulving and Donaldson (1972) differentiated 
between “knowing”, which is more factual (semantic), and “remembering”, which is 
a feeling that is located in the past (also called time travelling). Figure 4 summarizes 
memory classification.  
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Another classification of memory is that of retrospective and prospective memory.  
Retrospective memory is remembering people, numbers, words, and events that 
happened or were faced in the past. Retrospective memory includes all other types 
of memory such as implicit or explicit, episodic and semantic memories (Baddeley, 
2007). On the other hand, prospective memory is remembering something or 
remembering to do something after a delay, such as failing to mention or give 
something to a visitor that you were asked to pass on.  
 
1.8. International Classification of Functioning, Disability and 
Health (ICF) model 
The International Classification of Functioning (ICF) framework describes aspects of 
a person’s health and health-related wellbeing at three levels: the individual body 
parts and functions; the individual as a whole (activity); and the individual in a social 
context (participation) (Cad, 2001). Within the ICF framework, each of these three 
levels encompasses different domains. 
 
According to the ICF, body structures can be defined as the anatomical parts of the 
body, whereas body functions are defined as the physiologic functions of body 
systems (Cad, 2001). A problem in body function or structure, such as a significant 
loss, is interpreted as an impairment. For example, the ICF outlines that balance is 
an integrated function of the vestibular, visual, somatosensory as well as the 
musculoskeletal systems. Balance underlies a wide range of mobility activities that 
constitute normal daily life, including walking, and, therefore, impairment in balance 




Figure 4: Classification of human memory
Human memory 
Short term memory Long term memory 
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memory




Activity forms the intermediate level of the ICF model and is a component of 
function that involves execution of a task or action by an individual (Cad, 2001). 
Among the most important and common day-to-day activities are tasks that involve 
mobility components. The World Health Organization (WHO) defines mobility as the 
“individual’s ability to move about effectively in his/her surroundings” (Minaire, 
1992). In a more general and comprehensive sense, mobility can be defined as the 
process of moving oneself and of changing body position or location (Cieza et al., 
2009).  
 
Participation forms the third and the last level of the ICF and can be viewed as the 
involvement in a life situation, and participation restrictions are problems that 
individuals may experience in involvement in life situations (Cad, 2001). 
Participation may be best presented by health-related quality of life measures 
(Power et al., 1999). Quality of life can be defined as the physical, social and 
psychological functioning of an individual as being influenced by a disease or 
therapy (Gotay and Wilson, 1998). It refers to the subject’s appraisals of his or her 
current level of health, functioning, and satisfaction compared to what that person 
perceives to be ideal. In PLwP, the progressive loss of mobility may put them at risk 
of falls and lead to functional dependence, the aspects that may detract from health-
related quality of life (Vojciechowski et al., 2016).  
 
The ICF takes into account both the personal and environmental contexts that may 
impact on the functional performance of an activity. In PLwP, personal factors, 
including cognitive impairments and environmental factors, such as the physical 
environment and level of supervision required, may have an impact on the mobility 
tasks (Vojciechowski et al., 2016). Figure 5 shows how the different domains of the 




Figure 5: An example of the International Classification of Functioning, Disability and Health (ICF) model for people living with Parkinson’s.
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1.9. Pulmonary function in Parkinson’s 
Restrictive and obstructive pulmonary diseases are the main cause of mortality and 
morbidity in end-stages of Parkinson’s (stages IV-V in Hoehn and Yahr) (Ebmeier et 
al., 1990). However, symptoms of pulmonary impairment do not appear in the early 
stages of Parkinson’s (stages I-III in Hoehn and Yahr) due to the low levels of 
physical activity caused by motor symptoms, during which respiratory function is 
unchallenged and subsequently the symptoms do not appear (Polatli et al., 2001). 
Thus, respiratory impairment might act as a silent threat in the early stages of 
Parkinson’s. A systematic review reported that little is known about respiratory 
function in neurodegenerative diseases including Parkinson’s, and recommended 
researchers to investigate pulmonary function throughout disease progression, to 
identify when changes occur and therefore when physiotherapy interventions, for 
both preventative and restorative, should be implemented (Jones et al., 2016). 
Therefore, it is important to know whether PLwP have respiratory impairment in the 
early stages of the disease, and to investigate interventions that might help in 
improving or delaying respiratory impairment in Parkinson’s, so it can be managed 
early, before symptoms appear.  
 
Lung volumes may be altered in PLwP due to many factors. For example, PLwP 
have chest wall rigidity, which could lead to decrease in the ability of the lung to 
stretch and expand in inhalation, leading to decreased lung volumes. Additionally, 
the impairments in biomechanics of ventilation including diaphragmatic impairment 
and bucket handle movement impairment might further affect the ability to expand 
and recoil (Shill and Stacy, 2002). Furthermore, the decreased level of physical 
activity, might lead to decreased lung volumes and, over time, development of 
pneumonia and atelectasis (Torsney, 2017). Moreover, the pathophysiology of 
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Parkinson’s itself might include impairment of the respiratory centres in the 
brainstem, leading to abnormal response to the hypoxemia and hypercapnia (Braak 
et al., 2011), and subsequently, inability to expand and recoil as needed. Thus, it is 
important to study lung volumes in PLwP. 
 
The following sections contain a brief introduction to pulmonary function and 
cardiovascular response to exercise, in which important terminology is defined prior 
to the subsequent chapters.  
 
1.10. Overview of pulmonary function 
This section will describe the pulmonary function terminology and definitions that 
are used in some chapters within the thesis. Pulmonary function tests (PFTs) are a 
group of tests that measure how well human ventilation works, the primary purpose 
being to identify the severity of pulmonary impairment (Burrows, 1975). The PFT is 
mainly done using a spirometer, which is a device that measures the volume of air 
that moves in or out of the lungs (Burrows, 1975). Spirometry results include a 
range of measurements that are summarized in table 1. 
 
Depending on the results of the PFT, pulmonary impairments are mainly divided 
into two categories: restrictive and obstructive pulmonary diseases (Burrows, 1975). 
Restrictive pulmonary disease, or restrictive pattern, is characterized by decreased 
lung volumes, increased work of breathing, and inadequate ventilation and 
oxygenation, and include pulmonary fibrosis, pneumonia and pulmonary oedema 
(Saxena, 2015). Obstructive pulmonary disease, or obstructive pattern, is generally 
characterized by inflamed and collapsible airways and obstruction to airflow; 




In restrictive pulmonary disease, both forced expiratory volume in one second 
(FEV1) and forced vital capacity (FVC) are reduced; however, the FEV1/FVC ratio is 
normal or increased (Quanjer et al., 1993). On the other hand, FEV1 is decreased 
more than any decrease in FVC in obstructive pulmonary disease, i.e. a decrease in 
the FEV1/FVC ratio (Quanjer et al., 1993). Table 2 summarizes spirometry 
interpretation for restrictive and obstructive patterns.  
 




Abbreviation Definition  




IRV The extra volume of air that can be inspired 
over and above the normal tidal volume when 
the person inspires with full force. 
Expiratory 
reserve volume 
ERV The maximum extra volume of air that can be 
expired by forceful expiration after the end of a 
normal tidal expiration. 
Residual 
volume 
RV The volume of air remaining in the lungs after 
the most forceful expiration. 
Inspiratory 
capacity 
IC The amount of air a person can breathe in, 
beginning at the normal expiratory level and 
distending the lungs to the maximum amount. It 
equals the tidal volume plus the inspiratory 
reserve volume. 
Vital capacity VC The maximum amount of air a person can 
expel from the lungs after first filling the lungs 
to their maximum extent and then expiring to 
the maximum extent. It equals the inspiratory 
reserve volume plus the tidal volume plus the 
expiratory reserve volume.  
Forced vital 
capacity 
FVC The volume of air that can forcibly be expired 
after full inspiration. 
Forced 
expiratory 
volume in 1 
second 
FEV1 The volume of air that can forcibly be expired in 
one second, after full inspiration 
Peak 
inspiratory flow 





PEF The maximal flow achieved during the 






MVV A measure of the maximum amount of air that 




Table 2: Spirometry interpretation for restrictive and obstructive patterns. 
Parameter Obstructive pattern Restrictive pattern 
FVC ↔ or ↓ ↓ 
FEV1 ↓ ↓ 
FEV1/FVC ↓  ↔ or ↑ 
FVC: Forced vital capacity; FEV1: Forced expiratory volume in 1 second; ↓: 
decreased; ↑: increased; ↔: no change. 
 
 
1.11. Cardiovascular response to exercise  
This section explains cardiovascular response terminology and definitions that are 
used in some chapters within the thesis. A cardiopulmonary exercise test (CPET), 
the golden standard measure of aerobic fitness, is a physical test that measures 
cardiovascular and respiratory ability to respond to external stress in a controlled 
clinical environment (Kisner et al., 2017). The CPET is done by challenging the 
cardiovascular and respiratory system, either by exercise on a treadmill or pedalling 
on a stationary cycle (Kisner et al., 2017). It is mainly used for fitness level 
assessment and as a diagnostic tool for coronary heart disease (Medicine, 1991). 
The CPET assesses cardiopulmonary response to physical stress by a gradual 
increase in resistance of the cycle ergometer or the speed or incline of the treadmill 
until the person reaches a maximal exercise capacity (Wasserman et al., 1987). 
Maximum exercise capacity is defined as “the maximum ability of the cardiovascular 
system to deliver oxygen to exercising skeletal muscle and of the exercising muscle 
to extract oxygen from the blood” (Krikler, 1992). The main cardiopulmonary 
responses during the CPET are: increases in oxygen consumption (VO2),  heart rate 
(HR), blood pressure (BP), respiratory rate (RR) and respiratory exchange ratio 
(RER) (Krikler, 1992). Definitions of CPET measures are summarized in table 3.  
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Table 3: Definitions of the main measures derived while doing the cardiopulmonary 
exercise test (CPET). 
CPET measure Definition  
Oxygen consumption 
(VO2) 
The amount of oxygen consumed by the tissues of the 
body, usually measured as the oxygen uptake in the lung. 
Workload (W) The speed and/or grade of the treadmill or the resistance 
on the bicycle ergometer that the person can achieve. 
Heart rate (HR) Number of heart beats per minute.  
Respiratory rate (RR) Number of breaths per minute 
Systolic blood 
pressure (SBP) 
Maximum arterial pressure during contraction of the left 
ventricle of the heart. 
Respiratory 
exchange ratio (RER) 
The ratio of carbon dioxide output/oxygen uptake. 
Test duration The maximum number of minutes that the patient can 
tolerate while doing the cardiopulmonary exercise test. 
 
1.12. Respiratory impairment management guidelines for 
Parkinson’s  
The European Physiotherapy Guidelines for Parkinson’s Disease (2018) and the 
National Institute for Health & Care Excellence (NICE) guidelines for Parkinson’s 
disease (2019) included recommendations for respiratory muscle training, and 
management of ineffective cough using air stacking, mechanical insuflation-
exsufflation, glossopharangeal breathing, and manually assisted cough. However, 
the guidelines did not include techniques to improve lung volumes, and did not 
include recommendations for management of respiratory impairment in the early 
stage of Parkinson’s. Similarly, the British Thoracic Society / The Association of 
Chartered Physiotherapists in Respiratory Care (Bott, 2009) guidelines for 
spontaneously breathing patients focuses on neuromuscular disease but does not 
give detail for neurodegenerative conditions including Parkinson’s. Thus, it is 
important to investigate if any other physiotherapy/ exercise interventions are going 
to improve respiratory function in PLwP. 
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1.13. Chapter summary   
This chapter has presented the definition of Parkinson’s, pathophysiology of the 
disease, prognosis, clinical features and the ICF model. Also, it explained the main 
terminology used in pulmonary function, cardiovascular response, and memory, 
which will be used in this thesis.   
 
Additionally, this chapter presented factors in PLwP that might contribute in 
developing type 1 and type 2  respiratory failure, including: chest wall rigidity; 
ankylosis of costosternal and thoracovertebral joints; kyphoscoliotic posture; 
decreased physical activity level; atelectasis; aspiration pneumonia; and impaired 
respiratory drive. However, more information is needed about respiratory function in 
PLwP in terms of having restrictive or obstructive pulmonary pattern, and if any 
intervention is going to improve lung volumes at the early stages of Parkinson’s.  
 
Thus, the thesis will continue with the next chapter, which presents reviews of what 
is known about pulmonary function, cardiovascular response to exercise, and the 
effects of aerobic training on cardiopulmonary function in PLwP, and provides 
further context for the research and development of the research questions.      
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Chapter 2: Literature Review  
2.1. Overview 
In developing the research presented in this thesis, a systematic search of the 
literature was conducted, with narrative synthesis of findings, to identify the 
prevalence of cardiopulmonary impairments in Parkinson’s, and determine the 
effects of aerobic interventions on pulmonary function and cardiovascular response 
to exercise.  
 
This chapter is divided into six main sections. This first section provides an overview 
of the chapter. Sections 2.2 to 2.4 include reviews of the following literature:  
• Pulmonary function in Parkinson’s 
• Cardiovascular response to exercise in Parkinson’s 
• Cardiopulmonary function and aerobic exercise in Parkinson's 
Section five will include a summary of the three reviews and development of 
research questions. The last section will include specific objectives for the thesis.  
 
2.2. Pulmonary function in Parkinson’s 
Although respiratory diseases are considered to be the main complaint in end-
stages of Parkinson’s (stages IV-V in Hoehn and Yahr) (Ebmeier et al., 1990), 
respiratory symptoms do not usually appear in the early stages of the disease 
(stages I-III in Hoehn and Yahr) (Polatli et al., 2001), acting as a silent threat. Thus, 
it is important to know if abnormal respiratory patterns (obstructive, restrictive or 
mixed pattern) exist in the early stages of Parkinson’s. Subsequently, this review 
aims to review and summarise published literature on the prevalence of obstructive 
and restrictive pulmonary disease in Parkinson’s. 
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2.2.1.  Methodology 
2.2.1.1.  Purpose 
The study objective was to review the published literature on prevalence of 
pulmonary function during the early stages of Parkinson’s, and factors affecting 
pulmonary disease if found. To achieve this, the outcomes were defined as 
prevalence of abnormal pulmonary pattern as measured by the forced expiratory 
volume in one second (FEV1) forced vital capacity (FVC) and FEV1/FVC. 
  
2.2.1.2.  Design 
A literature review with systematic search, quality assessment and narrative 
synthesis of relevant published literature. 
 
2.2.1.3.  Search strategy 
A search was conducted through EBSCO using the following electronic databases: 
MEDLINE, AMED, and CINAHL Plus. The databases were searched for studies 
published between 1st January 1970 and 1st May 2020, with results of the searches 
managed using Endnote Version X7 (Clarivate Analytics, Philadelphia, USA). 
Keywords used in the search included “Parkinson’s disease”, “Parkinson’s”, 
“pulmonary function”, “respiratory function”, “spirometry” and “spirometer”. Both 
retrospective and prospective observational studies were included. Papers were 
included if they reported pulmonary function tests (PFTs) in PLwP. Papers were 
excluded if they: examined PFT after interventions; were a pre-clinical study (animal 
model studies); were not written in English; or were a conference abstract.  
 
2.2.1.4. Study selection 
Following the search and subsequent removal of duplicates, titles and abstracts 
were screened independently by two researchers for relevance. Full texts of 
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relevant observational studies were then screened for eligibility against inclusion 
and exclusion criteria. 
 
2.2.1.5.  Data extraction 
The following data were extracted from the included studies and recorded: age, sex, 
disease severity (by means of Hoehn and Yahr), sample size, pulmonary pattern 
(restrictive, obstructive, mixed obstructive and restrictive or normal pattern), and 
main results.  
 
2.2.1.6.  Risk of bias and quality of reporting 
The quality of reporting of the studies was assessed by one person using the cross-
sectional studies assessment items of the Strengthening the Reporting of 
Observational Studies in Epidemiology (STROBE) Statement checklist (Von Elm et 
al., 2007); see table 4.  
 
2.2.2.  Results 
In total, 205 citations were identified from the databases. Duplicates (n=36) were 
removed, and titles and abstracts of the remaining 169 citations were screened for 
inclusion/exclusions based on relevance. Then, full-text screening was conducted 
(n=33) according to the inclusion and exclusion criteria. Following exclusion of 155 
citations, 14 articles were included in this review. None of the studies reported the 
ethnicity of the participants. Figure 6 represents search records and number of 
excluded and included articles. Results of the STROBE checklist for the included 
articles are presented in table 4. 
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Table 5 represents a summary of the main results of the 14 included studies, of 
which one reported movement of chest wall muscles and 13 reported pulmonary 
patterns on spirometry (restrictive or obstructive, or mixed of both patterns).   
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Table 4: Results of the adapted STROBE Statement—Checklist of items that should be included in reports of cross-sectional 
studies. 
 







































































































































































































































 (a) Indicate the study’s design with a 
commonly used term in the title or the 
abstract 
 ×     ×  × ×  ×   
(b) Provide in the abstract an 
informative and balanced summary of 
what was done and what was found 
              
Background/ 
rationale 
Explain the scientific background and 
rationale for the investigation being 
reported 
              
Objectives State specific objectives, including any 
prespecified hypotheses 
              
Study design Present key elements of study design 
early in the paper 
 ×     ×   ×     
Setting Describe the setting, locations, and 
relevant dates, including periods of 
recruitment, exposure, follow-up, and 
data collection 
 ×  × ×  ×  ×    ×  
Participants (a) Give the eligibility criteria, and the 
sources and methods of selection of 
participants 
      ×        
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Variables Clearly define all outcomes, exposures, 
predictors, potential confounders, and 
effect modifiers. Give diagnostic criteria, 
if applicable 
              
Data sources/ 
measurement 
For each variable of interest, give 
sources of data and details of methods 
of assessment (measurement). 
Describe comparability of assessment 
methods if there is more than one group 
 ×             
Bias Describe any efforts to address 
potential sources of bias 
× × ×  ×  × × × × × × × × 
Study size Explain how the study size was arrived 
at 
× × × × × × × ×  × × × × × 
Quantitative 
variables 
Explain how quantitative variables were 
handled in the analyses. If applicable, 
describe which groupings were chosen 
and why 
× ×     ×        
Statistical 
methods 
(a) Describe all statistical methods, 
including those used to control for 
confounding 
      ×        
(d) Describe any sensitivity analyses × × × × × × × × × × × × × × 
Participants (a) Report numbers of individuals at 
each stage of study—e.g. numbers 
potentially eligible, examined for 
eligibility, confirmed eligible, included in 
the study, completing follow-up, and 
analysed 
              
Descriptive data (a) Give characteristics of study 
participants (e.g. demographic, clinical) 
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Full-text articles assessed 
for eligibility (n=33) Excluded: n=19 
Reasons for 
exclusion:  
did not include 
baseline PFT 
(n=13), animal 
studies (n=4), not 
in English (n=2) Studies included in 
narrative synthesis (n=14) 
Excluded:  n=136 
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Table 5: A summary of the main findings of studies included in the review of prevalence of pulmonary function in people with 
Parkinson’s. 













Alonso et al., 
1994 
63 67.1 (0.9) 24:39 I-V Mixed Abnormal flow-volume loop in 49.2% of the 
sample. 
Lower FVC (p<0.05), and FEV1 (p<0.001) than 
healthy controls. 
De Pandis et al, 
2002 
12 67.7 (5.4) 4:12 >III 
(severe) 
Restriction  Lower FVC (mean (SD)=76.83 (26.74), 
p<0.005) and FEV1 (mean (SD)= 77.91 (28.88), 
p<0.05) in PLwP compared to healthy controls. 
Guimarães et 
al., 2018 
60 69 (5) N/A II-III Mixed Mixed pattern with low FEV1/FVC (mean 
(SD)=63.25(18.60)). 
Hampson et al., 
2017 
86 62.4 (8.7) 57:29 I-III Normal  All spirometer values were within normal 
reference ranges of FEV1 (mean 
(SD)=89.7(15.5)), FVC (mean 




31 64.6 (9.1) 16:15 >III 
(severe) 
Obstruction Upper airway obstruction when compared with 
healthy controls indicated by low PIF (p < 0.01) 
and PEF (p < 0.01). 
Monterio et al., 
2014 
30 61.6 (10.7) 17:13 I-III Obstruction Lower FVC (mean (SD)=66.2(15.3) in PLwP vs.  
90.2 (18.6) in controls, p<0.001)), FEV1 (mean 
(SD)= 75.0 (16.0) in PLwP vs 90.2 (18.6) in 
controls, p<0.005)), and FEV1/FVC (mean 
(SD)=84.4 (5.8) in PLwP vs.86.3 (27.5) in 
controls, p<0.04).  
Obenour et al., 
1972 
31 67.4 (8.1) 18:13 N/A Obstruction Lower FEV1 (mean (SD)=1.8 (0.7)) and 
FEV1/FEV (mean (SD)= 60(11)) compared with 


















Owolabi et al., 
2016 
78 63.3 (8.6) 60:18 N/A Obstruction  Lower FEV1 (mean=1.887), FVC (mean=2.48), 
and FEV1/FVC (mean= 75.812) in PLwP than 
healthy controls (p<0.0001). 
Polatli et al., 
2001 
21 62.5 (11.3) 10:11 I-III Mixed Lower FEV1 (mean (SD)= 68.6 (19.7), P<0.03), 
FVC (mean (SD)= 83.42 (12.24), P<0.01), and 
MVV (mean (SD)= 52.83 (15.52), p<0.0001).  
Sabaté et al., 
1996 
58 67.7 (1.0) N/A N/A Mixed Lower FVC, FEV1 (mean (SD)= 88.7 (23.8), 
p<0.001) and FEV1/FVC (mean (SD)= 86.3 
(10.1), p<0.0001). 
Santos et al., 
2019 
49 63 (8) N/A I-III Mixed  Respiratory muscle strength and lung function 
are impaired from the early stages of 
Parkinson’s. Bradykinesia and rigidity being the 
cardinal signs that correlate  
strongly with impairment of PFT values 
(p<0.001). FEV1 (mean (SD) in H&Y stage 1= 
2.4 (0.5), stage 2=2.2 (0.7), stage 3=1.7 (0.7)). 
FVC (mean (SD) in stage 1=85 (12), stage 2= 
79 (18), stage 3=61 (22)).  
Sathyaprabha 
et al., 2005 
53 53.0 (10) N/A I and II Restriction Lower FVC (mean (SD)= 56.0 (14.5), p<0.001), 
FEV1 (mean (SD)= 61.7 (16.5), p<0.001) in 
PLwP compared with healthy controls.  
Tamaki et al., 
2000 
7 57.3 (14.5) 6:1 N/A N/A  Thoraco-abdominal movement was associated 
with VC and FVC. 
Wang et al, 
2014 
30 61.8 (4.2) 16:14 II-V Mixed Lower FVC (mean (SD)= 74.77 (13.92)), higher 
RV (mean (SD)= 122.66 (26.54), lower FEV1 
and lower FVC (mean (SD)= 56.67 (20.10) 
p<0.05. 
FVC: forced vital capacity; FEV1: forced expiratory volume in the first second; VC: vital capacity; MVV: maximum ventilatory 
volume; PEF: peak expiratory flow; PIF: peak inspiratory flow; RV: reserve volume; N/A: information not available.  
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Restrictive pulmonary pattern was reported in 28% to 94% in people in the early 
stages of Parkinson’s (De Pandis et al., 2002; Sathyaprabha et al., 2005) while 
obstructive pulmonary pattern varied from 6% to 67% (Hovestadt et al., 1989; 
Monteiro et al., 2014; Obenour et al., 1972; Owolabi et al., 2016). Additionally, six 
studies reported mixed obstructive and restrictive pattern in PLwP during the early 
stages of the disease (Guimarães et al., 2018; Izquierdo-Alonso et al., 1994; Polatli 
et al., 2001; Sabaté et al., 1996; Santos et al., 2019; Wang et al., 2014). Eight 
studies included people in the early stages of Parkinson’s (I-III in Hoehn and Yahr), 
two studies included severe stages, and four studies did not report Hoehn and Yahr 
stages in their publication (table 5).  
 
In contrast, one study reported normal pulmonary function test values, with no 
restrictive or obstructive pattern (Hampson et al., 2017). Although this study 
included the largest sample size (n=96), inclusion was restricted to people with an 
FEV1/FVC >75% of the predicted value, excluding people who already have 
obstructive pulmonary disease (Hampson et al., 2017).  This could explain why the 
findings of this study were different from those reported by the other studies.   
 
2.2.3.  Discussion  
This is the first review summarising literature on prevalence of pulmonary function in 
the early stages of Parkinson’s (H&YI-III). The search included relevant studies from 
the last 40 years and involved independent screening by two reviewers. This review 
has shown that only a small number of studies have investigated impaired 
pulmonary function in the early stages of Parkinson’s. these studies did not report 
ethnic backgrounds. Subsequently, the results could not be generalised to all ethnic 
populations, as they have not been included in these studies, and there may be 
differences in pulmonary patterns with other populations. There may be differences 
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in pulmonary patterns with different ethnicities (Wyss, 2018), due to gene 
expression, and the multiethnic nature (Wyss, 2018). Additionally, differences in 
management of Parkinson’s in the early stages among different countries, and 
different physiotherapy, conservative and traditional treatment might cause 
differences in pulmonary function. However, no research was conducted on 
difference of pulmonary function among different ethnicities in PLwP, yet. Out of the 
14 studies, 13 studies reported pulmonary pattern and the other study investigated 
chest wall muscle movement. Out of those 13 studies reporting pulmonary pattern, 
two reported restrictive pattern, four reported obstructive pattern, six reported mixed 
obstructive and restrictive patterns, and only one reported normal pattern.  
 
This variation in results, in terms of obstructive, restrictive or mixed pattern, might 
be because of the difference in disease stages included in the studies and whether 
Levodopa was administered or whether smokers were included in the studies (De 
Pandis et al., 2002; Polatli et al., 2001; Sathyaprabha et al., 2005). For example, it 
has been reported that as the disease progresses to Hoehn and Yahr stages IV and 
V, the prevalence of restrictive patterns is higher than that in stages I–III (Izquierdo-
Alonso et al., 1994; Santos et al., 2019). Even between stages I-III, the results of 
pulmonary function tests have been reported to be more severe in people who are 
in Hoehn and Yahr stage II than in stage I (Santos et al., 2019; Sathyaprabha et al., 
2005). Similarly, obstructive pulmonary pattern has been found to have a higher 
prevalence in people with stage III than people in stage I and II (Polatli et al., 2001; 
Santos et al., 2019; Sathyaprabha et al., 2005).  
 
The increase in severity and prevalence of restrictive and obstructive pulmonary 
patterns with progression of the disease could be explained by an increase in 
rigidity of chest wall muscles, which may result in kyphoscoliosis (Baille et al., 2016; 
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Santos et al., 2019); this may, in turn, lead to decrease in lung volume (Black and 
Hyatt, 1971; Sabaté et al., 1996). Furthermore, rigidity of chest wall muscles leads 
to decrease in the elasticity of the lungs’ parenchyma and subsequently ability to 
expand the lungs. The chest muscle rigidity in Parkinson’s is supported by an 
electromyographic study, which reported a decrease in respiratory muscle activity in 
Parkinson’s during inspiration (Estenne et al., 1984). 
 
The decrease in lung elasticity leads to decrease in the stretch during inspiration 
and recoil ability during expiration (Estenne et al., 1984). The decrease in lung 
stretching ability during inspiration may lead to a restrictive pattern, and the 
decrease of the recoiling ability during expiration may lead to an obstructive pattern 
(Estenne et al., 1984). It has been well known that the loss of alveolar wall elasticity 
leads to dynamic hyperinflation of the lungs, and subsequently increase in the 
residual volume and dead space, and decrease in the vital capacity (O'donnell et 
al., 2001).  
 
PLwP who are being treated with Levodopa have shown improvements in 
pulmonary function tests post-medication compared with pre-medication (Polatli et 
al., 2001; Sathyaprabha et al., 2005; Wang et al., 2014), and a 41%-48% lower 
prevalence of obstructive pattern prevalence than in untreated Parkinson’s 
(Obenour et al., 1972). This may be explained by the decrease in motor symptoms 
after taking the medication, and by improvement in aerobic fitness. Furthermore, 
taking the medication may result in decreased chest wall muscle rigidity and 
associated kyphoscoliosis, reducing their negative effect on lung elasticity and 
resultant impairment of pulmonary function (Obenour et al., 1972; Sathyaprabha et 
al., 2005; Stacy, 2002). 
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2.2.4.  Conclusion and recommendations 
Overall, it is too early to draw clear conclusions about lung function from these 
studies, and further studies are recommended with larger longitudinal samples to 
see the long-term respiratory manifestations, and with full respiratory file 
investigations, including spirometry, chest X-ray, exercise tolerance and clinical 
symptom investigations. Evaluation of pulmonary impairments is needed, as well as 
the investigation of interventions that could help to improve lung function in the early 
stages of the disease to decrease the impairment and to prevent the respiratory 
complications resulting from the abnormal patterns. Additionally, it is recommended 
to assess and report pulmonary function in PLwP with different ethnicities. 
 
2.3. Cardiovascular response to exercise in Parkinson’s  
A number of studies (for example: Cruise et al., 2011; Dibble et al., 2009) have 
assessed the effects of exercise and physical activity on balance, mobility, quality of 
life and cognitive function in PLwP. However, there has been limited research on 
cardiovascular response to exercise in Parkinson’s. This section includes a 
literature review that aimed to summarize cardiorespiratory response to exercise 
and factors that affect cardiorespiratory response in PLwP. 
 
2.3.1.  Methodology 
2.3.1.1.   Purpose and design 
The study objective was to review the published literature on cardiovascular 
response to exercise during the early stages of Parkinson’s, and factors affecting 
pulmonary disease, if found. To achieve this, the outcomes were defined as 
prevalence of high, low or similar cardiovascular response to exercise in PLwP 
compared with healthy people as measured by the VO2peak or VO2max (using the 
cardiopulmonary exercise test: CPET).  
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Study design: a review with quality assessment and narrative synthesis of relevant 
published literature. 
 
2.3.1.2.  Search strategy 
A search was conducted through EBSCO using the following electronic databases: 
MEDLINE, AMED, and CINAHL Plus. The databases were searched for studies 
published between 1st January 1970 and 1st May 2020, with results of the searches 
managed using Endnote Version X7 (Clarivate Analytics, Philadelphia, USA). 
Keywords included “Parkinson’s disease”, “Parkinson’s”, “cardiovascular response”, 
“cardiopulmonary response”, “exercise stress test”, “exercise test”, cardiopulmonary 
exercise test” and “graded exercise test”. Papers were excluded if they: did not 
include CPET; examined CPET after interventions; were not written in English; or 
were conference abstracts. Papers were included if they: were cross-sectional in 
design; included CPET; included PLwP. 
 
2.3.1.3.  Study selection 
Following the search and subsequent removal of duplicates, titles and abstracts 
were screened independently by two researchers for relevance. Full texts of 
relevant studies were then screened for eligibility against inclusion and exclusion 
criteria. 
 
2.3.1.4.  Data extraction 
The following data were extracted from the included studies and recorded: age, sex, 
disease severity (by means of Hoehn and Yahr), sample size, protocol used for the 
CPET, and main results.  
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2.3.1.5.  Risk of bias and quality of reporting 
The quality of reporting of the studies was assessed by one person using the cross-
sectional studies assessment items of the Strengthening the Reporting of 
Observational Studies in Epidemiology (STROBE) Statement checklist (Von Elm et 
al., 2007); see table 6.  
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Table 6: Results of the adapted STROBE Statement—Checklist of items that should be included in reports of  
cross-sectional studies. 
 








































































































































































































 (a) Indicate the study’s design with a 
commonly used term in the title or the abstract 
 ×     ×  × ×  × 
 
(b) Provide in the abstract an informative and 
balanced summary of what was done and 
what was found 
            
Background/ 
rationale 
Explain the scientific background and 
rationale for the investigation being reported 
            
Objectives State specific objectives, including any 
prespecified hypotheses 
            
Study design Present key elements of study design early in 
the paper 
 ×     ×   ×   
Setting Describe the setting, locations, and relevant 
dates, including periods of recruitment, 
exposure, follow-up, and data collection 
 ×  × ×  ×  ×    
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Participants (a) Give the eligibility criteria, and the sources 
and methods of selection of participants 
      ×      
Variables Clearly define all outcomes, exposures, 
predictors, potential confounders, and effect 
modifiers. Give diagnostic criteria, if applicable 
            
Data sources/ 
measurement 
For each variable of interest, give sources of 
data and details of methods of assessment 
(measurement). Describe comparability of 
assessment methods if there is more than one 
group 
 ×           
Bias Describe any efforts to address potential 
sources of bias 
× × ×  ×  × × × × × × 
Study size Explain how the study size was arrived at × × × × × × × ×  × × × 
Quantitative 
variables 
Explain how quantitative variables were 
handled in the analyses. If applicable, 
describe which groupings were chosen and 
why 
× ×     ×      
Statistical 
methods 
(a) Describe all statistical methods, including 
those used to control for confounding 
      ×      
(d) Describe any sensitivity analyses × × × × × × × × × × × × 
 
 
Participants (a) Report numbers of individuals at each 
stage of study—e.g. numbers potentially 
eligible, examined for eligibility, confirmed 
eligible, included in the study, completing 
follow-up, and analysed 
            
Descriptive 
data 
(a) Give characteristics of study participants 
(e.g. demographic, clinical, social) and 
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information on exposures and potential 
confounders 
Outcome data Report numbers of outcome events or 
summary measures 
            
Main results (a) Give unadjusted estimates and, if 
applicable, confounder-adjusted estimates 
and their precision (e.g., 95% confidence 
interval). Make clear which confounders were 
adjusted for and why they were included 
 ×           
Key results Summarise key results with reference to study 
objectives 
            
Limitations Discuss limitations of the study, taking into 
account sources of potential bias or 
imprecision. Discuss both direction and 
magnitude of any potential bias 
× ×   ×  ×  × × × × 
Interpretation Give a cautious overall interpretation of results 
considering objectives, limitations, multiplicity 
of analyses, results from similar studies, and 
other relevant evidence 
    ×  ×  × × × × 
Generalisability Discuss the generalisability (external validity) 
of the study results 
× × × × × × × × × × × × 
Funding Give the source of funding and the role of the 
funders for the present study and, if 
applicable, for the original study on which the 
present article is based 
× ×           
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2.3.2.  Results 
In total, 351 citations were identified from the databases. Duplicates (n=121) were 
removed, and titles and abstracts of the remaining 230 citations were screened for 
inclusion based on relevance. Then, full-text screening was conducted (n=33) 
according to the inclusion and exclusion criteria. Following exclusion of 218 
citations, 12 articles were included in this review. Figure 7 represents search 
records and number of excluded and included articles. Results of the STROBE 
checklist for the included articles are presented in table 6.  
 
Nine studies have investigated the cardiovascular response to exercise using a 
maximal CPET (Bryant et al., 2016; Canning et al., 1997; DiFrancisco-Donoghue et 
al., 2009; Haas et at., 2016; Kanegusuku et al., 2016; Mavrommati et al., 2017; 
Roberson et al., 2019; Strano et al., 2016; Yahalom et al., 2014), and three studies 
assessed cardiovascular response to exercise at submaximal CPET (Protas et al., 
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Figure 7: Flow-Chart of the search records. CPET: cardiopulmonary exercise test. 
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Around 60 % could not complete the test to the maximum 
intensity, reporting fatigue, shortness of breath, pain, 












In maximal exercise test, PLwP had similar peak VO2 and 










14/0 I-III CPET 
(Treadmill), 
Bruce protocol 
Lower HR and BP but not lower VO2 in PLwP than 







15/3 I-IV CPET (cycle).  16 out of the 18 terminated the test because of leg 
fatigue and one participant because of knee pain.  
Kanegusu





66(8) 35/13 I-III CPET using 
ramp protocol 
(cycle). 
In maximal intensity, PLwP showed lower HR, SBP and 
VO2 than healthy controls.  
Mavromm








67(8) 61/22 I-III CPET (cycle) Lower HR, VO2 L/min, VCO2 L/min and ventilation L/ 





61(10) 8/0 II-III CPET (cycle) Submaximal HR and VO2 were higher in the PLwP group 



























Around 50% didn’t complete the CPET. 
Height, weight and lower SBP were associated with the 























In submaximal exercise, no significant differences were 
found between the groups for HR or BP.  
At peak exercise, BP, but not HR, was significantly higher 


















Similar maximal heart rate profile for those who 
developed Parkinson’s compared to those who did not 
develop Parkinson’s.  
PLwP: people Living with Parkinson’s; CPET: cardiopulmonary exercise test; HR: heart rate; SBP: systolic blood pressure; VO2: 
oxygen consumption; BP: blood pressure.  
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Contradictory cardiovascular responses to maximal exercise test in PLwP have 
been reported (Bryant et al., 2016; Canning et al., 1997; Kanegusuku et al., 2016; 
Mavrommati et al., 2017; Protas et al., 1996; Roberson et al., 2019; Speelman et 
al., 2012; Strano et al., 2016; Werner et al., 2006; Yahalom et al., 2014). Some 
authors (Kanegusuku et al., 2016; Mavrommati et al., 2017; Roberson et al., 2019; 
Speelman et al., 2012; Strano et al., 2016; Werner et al., 2006) reported lower 
maximum responses of oxygen uptake (VO2), heart rate (HR) and systolic blood 
pressure (SBP) in the early stages of Parkinson’s (Hoehn and Yahr stages I-III) in 
comparison with age-matched controls in response to cycle and treadmill exercise 
tests. One study (Canning et al., 1997) found no differences in maximum 
cardiovascular responses between people with early stages of Parkinson’s (Hoehn 
& Yahr I-III) and healthy controls in response to the cycle exercise test, whilst 
another (DiFrancisco-Donoghue et al., 2009) reported lower heart rate and blood 
pressure, but not lower VO2, in a maximal cycle CPET in the early stages of the 
disease (I-III in Hoehn and Yahr).  
 
Achieving maximal responses may be difficult in PLwP because of the motor 
symptoms of the disease (Katzel et al., 2011). Thus, evaluation of the submaximal 
cardiopulmonary responses to exercise may bring added knowledge. Studies that 
assessed cardiovascular response to exercise using submaximal testing reported 
contradictory findings in PLwP. One study (Werner et al., 2006) reported similar 
submaximal responses to exercise at the same workload in PLwP and age-matched 
controls. Speelman et al. (2012) reported lower VO2 in PLwP compared with age 
matched healthy controls in submaximal intensities. On the other hand, Protas et al. 




In order to understand if the cardiovascular response is a pre-motor symptom in 
Parkinson’s disease, a retrospective cohort study was done, with 16841 PLwP 
(Yahalom et al., 2014). Those who developed Parkinson’s disease (n=28) had a 
similar maximum heart rate profile to those who did not. 
 
Termination of the CPET in PLwP seems to be related to factors other than 
cardiovascular disorders, including leg fatigue, arm fatigue, knee pain or shortness 
of breath (Bryant et al., 2016; Haas, 2016). In addition, height, weight and lower 
SBP have been associated with the inability to sufficiently increase heart rate during 
the submaximal CPET in PLwP (Speelman et al., 2012). None of the included 
studies reported information about ethnicities of the participants. 
 
2.3.3.  Discussion  
This review revealed contradictory findings about cardiovascular response to 
exercise in PLwP, with some studies reporting higher, lower or similar response 
compared to healthy people. These contradictory findings might be due to the 
variations in the CPET protocol used, or whether a cycle or a treadmill test was 
used. The absence of information about cardiovascular response to exercise in 
PLwP with different ethnicities, means that the results could not be generalised on 
different populations (Farrell, 1987). Cardiovascular response to exercise depends 
on physical activity level (Farrell, 1987). Different perception exercise and physical 
activity has been reported among different ethnicities (Horne, 2013). Accordingly, it 
is recommended to conduct and report cardiovascular fitness research with different 
ethnicities. 
 
Most studies that assessed maximal CPET reported higher cardiovascular response 
to exercise in PLwP compared with healthy controls. Only one study reported 
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normal cardiovascular response to exercise at maximal intensity (Canning et al,. 
1997). However, participants included in the Canning et al. (1997) experiment were 
exercising regularly, and this may explain the contradictory results compared with 
the other studies. In contrast, another study reported lower cardiovascular response 
to exercise than the normal population (DiFrancisco-Donoghue et al,. 2009). 
However, both Cannning et al. (1997) and DiFrancisco-Donoghue et al. (2009) 
included only small sample sizes (n=16 and n=14, respectively) compared to the 
rest of the included studies, and the sample size was not based on an appropriate 
calculation.  
 
The higher VO2 suggests higher energy demand for the same workload in PLwP 
which may influence cardiovascular responses (Protas et al., 1996). However, both 
Werner et al. (2006) and Protas et al. (1996) included only males and small sample 
sizes (n=16 and n=8, respectively).  
 
Results of the retrospective study (Yahalom et al., 2014) suggested that 
cardiovascular response is not a pre-motor symptom in Parkinson’s and may be 
developed as a result of other factors. Subsequently, further investigations are 
needed to assess what factors might affect cardiovascular response to exercise in 
PLwP.  
 
2.3.4.  Conclusion and recommendations 
In summary, studies that assessed cardiovascular response to exercise in 
Parkinson’s have reported contradictory results, with some reporting lower and 
insufficient cardiovascular response to exercise and some reporting normal profiles. 
These variations might be related to the sample size, gender differences or CPET 
protocols used. Thus, there is a need to assess cardiovascular response to exercise 
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in PLwP in maximal and submaximal intensities. In addition, there is a need to 
investigate rehabilitation programs that could improve cardiovascular response. 
Additionally, it is recommended to assess and report cardiovascular fitness in PlwP 




2.4. Effects of aerobic exercise on cardiopulmonary function in 
Parkinson’s  
Aerobic exercise refers to the use of oxygen to adequately meet energy demands 
during physical exercise (Kisner et al., 2017). In the general population, heart rate 
and respiratory rate increase during aerobic exercise in order to fulfil demands of 
the exercised skeletal muscles (Kisner et al., 2017). It has been found that regular 
aerobic exercise, such as walking, cycling or swimming, of 30 to 60 minutes three 
times per week could decrease blood pressure, improve oxygen consumption and 
decrease shortness of breath in the general population (Myers, 2003). However, 
these effects have not been widely explored in PLwP. Thus, this section aims to 




2.4.1.1.  Purpose 
The study objective was to review and discuss published literature on the effects of 
aerobic exercise on cardiopulmonary function and walking economy in PLwP. To 
achieve this, the primary outcomes were defined as pulmonary function test (PFT) 
variables including FEV1 and FVC and FEV1/FVC and cardiopulmonary exercise 
test (CPET) variables including oxygen uptake at maximal exertion (VO2 max) and 
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oxygen uptake at peak exertion (VO2 peak). Secondary outcome measures included 
maximum HR (HRmax) and peak HR (HRpeak), CPET duration, blood pressure pre‐ 
and post‐CPET, and walking economy. The study aimed to conduct a meta‐analysis 
for the primary outcome measures, where feasible. If conducting meta‐analysis was 
not possible, the study aimed to conduct a narrative synthesis. 
 
2.4.1.2.  Design 
The study was designed to provide a systematic review with quality assessment 
and narrative synthesis of relevant published literature. 
 
2.4.1.3.  Search strategy 
A search was conducted through EBSCO using the following electronic databases: 
MEDLINE, AMED, and CINAHL Plus. The selected databases were chosen 
because of the likely availability of Parkinson's physiotherapy‐ and exercise‐related 
articles in these databases. The databases were searched for studies published 
between 1st January 1970 and 1st January 2020, with results of the searches 
managed using Endnote Version X7 (Clarivate Analytics, Philadelphia, USA).  
 
Keywords used were structured by using the PICO approach (population, 
intervention, comparison and outcome) (Schardt et al., 2007). Table 8 summarizes 
the combinations of keywords included in the search strategies using the PICO 
approach. PICO search terms were combined using Boolean operators ‘AND’ and 
‘OR’. Study design was not restrictive due to the low number of records. Articles 
were included if they assessed cardiopulmonary function in PLwP after aerobic 
exercise programmes. Articles were excluded if: the intervention used did not 
include aerobic exercises; the outcome measures did not include CPET or PFT; 
they were not written in English language; or they were conference abstracts.  
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2.4.1.4.  Study selection 
Following the search and subsequent removal of duplicates, titles and abstracts 
were screened independently by two researchers for relevance. Full texts of 
relevant studies were then screened for eligibility against inclusion and exclusion 
criteria. 
Table 8: Keywords used in the search strategy presented by the PICO approach 
 
 
2.4.1.5.  Data extraction 
The following data were extracted from the included studies and recorded: age, sex, 
disease severity, and sample size. Exercise intervention mode, intensity, duration, 
and frequency were noted. 
 
2.4.1.6.  Risk of bias and quality of reporting 
Quality assessment of the included studies regarding the effects of aerobic exercise 
on cardiopulmonary function were done using the PEDro Scale (PEDro scale items 
and description in Appendix 1) (de Morton, 2009; Maher et al., 2003). The PEDro 
scale has been found to be a valid and reliable tool for assessment of quality of 
interventional studies specifically related to physical therapy interventions (de 
Morton, 2009; Maher et al., 2003). It contains 11 items (studies are awarded 




Aerobic exercise No intervention Cardiovascular 




 Physical activity  Pulmonary function 
 Training  Respiratory 
function 
   Cardiorespiratory 
function 
   Walking economy 
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between 0–10 points), depending on the number of criteria the articles meet (the 
first item is not used to calculate the summary score).  
 
Due to the nature of exercise interventions, no studies included blinding of subjects 
or investigators to the intervention allocation, and hence none could earn points on 
the PEDro Scale items 5 and 6. PEDro scores of four points or higher were 
classified as “high quality”, whereas studies with three points or less were “low 
quality” (Maher et al., 2003). PEDro scores for the studies were not used as a 
threshold for their inclusion or exclusion, but as a basis for best-evidence synthesis 
and to discuss the strengths and weaknesses of studies.  
 
2.4.2.  Results 
The systematic search identified 329 citations, of which 132 were duplicates. 
Consequently, 197 citations were screened from titles and abstracts and 172 were 
considered not to be relevant. Of the 25 remaining studies, 16 were excluded 
because they did not include aerobic exercise or CPET or PFT, or they were animal 
model studies or single‐case studies. Consequently, nine studies were included in 
the review: one was a non‐randomised controlled pilot study and eight were 
randomised controlled trials. None of the included studies reported information 
about ethnicities of the participants. Figure 8 represents the findings of the search. 
 
2.4.2.1.  Results of quality assessment 
Due to the nature of exercise interventions, no studies included blinding of subjects 
or investigators to the intervention allocation; therefore, no points were awarded on 
the PEDro Scale for items 5 and 6. Table 9 shows the PEDro quality assessment 
scores for the included studies. Scores ranged from 5 to 8. 
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To assess the feasibility of running a meta‐analysis, data were extracted and 
summarized in table 10 and focused on: pulmonary function test variables; the 
protocols used for CPET; mode of the test: treadmill or cycle test; CPET test 
primary outcomes (VO2max and VO2peak); secondary outcomes including HRmax; 
HRpeak; CPET test duration; blood pressure (BP) pre‐ and post‐CPET; and walking 
economy. None of the studies investigated the effects of aerobic exercise on 
pulmonary function; therefore, no data related to FEV1, FVC, and FEV1/FVC could 
be reported. Meta‐analysis of data was not undertaken owing to the heterogeneity 
of the studies, specifically: inclusion/exclusion criteria, exercise test protocol, mode 
of exercise test (cycle or treadmill), exercise intensity (maximum or sub‐maximum), 
physiological outcomes (HR, VO2peak, VO2max), and systolic or diastolic BP. Instead, 
a narrative review was conducted. Furthermore, it was not possible to calculate 
effect sizes from the data provided in the published papers. Authors were contacted 
by email to request the additional relevant data, but none responded.
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Figure 8: Flow-Chart of the search records. PFT: pulmonary function test; CPET: 




Screening from titles 









exclusion:  animal 
model (n=5) 
Single case study 
(n=3) 
did not include 
aerobic exercise 
or CPET or PFT 
(n=8) 
Studies included in 
qualitative synthesis 
(n=9) 
Excluded:  n=172 
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Table 9: PEDro scores for the studies that investigated the effects of aerobic training on cardiopulmonary function in people 


































































































































































































































































































































































































































































































Bergen et al, 
2002 




1 1 1 1 0 0 1 1 1 1 1 8 
Burini et al, 
2006 
1 1 1 1 0 0 1 1 1 1 1 8 
Corbianco et 
al, 2018 




1 1 0 1 0 0 0 1 1 1 1 6 
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Mavrommati 
et al, 2017 
1 1 1 1 0 0 1 1 1 1 1 8 
Ridgel et al, 
2016 
1 1 1 1 0 0 1 1 1 1 1 8 
Schenkman 
et al, 2012 
1 1 1 1 0 0 1 1 1 1 1 8 
Shulman et 
al, 2012 
1 1 1 1 0 0 1 1 1 1 1 8 
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Table 10: Summary of studies that investigated the effects of aerobic training on cardiopulmonary function and walking economy in 

























G1: Cycling or 
treadmill walking 
for 3 times/week 
for 16 weeks.  




Increased VO2peak and achieved 
workload in the intervention group 
(from 19.5 to 24.5 ml.kg.min-1).  
Decreased VO2peak in the control 









67.3(3.9) 9:4 RCT G1: 12 weeks 
aerobic exercise 
(walking).  
G2: Usual physical 
activity level 
CPET Improvement in exercise test duration 
and HR in the exercise group 
• The exercise group had a 
minimum target heart rate of 82.92 
± 9.98 beats per minute (mean ± 
SE) and exercised at an intensity 
that produced a maximum HR of 
121.27 ± 16.74 beats per minute 
(mean ± SE). 
• Significant group by session 
interactions between the exercise 
and control groups in mean CPET 






65.2(6.5) 9:17 RCT G1: Aerobic 
training 3 




times/week for 7 
weeks. 
CPET • G1: mean (SD) VO2peak (ml.kg.min-
1 ) at baseline =1201.4(368), and 
951 (337) after 7 weeks, within-
group mean difference = 250 
(t=2.3, p=0.04) 
• G2: mean (SD) VO2peak (ml.kg.min-
1 ) at baseline =1064.7(229), and 
1158(307) after 7 weeks, (mean 
difference=-94); within-group 
mean difference = -94 (t= 3, 
p=0.02) 
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• Significant between-group 
difference for VO2peak (F: 4.8, 
p=0.007).  
Corbian




58.8(3.9) 20:0 RCT G1: treadmill 
training 20 minutes 
per day, 4 
days/week for 4 
weeks  
G2: Whole body 
vibration 20 
minutes per day, 4 
days/week for 4 
weeks 
 VO2 peak increased in both groups 
(ml.kg.min-1): 
G1: baseline mean (SD) V̇O2peak 
(13.46(4.96)), after 4 weeks 
(18.55(1.11)) 
G2:  baseline mean (SD) VO2peak 
(13.22(6.16)), after 4 weeks 
(20.70(1.16)) 





al, 2014  
11 G1 
11 G2 
58.7(10) 13:9 RCT G1: Treadmill 
training 3 









Treadmill training but not overground 
training reduced overground walking 
economy (t=5.61, p <0.001 for 
treadmill training). 






al, 2017  
36 G1 
47 G2 




2 times/week for 
24 weeks.  
G2: Usual activity 
CPET G2 obtained higher maximum values 
for HR, VO2 peak. 
• Mean (SD) VO2peak (ml.kg.min-1): 
G1 =1.66 (2.35), G2= 1.69 (2.57)  
• Mean (SD) HR peak (beats.min-1): 
(G1=136 (114), G2=152 (108)) 
Significant difference between the two 






22 G2  





CPET No significant differences between 
both groups for cardiovascular 
variables (resting HR (p=0.59), VO2 




3 times/week for 
12 weeks. 
G2: Usual activity. 
Schenk
man et 






76:45 RCT G1: Supervised 
flexibility, balance 
and function, 3 
days/week for 3 
months. 
G2: Supervised 
aerobic exercise, 3 
days/week for 16 
months. 
G3: Control (home 
exercise), single 
supervised session 
and then 5–7 
days/week for 16 
months at home.  
Walking 
economy  
Walking economy was improved in 
the aerobic exercise group but not in 
the flexibility, balance and function 
group or the control group (mean 
difference= -1.2 ml.kg.min-1, 95% CI= 
-1.9 to -0.5). 
Shulma




28 G3  
65.8(10.7
) 
50:17 RCT G1: Low-intensity 
treadmill training, 3 
times/week for 3 
months. 
G2: High-intensity 
treadmill training, 3 
times/week for 3 
months. 
G3: Stretching and 
resistance training, 
3 times/week for 3 
months. 
CPET Low-intensity treadmill intervention 
had the greatest effect in improving 
gait speed. 
Both treadmill interventions decreased 
maximum VO2. 
Mean difference (SD) between 
baseline and post training (ml.kg.min-
1):  
• Low intensity (1.54 (0.4)) 
• High intensity (1.53 (0.7)) 
Statistically significant with p=0.003 
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Aerobic training in PLwP has been reported to improve peak VO2 (Bergen et al., 
2002; Bridgewater and Sharpe, 1996; Burini et al., 2006), decrease breathlessness 
(Burini et al., 2006), increase maximum workload tolerated (Bergen et al., 2002) and 
increase test duration of the CPET (Bridgewater and Sharpe, 1996).  
 
2.4.2.2.  Frequency and duration of exercise  
Frequency of exercise in the included studies ranged from 2 to 3 times per week, 
with varied exercise programme durations (Bergen et al., 2002; Bridgewater and 
Sharpe, 1996; Burini et al., 2006; Ridgel et al., 2016). For example, Bergen el al. 
(2002) investigated the effects of a 16-week exercise programme (n=4), whereas 
Bridgwater and Sharpe (1996), Ridgel et al. (2016) and Shulman et al. (2012) 
investigated the effects of 12-week exercise programmes (n=13, n=24 and n=67 
respectively). Shorter programme durations of 7 weeks (Burini et al., 2006, n=26) 
and 6 weeks (Pelosin et al., 2009, n=10) have also been investigated. Although the 
duration of the aerobic exercise intervention varied in these studies, all of them 
reported improvement in exercise test outcomes, including HR and VO2, except two 
studies. 
 
2.4.2.3.  Intensity of exercise  
In order to investigate the effects of different intensity of the aerobic exercises, 
Shulman et al. (2013) assessed oxygen consumption and gait speed after high- and 
low-intensity treadmill training. The high intensity treadmill group started at a 40% to 
50% of maximal heart rate and increased up to 70% to 80% of a maximal heart rate, 
whereas low intensity treadmill training started at 20% and increased up to 40-50% 
of maximal heart rate. Both high and low intensity treadmill training improved 
oxygen consumption (VO2) similarly (1.54 ml/kg/min increase after low intensity and 
1.53 ml/kg/min increase after high intensity treadmill training) (Shulman et al., 
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2013). On the other hand, Ridgel et al. (2016) reported no change in VO2 or any 
change in the cardiovascular response after aerobic training. However, his study 
included a combined aerobic-strengthening program and was not solely focused on 
aerobic training (Ridgel et al., 2016). 
 
2.4.2.4.  Walking economy and aerobic exercise  
Walking economy is defined as the required energy to perform a sub-maximal 
walking intensity (Christiansen et al., 2009). It is measured by the rate of oxygen 
consumption per distance during walking (Christiansen et al., 2009). PLwP suffer 
from a high walking economy in comparison with a non-Parkinson’s population (i.e., 
PLwP require higher energy for the same distance walked by age-matched healthy 
people) (Christiansen et al., 2009). Walking economy in PLwP was found to be 
affected by stride patterns, jerky movements and instability (Martinez-Martin, 1998). 
It was found that walking economy decreased after aerobic treadmill walking in 
PLwP (decrease in oxygen consumption around 1.3-1.21 mL/kg/ min) (Pelosin et 
al., 2009; Schenkman et al., 2012). However, these studies assessed treadmill 
walking economy but not overground walking economy (i.e., they assessed the 
energy required to walk on the treadmill, not on the ground). Only one study 
examined the effect of treadmill training and overground walking on overground 
walking economy in Parkinson’s (Fernández-del-Olmo et al., 2014). To achieve this, 
22 people with mild to moderate Parkinson’s (Hoehn & Yahr scale stage I-II) were 
randomly grouped into an overground walking intervention group and a treadmill 
training group for five weeks. Both groups were to walk at their preferred speed. 
Results of the study indicated that treadmill training, but not overground training, 
reduced overground energy expenditure (15.54 ± 3.24 ml/kg/min versus 
19.40 ± 4.78 ml/kg/min, respectively). Although this study used a small sample size 
(n=22), it is the only study that assessed overground walking economy in PLwP.  
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The increase in walking economy in Parkinson’s leads to excess fatigue and, in 
turn, could affect independence and quality of life (Christiansen et al., 2009). 
Further studies are needed to investigate functional (overground) walking economy, 
since this might affect participation and overall quality of life in this population. 
Cardiopulmonary parameters in Parkinson’s have not been extensively investigated. 
Moreover, there is a need to investigate whether non-motor impairments such as 
pulmonary impairment, including restrictive and obstructive patterns, and 
cardiovascular fitness are associated with walking economy in PLwP. There is a 
need to investigate the effectiveness of specific interventions aimed at improving 
cardiopulmonary function and walking economy in Parkinson’s. Table 10 
summarizes the main findings of the studies that investigated the effect of aerobic 
training on cardiopulmonary function and walking economy in PLwP.  
 
2.4.3.  Discussion 
Only a small number of studies have investigated the effects of aerobic exercise on 
cardiopulmonary function in PLwP, and revealed that aerobic exercise could help in 
improving cardiac fitness (by means of CPET). The advantages of aerobic exercise 
as an intervention include: considered as a cheap intervention; widely accepted; 
and could be conducted as a self-management intervention with minimum 
supervision needed.  
 
Most of the studies used similar intensities and frequencies recommended by the 
World Health Organization (WHO) (30–45 minutes of moderate intensity, three 
times per week) (World Health Organization, 2020). However, none of these studies 
investigated the effects of aerobic exercise on pulmonary function. Thus, future 
trials are recommended to investigate the effects of aerobic exercise on cardiac 
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fitness and pulmonary function in PLwP.  
 
The decrease in walking economy in PLwP could lead to more fatigue and, 
subsequently, could affect quality of life (Christiansen et al., 2009). Only two studies 
(Fernández-del-Olmo et al., 2014; Schenkman et al., 2012) assessed walking 
economy in PLwP. Investigating walking economy could help in understanding if 
PLwP are in need to consume more energy to walk, and if different interventions 
could affect energy consumption. It is obvious that there is a lack of knowledge 
about the factors that might affect walking economy in PLwP. Further studies are 
needed to determine functional (overground) walking economy, because this might 
affect functional activity and overall quality of life in this population. 
 
2.4.4.  Strengths and Limitations of the Review 
This review is the first review addressing the effects of aerobic exercise on 
cardiopulmonary function in PLwP. The search included studies from the last 
40 years and involved screening by two reviewers. It was not feasible to do meta‐
analysis because of the heterogeneity of the data and the outcome measures, and 
protocols used in the included studies.  
 
2.4.5.  Conclusion 
This review has addressed the effects of aerobic exercise training on 
cardiopulmonary function and walking economy in PLwP and revealed that aerobic 
exercise could help in improving cardiac fitness and walking economy. However, no 
studies have been conducted to investigate the effects of aerobic exercise on 
pulmonary function using spirometry in PLwP. Therefore, further research that may 




2.5. Summary of the literature review  
This chapter included three reviews that brought together findings from the 
published literature in order to achieve three goals:  
 
1. To review and discuss the published literature about prevalence and 
causes of pulmonary function impairments in PLwP. It is clear that there 
is a limited knowledge base in the area of pulmonary function in Parkinson’s. 
The review also reported different findings about the prevalence of 
obstructive and restrictive pulmonary patterns in PlwP in the earlier stages of 
the disease.  
 
2. To review and discuss the published literature about cardiopulmonary 
response to cardiopulmonary exercise test in PLwP. This review 
revealed contradictory findings in cardiopulmonary response to exercise 
when measured by CPET, which included higher, lower or similar 
cardiovascular response to exercise between PLwP and age-matched 
healthy controls. 
 
3. To review and discuss the published literature reporting the effects of 
aerobic training on cardiopulmonary function in PLwP. This review 
showed that there was an improvement in cardiopulmonary function in PLwP 
who participated in an exercise intervention, with key improvements reported 
in oxygen consumption, heart rate, respiratory rate and duration of exercise 
test. However, studies that investigated aerobic exercise effects on 
cardiovascular function did not include a pulmonary function test to assess the 
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effects on pulmonary function. Two studies investigated aerobic training 
effects on walking economy in Parkinson’s, and showed that high walking 
economy was present in mild to moderate Parkinson’s. These studies also 
showed a decrease in walking economy after aerobic interventions.  
 
2.6. Next steps 
Based on the findings of these three reviews, it seemed important to consider 
developing an exercise trial that could address pulmonary function, cardiopulmonary 
response to exercise (cardiac fitness), and to investigate if aerobic exercise has 
positive effects on cardiopulmonary fitness and pulmonary function in the early stages 
of Parkinson’s. However, it is important to run a pilot study before running the larger 
trial, and investigate aspects of feasibility of such a clinical trial, that could help in 
answering these questions. The next three chapters (Chapters 3-5) report on a pilot 
and feasibility study, the EXoCARP trial (also referred to as Study 1 in the thesis), 
with Chapter 3 outlining aspects of methodology, Chapter 4 reporting the findings of 
the trial, and Chapter 5 providing a discussion of the results.
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Chapter 3: Study 1: The effects of exercise on 
cardiorespiratory function in Parkinson’s - 
Methodology  
This chapter is about the methodology and methods of study 1, which aims to 
answer the below research question about the feasibility of conducting a future 
clinical trial of  aerobic exercise to improve cardiorespiratory function in Parkinson’s. 
The chapter starts with research questions and objectives, methodology and study 
design, methods, and end-up with description of the statistical analysis and 
qualitative data analysis used.  
 
3.1.  Research Questions  
A number of questions have arisen from the previous chapter (the three reviews’ 
findings): 
1. Is asymptomatic pulmonary impairment / pulmonary pattern present 
in people in the early stages of Parkinson’s? 
2. Are PLwP suffering from abnormal cardiovascular response to 
exercise (cardiac fitness) in the early stages of Parkinson’s (I-III in 
Hoehn and Yahr)? 
3. What are the effects of aerobic exercise training on cardiopulmonary 
function in people in the early stages of Parkinson’s?  
 
To answer these questions, a study that assesses the effects of aerobic exercise on 
pulmonary function and cardiac fitness is needed. However, before running a large 
clinical trial, conducting a study on a smaller basis is needed to understand if it is 
feasible and practical to conduct the main study. A pilot study is a small-scale, 
preliminary study which aims to investigate whether crucial components of a main 
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study, such a randomised controlled trial (RCT), will be feasible (Sim and Wright, 
2000). Accordingly, it is important to run a pilot and feasibility trial before running a 
larger trial that could help in answering these questions. Thus, the study aims to 
answer the key research question: 
Is it feasible and acceptable to run a trial that investigates the effects of aerobic 
exercise on pulmonary function and cardiovascular response in PLwP?  
 
3.2. Specific objectives of the study 
The primary purpose of this study was to pilot and establish feasibility of recruitment 
to, and delivery of, a clinical trial of an eight-week community-based and patient-led 
aerobic exercise programme compared with usual care to improve pulmonary 
function and cardiovascular response to exercise in PLwP. The research included a 
mixed methods pilot and feasibility study of an aerobic exercise programme 
compared with usual care, involving focus group interviews with trial participants to 
explore acceptability and feasibility of the exercise intervention and the outcome 
measures.  
 
3.2.1 Primary objective of the research was: 
The primary objective of the trial was to investigate the feasibility and acceptability 
to participants’ of delivering a trial of a self-managed 8-week aerobic exercise 
programme versus usual care, in the community, for PLwP at Hoehn and Yahr 
stages I-III.  
 
This study objective involved the following sub-objectives:  
1a:  assess if recruitment methods were effective, by calculating the  
 recruitment rate, number of people who contacted the research team, 
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 and number of people who were eligible to participate and ultimately 
 gave informed consent. 
1b:  calculate the attrition rate from the number of participants recruited 
 who subsequently dropped out. 
1c:  evaluate the screening tool and inclusion/exclusion criteria. 
1d:  evaluate feasibility, acceptability and practicalities of using the  
 outcome measures. 
1e:  explore feasibility of delivering the exercise intervention.  
1f:  explore participants’ experiences and the acceptability and suitability 
 of the aerobic exercise intervention, the outcome measures and  
 adherence to the intervention. 
 
3.2.2.  Secondary objective of the research:  
1. To assess pulmonary function in people with mild to moderate Parkinson’s. This 
objective helps to inform the next trial to target people who have abnormal 
pulmonary pattern (if found).  
 
3.2.3.  Criteria for assessing feasibility:  
 
1a:  Recruit 50 participants within a period of 20 months (from April 2019 to  
 December 2020), achieving a recruitment rate of >5%. 
1b:  Attrition rate <15%. 
1d:  Gain data about the practicalities of using the outcome measures and  
 devices, and conduct the assessment tests safely without adverse reactions 
 for the participants (assessed by the ability to conduct the tests with all 
 participants included, adverse reactions reported and participants’  
 experience data gained from the focus groups). 
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1e:  Deliver the interventions to the participant safely with the prescribed dose of 
 exercise (monitored by participants’ opinions and experiences about the  
 intervention, the dose and adverse reactions - where found). Additionally,  
 adherence to the exercise intervention monitored by the ability of   
 participants to perform around 30 minutes of moderate aerobic exercise per 
 day, three days per week, verified by the activity monitors and the daily  
 exercise diaries.  
 
A traffic light system was used to indicate the recommendations for the next trial 
according to the feasibility and acceptability results.  
 
3.2.4.  Criteria for assessing acceptability: 
1c:  Participants report that the outcome measures are comfortable and  
 acceptable (monitored from the focus groups).  
1d:  Participants report that the aerobic exercise intervention is comfortable and 
 acceptable (monitored from the focus groups). 
 
3.3.  Methodology  
In order to achieve the study aims, the methodology involved a randomised, single-
blinded mixed-methods feasibility study (The EXoCARP trial: Exercise effects On 
Cardio-Respiratory function in Parkinson’s), which included collection and analysis 
of both quantitative and qualitative data, as recommended by the Medical Research 
Council (MRC) guidance (Craig et al., 2008).  
 
The RCT is considered a methodology that can decrease bias within comparative 
studies (Boutron et al., 2007), by means of decreasing the preferential allocation of 
individual participants to one group or the other (allocation bias). Additionally, to 
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further reduce researcher-based-bias, blinding is used to prevent the assessor 
knowing to which group the participant belongs (Sim and Wright, 2000).  
 
A mixed-methods research design offers the ability to gain a larger image about 
experimental research in one research study (Albright et al., 2013). Incorporating 
qualitative data to gain more information about participants’ experiences in a 
specific intervention or event can allow detailed understanding of what is happening 
in the study and offers deeper analysis beside the quantitative data (Waterfield, 
2003). Additionally, it has been recommended previously that mixed-methods 
research could help in triangulating both quantitative and qualitative insights in a 
way that both sets of results complement each other with the flexibility to answer 
research questions more comprehensively (Albright et al., 2013). A combination of 
qualitative and quantitative methods has been used in social and behavioural 
sciences, within a research paradigm named as pragmatism, with mixed 
methodologies emerging that combine both quantitative and qualitative approaches 
(Tashakkori and Teddlie, 1998). 
 
There are around 40 mixed-methods research designs (Tashakkori and Teddlie 
2003). One of those designs is the mixed-methods sequential design. The mixed-
methods sequential design is commonly used by health researchers and includes 
collecting first quantitative and then qualitative data in two consecutive phases 
within one study (Ivankova, 2006). In EXoCARP, the mixed-methods sequential 
design was chosen with quantitative data collection followed by qualitative data 
collection in order to achieve the study goals. For example, the study goals 1d and 
1e necessitate the need to deliver the intervention and to run the assessment tests 
(for example the spirometer and CPET), then to collect data about participants’ 
experiences and opinions towards the intervention and outcome measures used. 
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Thus, the mixed-methods sequential design was considered to be the most 
appropriate design to serve the study goals of this trial.  
 
Research studies are categorised into explanatory, descriptive or exploratory 
studies (Elman, 2020). Explanatory research is about trying to find out if a specific 
hypothesis is correct i.e: attempts to clarify why and how a relationship, association 
or if relationships exist between two aspects of a situation or phenomenon (Elman, 
2020). Descriptive research presents specific details of a situation, social setting, or 
relationship, and aims to describe what is prevalent regarding a group of people or 
phenomenon or a program / intervention (Elman, 2020). Exploratory research 
investigates the possibilities of undertaking a particular research study and may 
function to test feasibility of a more systematic study or develop methods for a 
subsequent trial (Elman, 2020). Accordingly, EXoCARP is a mixed-methods 
sequential exploratory study, as it explores the feasibility of conducting a 
subsequent larger trial.  
 
Pilot studies are small-scale, preliminary studies which aim to assess whether 
components of a main study, such as an RCT will be feasible (Thabane et al., 2010; 
Van Teijlingen and Hundley, 2001). For example, they may be used in an attempt to 
predict an appropriate sample size for the full scale/larger study or to improve 
various aspects of the study design, interventions or outcome measures. This is 
because RCTs require time and money to be conducted, so it is crucial that the 
researchers have confidence in the key steps they will take when conducting large 
studies to avoid wasting time and resources (Van Teijlingen and Hundley, 2001). 
 
Feasibility and acceptability were the main focus of this study. Feasibility aims to 
monitor, evaluate and study the methods used in a study (O’Cathain et al., 2015), 
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aiming for a potential more definitive study. Feasibility includes monitoring 
recruitment of participants to a trial, evaluation of sites and settings, evaluation of 
inclusion/exclusion criteria of a trial, evaluation of ability to conduct the intervention 
and outcome measures used in a trial (O’Cathain et al., 2015). Acceptability covers 
important additions such as ability to accommodate the intervention in participants’ 
day-to-day life and perceptions of the intervention and outcome measures (Sekhon 
et al., 2017p.8).  
 
To gain insights into participants’ experiences related to the feasibility and 
acceptability objectives, a phenomenological approach was used, as it gives insight 
to and understanding of the human condition and experiences (Finlay and Ballinger, 
2006). Therefore, in order to explore participants’ experiences of the trial, a 
phenomenological approach was the most relevant approach to fulfil this objective. 
This was to explore, in particular: experiences of the intervention, including any 
challenges, barriers, or practical difficulties in adhering to it; experiences of and 
ability to wear the Actigraph; and experiences of and ability to do the assessment 
tests including the pulmonary function test and the cardiopulmonary exercise test. 
Overall, a mixed-methods randomised controlled trial that incorporates feasibility 
and acceptability will inform a subsequent larger clinical trial.  
 
According to the Medical Research Council (MRC) guidance (MRC, 2006) for 
developing complex interventions, the process of development of a complex 
intervention may take a wide range of different forms. The MRC (2006) guidance 
recommends developing interventions systematically, using a carefully phased 
approach, starting with a series of pilot and feasibility studies targeting the key 
uncertainties in the design, recruitment, outcome measures and intervention, then 
moving on to an evaluation phase, implementation, and development. However, 
evaluation still needs to be undertaken at the end of each stage, with a final 
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evaluation process at the end of all stages. This framework highlights the 
importance of taking time to develop and implement complex interventions, in order 
to enable rigorous analysis in future larger trials. The four distinct phases that have 
been identified for the development and implementation of research include 
feasibility/piloting, evaluation,  
implementation and development, presented in figure 9 below (Craig et al., 2008). 
According to the MRC framework, EXoCARP trial fits within the first phase 
(feasibility and piloting), as it includes testing feasibility of recruitment, the 
intervention, outcome measures and screening tools.  
 
 
Figure 9: Key elements of the development and process of evaluating complex 
interventions, Reproduced with permission of the Medical Research Council (Craig 
et al., 2008). 
 
3.4.  Outline of overall study design  
The chosen design was a mixed-methods, single blind, pilot and feasibility 
randomised controlled trial (RCT) with participants randomised to one of two 
groups: an aerobic exercise programme (intervention), or usual care (control, with 
usual care defined as participants’ usual physical activity level). Focus groups were 
conducted with participants from the exercise group to explore their experiences of 
the intervention and outcome measures. Double blinding was not feasible in this 
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trial, because participants need to know if they will be doing the exercise 
intervention or to continue their usual physical activity level as it is.  
 
Figure 10 represents the flow chart of the study. 
 
3.5.  Method  
3.5.1.  Research ethics approval   
The research team had reviewed the trial protocol and the trial was registered in the 
ISRCTN registry (ISRCTN14167992; https://doi.org/10.1186/ISRCTN14167992). 
Ethical approval was received from Keele University Ethical Review Panel (ERP) 
(Appendix 2), approved 07/03/2019, Faculty of Medicine and Health Sciences 
Research Ethics Committee (FREC) ref: MH-180006; MHFI-0003. 
 
During the early stages of the feasibility trial, one ethical amendment was required, 
relating to the randomization process. During the planning stages of the trial, 
randomization was stratified by age and sex; however, after conducting the first 
assessment session for the first participant (April 2019), we found that it would be 
more meaningful to randomize participants based on disease severity (Hoehn and 
Yahr score) and sex. Thus, approval for the amendment was received before 
continuing with further participants (Appendix 3).  
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Invitation to participate / recruitment of participants from Parkinson’s UK local groups  
Written informed consent  
Baseline measurements 
Computer randomization based on gender and disease severity  
Exercise group (n=25): aerobic 
exercise. 
Accelerometer worn during day-time 
Control group (n=25) to receive usual 
care. Accelerometer worn during day-
time  
Week 8 outcomes (post-intervention) 
Week 12 outcomes (follow-up) 
Focus groups  
Figure 10: Planned flow chart of the study. 
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All participants were required to provide informed consent (Appendix 4). 
Participants were free to withdraw at any time without giving any reason. Although 
individuals were subjected to testing used in standard clinical practice, any testing is 
not without some risk. The clinical assessment was unlikely to cause undue stress 
to participants. All participants were fully informed of testing procedures before 
participation and made aware they could withdraw from the study without reason at 
any time. Individuals were carefully monitored during testing by the researcher (PhD 
student, an HCPC registered physiotherapist). The care and comfort of the 
participants were ensured at all times. 
 
3.5.2.  Patient and public involvement and engagement (PPIE) 
During the trial planning phase, stakeholder meetings were undertaken to explore 
the interest and views of members of Parkinson’s UK. Thus, PPIE meetings were 
conducted with community-based Parkinson’s support groups in Stafford (n=32), 
Whitchurch (‘Friends of Parkies’) (n=26), Chester (n=12), Crewe (n=22), and Telford 
(n=26), at which an introduction to and overview of the proposed study were 
presented to group members. Members were asked for their feedback, suggestions, 
and comments on the proposed protocol. Participants’ feedback was taken into 
consideration while developing the protocol. In particular, they were asked to 
comment on: the study’s proposed requirement for participants to be able to get on 
and off a stationary bike; preference towards running on a treadmill compared to 
stationary cycling; ability to attend the assessment sessions at Keele University; 
and acceptability of wearing an accelerometer every day during the trial.  
 
Group members reported that they would prefer the cycle test to the treadmill test 
and reported that they felt it would be more stable even if they had a harness for the 
treadmill. Also, most of them reported that they would feel uncomfortable wearing 
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the oxygen consumption face mask during an exercise test, with some reporting 
experiences of claustrophobia. Additionally, most of them confirmed that they would 
be able to get on and off a stationary cycle.   
 
3.5.3.  Study protocol 
The study protocol was published in the IRCTN registry (ISRCTN14167992, 
https://doi.org/10.1186/ISRCTN14167992) under the title: Can exercise improve 
heart and lung function in people with Parkinson’s? The EXoCARP study. The 
protocol is described within the below sections in this chapter. The SPIRIT checklist 
(Standard Protocol Items: Recommendations for Interventional Trials), was followed 
while writing the following sections to aim for a better quality of reporting. The 
SPIRIT checklist for the trial is represented below. 
 
3.5.4.  Population and sample size  
3.5.4.1.  Sample size 
According to recommendations for pilot and feasibility studies (Browne, 1995; 
Lancaster et al., 2004), a sample size of at least 30 is needed. We aimed to recruit 
a maximum of 50 participants (25 per group) to allow for 10% attrition (drop-out) 
(Sim and Wright, 2005), and to provide a sufficiently large sample to estimate 
values (standard deviation) for the primary outcome measure, which will inform a 







SPIRIT 2013 Checklist: Recommended items to address in a clinical trial protocol 





Title Descriptive title identifying the study design, population, 




Trial identifier and registry name. If not yet registered, name 




Rationale Description of research question  ___59__ 
Objectives Specific objectives or hypotheses __60-61_ 
Trial design Description of trial design including type of trial, allocation 





Study setting Description of study settings  __74__ 
Eligibility 
criteria 
Inclusion and exclusion criteria for participants.  __73-74_ 
Interventions Interventions for each group  _92_ 
Outcomes Primary, secondary, and other outcomes _75-91_ 
Participant 
timeline 
Time schedule of enrolment, interventions and assessment 
sessions. A schematic diagram is highly recommended  
_68__ 
Sample size Estimated number of participants needed to achieve study 
objectives  
___70___ 
Recruitment Strategies for achieving adequate participant enrolment to 
reach target sample size 
__74--_ 
Allocation:   
Sequence 
generation 
Method of generating the allocation sequence (eg, computer-









Who will be blinded after assignment to interventions (eg, trial 





Statistical methods for analysing primary and secondary 
outcomes. Reference to where other details of the statistical 






Plans for seeking research ethics committee/institutional 




Plans for communicating important protocol modifications (eg, 
changes to eligibility criteria, outcomes, analyses) to relevant 
parties (eg, investigators, REC/IRBs, trial participants, trial 




Who will obtain informed consent or assent from potential trial 







Model consent form and other related documentation given to 
participants and authorised surrogates 
_276-277 
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3.5.4.2.  Inclusion criteria: 
• Adults over 18 years old, diagnosed with Parkinson’s according to the UK Brain 
Bank Criteria (Appendix 5). 
• Disease severity classified between I-III according to the Hoehn and Yahr scale 
(Appendix 6). People with Hoehn and Yahr score I-III are able to walk 
independently without assistance from others. Since participants were 
requested to do aerobic exercise, they needed to be walking independently 
during the study.  
• Ability to stand and walk for at least 10 meters without assistance from another 
person. However, walking aids such as sticks were acceptable.  
• Mini-Mental State Examination score (MMSE) >24 (Appendix 7). Participants 
with cognitive impairment were excluded because they need to understand 
instructions relating to the intervention and the assessment tests.  
 
3.5.4.3.  Exclusion Criteria 
• Pre-existing diagnosis of lung disease, e.g. chronic obstructive pulmonary 
disease (COPD), asthma, bronchiectasis, emphysema, lung cancer.  
• Current smoker. 
• Participants with a history of heart disease that would present a risk of adverse 
cardiac event in response to the sub-maximal exercise tests (in accordance with 
the American Heart Association/ American College of Sport Medicine 
guidelines): such history includes myocardial infarction, congenital heart 
disease, heart attack, pacemaker/implantable cardiac defibrillator, heart valve 
disease or surgery within 3 months, unstable angina, uncontrolled arrhythmias, 
uncontrolled heart failure and angioplasty, as identified using the American 
Heart Association/ American College of Sport Medicine (AHA/ACSM) 
Health/Fitness Facility Pre-Participation Questionnaire (Appendix 8). 
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• Any other previously diagnosed musculoskeletal or neurological disorder that 
may prevent participation in physical activity.  
• Inability to understand English language (for the purpose of understanding 
instructions and information related to the study, as no interpreter is available).   
 
3.5.5.  Recruitment 
Participants were recruited from local Parkinson’s UK groups. Permission was 
obtained from group leaders to approach group members. Then, an invitation letter 
(appendix 9), a participant information sheet (appendix 10), and a consent form 
(appendix 4) were sent to group members with Parkinson’s by the group leader, by 
either email or post, according to preference. Those interested in the study were 
asked to contact the research team by email, telephone or letter, and were given 
opportunity to ask further questions about the study before deciding whether to 
participate or not. An appointment was made for them to attend their first 
assessment, which took place in the School of Allied Health Professions at Keele 
University, at which they were asked to sign the consent form and complete a 
health screening questionnaire (AHA/ACSM Health/Fitness Facility Pre-participation 
Screening Questionnaire – Appendix 8) to screen for eligibility/inclusion. 
Recruitment was not limited to a specific ethnicity, gender or age group (except 
being an adult). 
 
3.5.6.  Assessment sessions   
Demographic and clinical data including age, sex, current medications, weight, 
height, years since Parkinson’s diagnosis, Hoehn and Yahr stage, and dominant 
symptoms, were collected from those who consented to participate and were found 
to be eligible for inclusion. Baseline measurements (first assessment session) were 
recorded by the principal investigator (AA). Assessment included spirometry, CPET 
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and the questionnaires (PDQ-39, Barthel Index, Non-Motor Symptoms 
Questionnaire, Prospective-Retrospective Memory Questionnaire, and the Geriatric 
Depression Screening Questionnaire; details about the outcome measures are in 
the following sections). All participants (both groups) were given Actigraph 
accelerometers and asked to wear them for a period of eight weeks (further 
information about the accelerometer in the following sections).  
 
On completion of baseline assessments, participants were randomly allocated to 
their groups. Participants in the control group were asked to behave as they usually 
do and not to change in their lifestyle. 
 
The second assessment session was after eight weeks (end of intervention), at 
which accelerometer data was downloaded, and spirometer, CPET and the 
questionnaires were measured. 
 
The third assessment session was after four weeks post intervention (follow-up), 
where spirometry and CPET were measured.   
 
3.5.7.  Outcome measures   
3.5.7.1.  Physiological measures 
3.5.7.1.1.  Pulmonary function test (PFT) 
Pulmonary function test (PFT) is an evaluation of the respiratory function (Burrows, 
1975). The primary goal of PFT is to investigate the severity of pulmonary 
impairment (Burrows, 1975). The gold standard for performing the PFT is 
spirometry (Burrows, 1975). The spirometry was assessed using a spirometer 
(CareFusion, Microlab, figure 11), and in accordance with the European Respiratory 
Society/American Thoracic Society (ERS/ATS) guidelines (Miller et al., 2005). The 
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best of three consecutive blows was used to obtain the FEV1, FVC and FEV1/FVC 
ratio (Miller et al., 2005).  
Results were compared with norms from the Global Lung Initiative, to get the 
predicted percent values (Global Lung Initiative, 2012). The following instructions 
and procedures were followed:  
 
Participant preparation (pre-test) 
Before conducting the pulmonary function test, participants were asked not to 
smoke or to eat a large meat at least one hour prior to the test and not to wear 
clothes that would be restrictive to movement. 
 
Position of the participant during the test 
Participants were seated upright with back supported, feet flat on the floor using a 
chair with arm rests and without wheels. The participants put on a nose-clip and 
breathed through a rigid mouth-piece that was connected to the spirometer. 
 
Performing and recording the test (according to the standardized European 
Respiratory Society/American Thoracic Society guideline) (Miller et al., 2005) 
The assessor explained and demonstrated the test manoeuvre to the participants, 
and instructed the participants to place the disposable mouthpiece in their mouth 
and to put a nose-clip on the nose. The participants were encouraged to breath 
quietly to become accustomed to the apparatus and to attain a steady breathing 
pattern. At the end of expiration, the participants were encouraged to inhale 
maximally and rapidly to attain the total lung capacity (TLC). The participants were 
instructed to make maximal expiratory effort, blowing out as hard and as fully as 





Figure 11: MicroLab Spirometer. 
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The participants were instructed to return to their normal breathing pattern and 
remove the mouthpiece and nose-clip and rest. The procedure was repeated for a 
minimum 
 
Criteria for accepting the manoeuvres 
Manoeuvres were rejected if: participants did not inspire to TLC initially; participants 
coughed during the first second of exhalation; mouthpiece was obstructed by 
tongue or teeth; participants started the expiratory effort poorly coordinated; there 
was an air leak at the mouthpiece; participants failed to expire fully to reserve 
volume (RV); or effort appeared submaximal. 
 
Between-manoeuvre criteria 
After three acceptable manoeuvres had been obtained, the following were applied: 
• The two largest values of FVC must be within 0.150 L of each other.  
• The two largest values of FEV1 must be within 0.150 L of each other. 
If both of these criteria were met, the test session was concluded. If both of these 
criteria were not met, the test was continued until: 
• Both of the criteria were met with analysis of additional acceptable 
manoeuvres; or  
• A total of eight tests had been performed (optional); or  
• The participant could not or should not continue. 
 
3.5.7.1.2.  Cardio-Pulmonary Exercise Test (CPET) 
Exercise work capacity was measured using incremental cycle ergometry. Tests 
were performed on an electrically braked cycle ergometer while monitored with 
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workload (resistance of the cycle ergometry), heart rate (measured by a Polar H10 
(Polar, Kempele, Finland)), estimated peak oxygen consumption (VO2 peak = 15 x 
(HR peak ÷ HR resting)) and rate of perceived exertion (RPE), measured by the 
Modified Borg Scale (Appendix 11). The Modified Borg scale allows individuals to 
subjectively rate their level of exertion during exercise or exercise testing by asking 
participants to rate the exertion level on a scale from 0 to 10, where 0 means resting 
state (no exertion at all) and 10 means maximum exertion (American College of 
Sports Medicine, 2010). The CPET was carried out in accordance with the 
standards and recommendation of the American College of Sport Medicine (ACSM) 
(American College of Sports Medicine, 2013). Written instructions along with a 
description of the evaluation were provided well in advance of the appointment so 
the participant could prepare adequately. Prior to the test, participants were 
instructed to: refrain from ingesting food, alcohol, or caffeine or using tobacco 
products within 3 hours of testing; be rested for the assessment, avoiding significant 
exertion or exercise on the day of the assessment; wear clothing that permits 
freedom of movement and includes walking or running shoes; be aware that the 
evaluation may be fatiguing and that they may wish to have someone accompany 
them to the assessment to drive home afterward; continue their medication regimen 
on their usual schedule so that the exercise responses are consistent with 
responses expected during exercise training; bring a list of their medications, 
including dosage and frequency of administration, to the assessment and should 
report the last actual dose taken; drink ample fluids over the 24-hour period 
preceding the test to ensure normal hydration before testing; and fill the AHA/ACSM 
Health/Fitness Facility Pre-Participation Questionnaire (Appendix 8).  
 
The following was accomplished before starting the test 
Prior to conducting the test, the assessor provided participants with the consent 
form and allowed time for the individual undergoing assessment to have all 
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questions adequately addressed before signing the form, maintained the room 
temperature between 68F and 72F (20C and 25C), re-explained the CPET to the 
participants to confirm that they understood it.  
 
The CPET was done within the “on” state of the antiparkinsonian drugs (i.e.; 
approximately 45 minutes to one hour after taking the drug). The assessor 
calculated 70% of the age-predicted HR prior to conducting the test. For example, 
for a 50-year-old person, the estimated maximum age-related heart rate would be 
calculated as 220 - 50 years = 170 beats per minute (bpm).  
 
The 70% levels would be: 
70% level: 170 x 0.70 = 119 bpm 
Thus, a 50-year old participant would complete the exercise test below 119 bpm.  
 
Procedure of the CPET 
The assessor recorded resting heart rate (HR) and blood pressure before the test 
after an initial resting period for at least 30 minutes. Then, a three-minute warm-up 
period of slow pedalling without resistance was conducted. After that, the test 
started with an individualized ramp protocol, to aim for a sub-maximum exercise 
capacity to be achieved within 8-12 minutes, with a target cadence of approximately 
50-60 round per minute (rpm). 
 
Predicted maximum workload and work rate (ramp rate) was calculated using the 
following formulae:  
Wmax= -115.756+(2.271*age) + (4.043*weight) 
For example; if the participant was 70 years old and weighted 65 Kg, then 
the predicted maximum workload would be: 
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Wmax= -115.756+(2.271*70) + (4.043*65) = 306.009 Watts 
To aim for an exercise duration around 12 minutes, work rate would be: 
Wrate = Wmax/12= 306.009/12 = 25.5 Watts for an estimated 12-minute 
exercise test. 
Therefore, 25 Watts could be selected, or otherwise the closest appropriate 
option offered by the software.  
 
Finally, the test finished by doing a six-minute recovery period (slow pedalling 
without resistance).  
 
Blood pressure, HR, perceived rate of exertion (Borg scale- Appendix 11), and VO2 
measurements were recorded throughout the test (each minute) and during the 
recovery period. Test duration and maximum workload achieved were recorded.  
 
The exercise was stopped if any of the following occurred  (American College 
of Sports Medicine, 2013) 
• Onset of angina or angina-like symptoms. 
• Significant drop in systolic blood pressure or a failure of the systolic blood 
pressure to rise with an increase in exercise intensity. 
• Excessive rise in blood pressure. 
• Signs of poor perfusion: light-headedness, confusion, poor muscle 
coordination, paleness, blue or gray skin color, nausea, or cold and clammy 
skin.  
• Failure of heart rate to increase with increased exercise intensity. 
• Subjects request to stop. 
• Physical or verbal manifistations of severe fatigue. 
• Failure of the testing equipment.  
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• HR raised above 70% of age-predicted HR.  
 
3.5.7.2. Function and activity outcome measures 
3.5.7.2.1. Physical activity level   
Level of physical activity was measured objectively by using an Actigraph 
accelerometer (ActiGraph, Florida). The Actigraph (figure 12) is a triaxial 
accelerometer that detects human movement, levels of physical activity, and energy 
expenditure. Actigraph devices were found to have high construct validity when 
compared with self-reported physical activity measures in PLwP in terms of step 
count (r= 0.56, p = 0.003), and moderate to vigorous physical activity level (r=0.98, 
p=0.0003) (Mantri et al., 2019).  
 
While the researcher was searching for the best activity monitor for this study, two 
main devices came out of the search for PLwP. These were: the Actigraph and the 
activPal. However, after contacting the activPal producer and attending a seminar 
for the developer, the researcher confirmed that the activPal was not able to pick up 
very slow movements, such as bradykinesia, and might include tremor as a physical 
activity. In contrast, Actigraph has separate formulae that are validated for PLwP to 
record bradykinesia and to avoid recording tremor as a movement (Pan et al., 
2013). Thus, for this study, the Actigraph data was used as the main outcome for 
monitoring physical activity and adherence to the intervention.  
 
Participants were given the Actigraph in the first assessment session and were 
asked to wear it, using the belt provided (Figure 12), around their waist during 
daytime except for showering or swimming. At the end of the intervention, at week 
8, the devices were returned by the participants and data were downloaded using 














Figure 12: The Actigraph activity monitor and wearing in around the waist. 
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Choosing the area “around the waist” for PLwP is recommended to: 1) avoid 
overestimation of movement due to wrist/ankle movement; and 2) to reduce tremor 
effects and counting tremor as a physical activity movement if worn around the wrist 
or ankle.  
 
Moderate to vigorous physical activity (MVPA) and number of steps/day were 
retrieved from the Actigraph. The following were the cut-points used for different 
activity levels as defined by the Actigraph: 1.5 to 2.9 METs or 100 to 759 counts per 
minute (cpm) for light physical activity; 3 METs or 760–2,019 cpm for moderate 
physical activity; and ≥3 METs or ≥2,019 cpm for vigorous physical activities 
(Matthew, 2005; Pan et al., 2013; Troiano et al., 2008).  
 
In order to know which activities are normal (usually conducted before the study), 
and which activities are extra (on top of a participant’s usual activity – as part of the 
intervention), participants were asked to complete a daily physical activity diary and 
to mark the extra amount of time spent on exercise on top of their usual physical 
activity level. While doing the Actigraph analysis, the researcher matched the time 
of the extra activities as reported by the diaries with the activities in the Actigraph 
results to identify usual and extra time of exercise in terms of intensities.  
 
3.5.7.3. Subjective outcomes and questionnaires  
3.5.7.3.1. Quality of life 
Quality of life was assessed using the Parkinson’s Disease Quality of Life 
Questionnaire (PDQ-39). PDQ-39 has been found to have acceptable internal 
consistency (α = 0.51 to 0.96) and to be reproducible (r =0.96, p < 0.001) (Peto et 
al., 1998). The PDQ-39 was chosen for this study due to its items being specified to 
aspects of PLwP life, and how Parkinson’s affects the participant’s life. This was not 
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the case with other quality of life scales such as the European Quality of Life Scale 
(EQ-5D), or the Older People's Quality of Life Questionnaire (OPQOL). 
 
The PDQ-39 (Appendix 12) is a widely used questionnaire with 39 questions 
measuring the effects of Parkinson's on quality of life, covering eight dimensions 
(Peto et al., 1998):  
• Mobility  
• Activities of daily living 
• Emotional well-being  
• Stigma  
• Social support  
• Cognitions  
• Communication  
• Bodily discomfort 
 
Participants were asked to think about their health and general well-being and to 
consider how often in the last month they had experienced certain events (e.g. 
difficulty walking 100 yards). They were asked to indicate the frequency of each 
event by selecting one of 5 options on an adverbial rating Scale:  
• Never 
• Occasionally  
• Sometimes 
• Often 
• Always or cannot do at all.  
 
 95 
The PDQ-39 provides scores on an ordinal scale for each of the eight scales and a 
sum of them for the overall score. Both subscales and the overall scores were 
calculated for the PDQ-39 data. The lower the PDQ-39 scores, the better the quality 
of life.  
 
3.5.7.3.2. Non-motor symptoms  
The non-motor symptoms general screening was assessed using the Non-Motor 
Symptoms questionnaire (NMS). The NMS is the only tool that assesses non-motor 
symptoms for Parkinson’s. The NMS (Appendix 13) is a single-page self-
administered questionnaire that contains 30 items that generally screen non-motor 
symptoms (Romenets et al., 2012). The symptoms are listed in items, and the 
participants can answer with Yes or No on each item (nominal scale). The NMS 
questionnaire has been found to have high sensitivity and specificity (71.8% and 
88.5% respectively) (Romenets et al., 2012).  
 
3.5.7.3.3. Independence in activities of daily living   
Independence in activities of daily living (ADL) was subjectively assessed using the 
Barthel Index (Appendix 14). The Barthel Index is widely used in geriatric 
populations, and has been found to have a high construct validity when compared 
with the PDQ-39 (r = 0.64, P < 0.00) tool to assess ADL in Parkinson’s (Morley et 
al., 2012). The Barthel Index consists of 10 items that measure a person's daily 
functioning, particularly the activities of daily living (ADL) and mobility (Morley et al., 










The scoring system depends on participants’ answers on each item, on a score 
from 0 to 2: 
• 0 = dependent  
• 1 = needs some help, but can do something alone  
• 2 = independent  
 
Scores on the items are added to create a total score. The total possible score 
ranges from 0 – 20, with lower scores indicating increased dependency (Morley et 
al., 2012). For this study, the total score of the Barthel Index was calculated and 
treated as ordinal data. The ten-item version of the Barthel Index was chosen over 
the other versions (for example: the short form 5-item, and the long form 15-item 




Memory was assessed using the Prospective-Retrospective Memory Questionnaire 
(PRMQ) (Appendix 15). The PRMQ is a 16-item questionnaire (eight items 
measuring prospective memory and eight items measuring retrospective memory) 
(Smith et al., 2000). Each participant was asked to rate the frequency of occurrence 
of each type of memory failure in their daily life on a 5-point ordinal scale (Smith et 
al., 2000). The answers were based on a five-point adverbial rating scale: 
• Very Often  
• Quite Often  
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• Sometimes  
• Rarely  
• Never 
 
The PRMQ has been found to have high sensitivity (93%) and specificity of 71% in 
older population (Foley, 2007). The PRMQ is the only tool that assesses 
prospective and retrospective memory. The optimum cut-off point is 31 for the 
PRMQ total score, 16.5 (mean rating of 3.3 points) for the prospective memory 
subscale, and 18.5 (mean rating of 3.08) for the retrospective memory subscale 
(Hsu et al., 2014). 
 
3.5.7.3.5. Depression 
The Geriatric Depression Scale (GDS) (appendix 16) has been tested and used 
extensively with an older population. The GDS Long Form is a brief, 30-item 
questionnaire (long form) and 15-item questionnaire (short form), in which 
participants are asked to respond by answering ‘yes’ or ‘no’ to statements based on 
how they felt over the past week (Sheikh and Yesavage, 1986). In the short form, 
10 items indicate the presence of depression when answered positively, while the 
rest (question numbers 1, 5, 7, 11, 13) indicate depression when answered 
negatively (Sheikh and Yesavage, 1986). Scores of 0–4 are considered normal, 
depending on age, education, and complaints; 5–8 indicate mild depression; 9–11 
indicate moderate depression; and 12–15 indicate severe depression (Sheikh and 
Yesavage, 1986).  
 
The GDS was found to have a 92% sensitivity and a 89% specificity when 
evaluated against diagnostic criteria (Lesher and Berryhill, 1994). The construct 
validity and test-retest reliability of the tool have been supported through both 
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clinical practice and research. In a validation study comparing the Long and Short 
Forms of the GDS for self-rating of symptoms of depression, both were successful 
in differentiating depressed from non-depressed adults with a high correlation (r = 
0.84, p < .001) (Sheikh and Yesavage, 1986).  
 
3.5.7.3.6. Physical activity survey 
In addition to the Actigraph data, participants were asked to fill in a physical activity 
survey (Appendix 17). The survey asks about number of minutes spent in aerobic 
exercise per week, mode of exercise, dyspnoea during exercise, and smoking 
status.  
 
Table 11 summarizes the outcome measures used in the trial.  
 
3.5.8. Randomization and blinding 
Participants were randomly allocated by computer to either an aerobic exercise 
program in addition to usual care, or to usual care, stratified according to Hoehn 
and Yahr stage and gender. Computerised block randomization was used, with a 
ratio of 1:1, and this was achieved using block randomization, with blocks of four 
and two. The outcome assessor (AA) was blind to group allocation. Following 
randomization, a second researcher (SH) provided the intervention or control group 
instructions for participants according to group allocation. After week 8 session, the 
assessor was asked to guess to which group each participant had been allocated, 
in order to assess for success of blinding. 
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Table 11: Outcome measures used in the trial 
Domain Outcome measure  
Pulmonary function Pulmonary function test (spirometry). FVC, FEV1 and 




Cycle-cardiopulmonary exercise test (CPET). The following 
were derived:  
•   Predicted peak oxygen uptake (VO2 peak). 
•   Heart rate (HR). 
•   Resting systolic blood pressure (SBP) and diastolic blood     
pressure (DBP). 
•   Maximum workload (power of the cycle) achieved. 
•  Test duration (how many minutes did the patient tolerate 
before stopping the test). 
•    The AHA/ACSM Health/Fitness Facility Pre-Participation 
Physical activity 
level 
Actigraph data including: 
•    Minutes spent in low, moderate, moderate to vigorous, 
vigorous and sedentary activities. 
•    Steps per minute  
 
Daily physical activity diaries  
 
Physical Activity Survey  
Quality of life Parkinson’s disease quality of life questionnaire (PDQ-39) 
Depression The Geriatric Depression Screening Questionnaire 
Independence in 





Non-motor symptoms questionnaire 
Memory Prospective-Retrospective Memory Questionnaire 
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3.5.9. Intervention 
Participants in the exercise group were asked to engage in an 8-week programme 
of aerobic exercise (e.g. outdoor walking in the community, walking on the treadmill, 
stationary cycling, rowing on a row machine, running) according to their preference. 
They were asked to maintain the aerobic exercise for at least 30 minutes per day, 
for at least three days per week, for the eight weeks. Participants were not 
supervised and only the activity monitors recorded their exercise level (refer to next 
section for more information about assessment of adherence). Moderate aerobic 
exercise intensity was defined as activities that make the person work hard enough 
to raise his/her heart rate and break into a sweat, but still be able to talk while doing 
it (American College of Sports Medicine, 2013). Behavioural change models were 
not considered during the development of the intervention of this trial. This is 
because the researcher wanted to explore the adherence to the intervention. If 
adherence to the intervention was found to be poor, then using a behavioural 
change model would be needed.  
 
The intervention was selected based on aerobic exercise training studies that have 
consistently resulted in improvements in cardiorespiratory fitness and maximal 
oxygen uptake (VO2max) in PLwP (Burini et al., 2006; Fernández-del-Olmo et al., 
2014; Mavrommati et al., 2017; Ridgel et al., 2016; Schenkman et al., 2012; 
Shulman et al., 2013). The intervention in most of these studies has involved 
exercise durations of 30 to 40 minutes per session, for two to five days per week. 
The eight weeks intervention period was used according to the recommendations of 
the British Thoracic Society (BTS) guidelines, which state that at least eight weeks 
of aerobic exercise is needed in pulmonary rehabilitation to improve quality of life in 
respiratory patients (British Thoracic Society, 2001).  
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Behavioural change models have been recommended to be used in interventions 
targeting behavioural change, including exercise interventions, in PLwP (Glanz et 
al, 2010). The Health Belief Model (HBM), the Theory of Reasoned Action (TRA), 
the Theory of Planned Behaviour (TPB), the Trans-Theoretical Model (TTM) and the 
Social Cognitive Theory (SCT) are the main behavioural change models (Taylor et 
al., 2006).  
 
The HBM includes objective demographic and other variables such as cues to 
action not included in the other models’ specifications (Rosenstock  et al., 1994). 
The model is based on the theory that a person's willingness to change their health 
behaviours is primarily due to their health perceptions. However, the HBM has a 
weak predictive power for changing the behaviour (Taylor et al., 2006). This is due 
to weaknesses in the predictive validity of the HBM’s core psychological 
components (Armitage and Conner 2000; Harrison et al., 1992). Thus, it was not 
used in EXoCARP.  
 
The TRA and the TPB are framed at higher levels of generalisation than the HBM 
(Ajzen, 1998). Both models share identical attitudinal and social norm related 
components (Fishbein and Ajzen, 1975). The TRA explains that an individual's 
decision to engage in a particular behaviour is based on the outcomes the individual 
expects will come as a result of performing the behaviour. The TPB explains that 
intentions are influenced by the attitude about the likelihood that the behaviour will 
have the expected outcome and the subjective evaluation of the risks and benefits 
of that outcome. The TRA and the TPB are statistically better specified than the 
HBM and the TTM, and they have more precisely defined components. This may 
enhance the efficiency and consistency of the use of both the TRA and TPB (Taylor 
et al., 2006). However, both the TRA and the TPB were found to change behaviour 
in non-health related research only as reported by a systematic review and a meta-
 102 
analysis (Taylor et al., 2006). Subsequently, both the TRA and the TPB were not 
suitable to be used in EXoCARP.  
 
Noar and Zimmerman (2005 ) assessed the components of HBM, the TRA, the 
TPB, and the TTM in terms of structures appertaining to: attitudinal beliefs; self-
efficacy and behavioural control beliefs; normative beliefs; risk related beliefs and 
emotional responses; and intention, commitment and planning. None of the models 
were considered to be specified enough to incorporate and interpret the significance 
of social, economic and environmental factors as predictors and determinants of 
health behaviour (Noar and Zimmerman, 2005); the components and psychological 
components they contain relate to cognitions and perceptions that are part of a 
person’s response to their environments (Kippax and Crawford 1993). Although 
descriptions of the HBM include demographic and socioeconomic variables, a 
systematic review and a meta-analysis identified that, in practice, the HBM has not 
normally been used effectively to reflect responses to environments (Taylor et al., 
2006). When these models are used, there might be failures to record information 
relevant to such factors (Taylor et al., 2006). This could lead to cost ineffectiveness 
for interventions aimed at changing the environmental and organisational 
determinants of health behaviour (Ferguson et al., 1996). Additionally, this might 
increase health inequalities (Taylor et al., 2006). Thus, the HBM, the TRA, the TPB, 
and the TTM were not suitable to be used in EXoCARP.  
 
Bandura’s (1986) Social Cognitive Theory (SCT) positions self-efficacy and 
outcome expectancies (related to situation and action) as the main determinants of 
behaviour. Outcome expectations depend on perception that some consequences 
are determined by the environment and are therefore divorced from personal control 
(Taylor et al., 2006). Additionally, outcome expectations are related to the belief that 
one’s actions are instrumental to a particular outcome. Self-efficacy relates to 
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confidence in person’s own ability to carry out a particular behaviour. Thus, the 
social cognitive theory predicts that behaviours are performed if a person perceives 
control over the outcome, few external barriers, and confidence in the person’s own 
ability (Taylor et al., 2006). t has been reported that PLwP with high self-efficacy 
were more likely to engage in regular exercise (Ellis et al., 2011). Subsequently, the 
SCT might be the most suitable health behavioural change model to be used in 
trials such as exercise trials. However, considering that EXoCARP was a feasibility 
trial, and did not aim for behavioural change, it was not considered necessary at this 
stage to use these models. 
 
Participant adherence 
Participants were provided with an accelerometer to wear constantly during daytime 
unless bathing, showering or swimming. This was one way of monitoring adherence 
to the exercise intervention. Additionally, participants were asked to complete an 
activity diary (Appendix 18) of their exercise during the eight weeks period. 
 
3.5.10. Participants’ experiences of the study and the 
acceptability and feasibility of the intervention, outcome 
measures (focus groups) 
Qualitative research is concerned with how people make sense of the world and 
experience events (Finlay and Ballinger, 2006). This cannot be extracted from 
quantitative research, but in mixed methods studies the combination of quantitative 
and qualitative data could provide a more holistic view on what is happening with 
the participants. In the case of this trial, it was beneficial to collect physiological 
outcomes, including pulmonary function and cardiac response, quantitatively. 
However, participants’ feedback about their experiences of participating in the 
study, experiences and acceptability of the intervention and the use of Actigraph 
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monitors and other outcome measures and tests undertaken as part of the trial were 
explored to generate qualitative data.  
 
3.5.11. Focus groups 
In order to address research objectives 1c, 1d, 1e, and 1f, to explore the feasibility 
and acceptability of the trial, focus groups were undertaken (Sim and Snell, 1996; 
Tong et al., 2007). A focus group is a type of group discussion, which is managed 
by a moderator who encourages interactive conversation and collects opinions from 
the participants of the group, aiming for qualitative data that is related to a specific 
topic area (Sim and Snell, 1996). Additionally, it is recommended that an observer 
and field-note taker attends the focus groups to provide additional insights behind 
the interactions of participants and to reduce bias associated with a single 
investigator (Archibald, 2016). 
 
 
The suitability of the focus group in exploring peoples’ experiences, attitudes, views, 
feelings and motives about health has been reported (Thomas et al. 
1992; Hyden & Bulow 2003). Focus groups were found to be a good tool for older 
people, as they tend not to provoke anxiety (Gray-Vickrey 1993). The advantage of 
using focus groups is that they do not discriminate against people who cannot read 
or write, or people with visual impairment (Kitzinger 1996). Additionally, focus 
groups can encourage participation from people who are shy to speak alone, or who 
might feel ‘put on the spot’ if interviewed alone (Kitzinger 1996). Furthermore, focus 
groups are helpful for people who feel they have nothing to say but may 
subsequently participate in a discussion initiated by others (Kitzinger 1996). 
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On the other hand, focus groups do have some disadvantages; for example, some 
people may feel uncomfortable discussing and expressing their views in front of 
others (Morgan 1988). However, the focus groups in this research were generally 
undertaken to discuss participants’ experience of the trial and did not include 
discussions about personal topics. The choice of focus group over the interviews 
was considered because the aim was to explore the overall experience of the trial 
being common for all participants, and to explore any individual differences in those 
common experiences, which might be discussed more fully in a focus group during 
wider discussion. For example, someone’s comments might trigger thoughts and 
words from someone else, which might not come out in an interview if the 
differences were not apparent.  
 
 
Participants who completed the exercise intervention were asked to participate in 
one focus group, lasting up to no more than one and a half hours. Invitation to 
participate in the focus groups was not limited to a specific ethnic group, age group 
or gender. Two focus groups were conducted, with the aim of a minimum of three 
and a maximum of 12 participants in each group. The optimum number of 
participants per group is approximately eight (Morgan, 1997), but this was 
dependent on the number of participants able and willing to attend. The groups 
were run after at least four weeks post-intervention, to explore the participants’ 
experiences and views of the intervention, and its perceived effects, including 
quality of life, and to identify and explore barriers to exercise. In the first focus 
group, participants sat around a table in a circle, so they could see each other and 
hear each other easily.   
 
A focus group topic schedule that included both open and closed questions 
(Appendix 20) was used to serve as a guide to the topics covered during the 
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interview. The focus group interview schedule was developed in advance by the 
researcher and members of the supervisory team. Additionally, the focus group 
questions were discussed with two physiotherapists who have experience in 
research related to older adults. The process of developing the focus group 
questions involved a series of back-and-forth revisions between the researcher, the 
supervisory team and the two physiotherapists until producing the final version. 
Appendix 19 is the first draft of the focus group questions, and Appendix 20 is the 
final version of the focus group schedule which was used.  
 
The questions were printed and distributed around to each participant. This acted 
as a reminder for them to keep focusing on the topic (Kroll et al., 2007). However, 
the second focus group was conducted online due to the Corona-Virus (COVID-19) 
pandemic governmental regulations to minimise the spread of the virus. Thus, the 
second focus group was conducted virtually (online) using the Google Meet 
platform.  
 
All the focus groups were audio recorded. The first focus group was held in the 
School of Allied Health Professions at Keele University. The groups were 
moderated by the first investigator (AA). The moderator introduced the questions 
and ensured that all the participants in the group were sharing their experiences 
and feedback. An observer (SH) was also present to take notes of any non-verbal 
interaction between the participants.      
 
3.5.12. Thematic analysis (qualitative data)  
In preparing the data from the focus groups (process evaluation) for analysis, all the 
data captured on audio tapes were transcribed verbatim and checked for accuracy. 
This process of full transcription helps to strengthen the trustworthiness of the data 
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by avoiding the selective recording of information (Patton, 2002). Ensuring the truth 
value of the study, the accuracy of the transcripts was also confirmed by another 
member of the research team listening to the tapes and checking the transcript to 
verify its accuracy.   
 
The data from the transcripts were analysed using thematic analysis. Thematic 
analysis is a flexible research tool, not related to a specific epistemological or 
theoretical approach (Braun and Clarke, 2006), aiming to discover meaning behind 
individual conditions and circumstances (Maguire and Delahunt, 2017). Thematic 
analysis was used in this study on the basis that it is a general and flexible 
approach to qualitative data analysis that can be used across a range of 
approaches to analysis, including phenomenological methodology. In retrospect, an 
approach that is more specifically geared to descriptive phenomenology, such as 
Colaizzi’s, could have been used and might have generated a fuller sense of the 
phenomenon of interest from the participants’ accounts (Morrow et al., 2015). 
However, Braun and Clarke’s six-step method is broadly similar to Colaizzi’s seven-
step method, except in respect of the emphasis in the latter on bracketing and the 
idea of respondent validation, but that both methods are based on identifying 
themes in the data (Morrow et al., 2015). The thematic analysis in this study was 
inductive, aimed to identify meanings from the data based on the participants’ 
answers and discussion (Braun and Clarke, 2006). Data were coded independently 
by two members of the research team, who then discussed codes, and 
independently identified themes. The data from the transcripts were analysed using 
the process described by Braun and Clarke (2006), outlined below:  
 
• Familiarisation with data 
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Braun and Clarke (2006) recommend that researchers read the transcribed data at 
least one time before starting to code. This is because ideas might be shaped as 
the researcher becomes familiar with the data. However, researchers are also 
advised to document their initial thoughts, reflection, values and interests in the data 
(Lincoln and Guba, 1986). The researcher can return to these ideas in the 
subsequent phases of analysis (Lincoln and Guba, 1986). 
  
• Generating initial codes 
After the familiarisation phase, the researcher needs to start initial production of 
codes from the data (Braun and Clarke, 2006). Coding is defined as the process of 
reflecting and interacting with and thinking about data (Savage, 2000). Simply put, 
when the researcher starts coding, he or she focuses on specific characteristics of 
the data, and, while in this phase, may start to identify important sections of text and 
label them (King, 2004). King (2004) suggested that a “good code” is one that helps 
to fulfil richness of the phenomenon.  
 
• Searching for themes 
After all the data have been initially coded, the third phase started by collecting all 
codes that are relevant into themes according to the recommendations of Braun 
and Clarke (2006). Themes are defined as “an abstract entity that brings meaning 
identity to a recurrent experience and its variant manifestations” (DeSantis and 
Ugarriza, 2000). Themes are significant concepts that link important sections of the 
data together (DeSantis and Ugarriza, 2000). Themes were created using an 
inductive approach.  
 
• Reviewing the themes 
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After identifying the themes, phase 4 started by refining themes. In this phase, 
researchers need to review the coded data extracts for each theme and to look at 
the overall pattern. King (2004) recommends that in this phase, researchers need to 
identify relevant text that has not already been coded, initiate codes for it, and link it 
to a relevant theme.  
 
• Defining and naming the themes  
In this phase, the researcher defines the area each theme covers and identifies how 
each individual theme “fits” with the overall story.  
 
• Producing the report 
The researcher starts the writing up phase and produces the report after final 
definitions of the themes. In this study, the researcher used examples, or 
quotations, to support the qualitative analysis as recommended by Braun and 
Clarke (2006). 
 
While the researcher followed the above-mentioned steps, the data were coded 
using NVIVO, independently by two members of the research team, who then 
discussed codes, and independently identified themes. Transcripts were read 
several times over and interview recordings listened to again so that the full sense 
of the interview could be remembered as a whole. Themes and sub-themes were 
discussed and agreed within the research team, following an iterative process over 
a series of meetings. 
 
3.5.13. Quality assurance of reporting qualitative data 
In order to ensure quality of reporting, the consolidated criteria for reporting 
qualitative research (COREQ) checklist was used. The COREQ checklist was 
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developed to help researchers report high quality transparent data, and to improve 
the rigor, comprehensiveness and credibility of studies that include interviews or 
focus groups (Tong et al., 2007). The COREQ has 32 items asking about three key 
issues: 1) research team; 2) study design; and 3) data analysis and findings. 
 
3.5.14. Trustworthiness  
In qualitative research, the researcher is the instrument for analysis, which puts the 
responsibility on the researcher him- or herself to ensure rigour, transparency and 
trustworthiness of the results (Nowell et al., 2017). Researchers need to follow 
trustworthiness and quality assurance recommendations while conducting the 
research and while reporting it, in order to convince the reader that the study results 
are convenient (Lincoln and Guba, 1986). Lincoln and Guba (1985, p.234) defined 
trustworthiness as “introducing the criteria of credibility, transferability, 
dependability, and conformability to parallel the conventional quantitative 
assessment criteria of validity and reliability”.  
 
These criteria were followed in this study and are reported in each phase of the 
analysis in the results chapter (Chapter 4). Below are the main criteria with brief 
definitions for each one: 
• Credibility: Credibility is the consistency between participants’ views and 
answers with the researcher’s representation (Tobin and Begley, 2004). In 
order to assure credibility in this study, a second researcher checked if the 
representation of data and findings were consistent with the data.  
• Transferability: transferability refers to the generalizability of the information 
to other cases, in which the researcher is responsible to provide a detailed 
description of the analysis and method in order to help people who wish to 
transfer the finding to their own situation (Lincoln & Guba, 1985).  
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• Dependability: Tobin and Begley (2004) recommended that researchers 
need to ensure the research process is logical, traceable, and documented 
in order to achieve dependability. To ensure dependability of this study, all 
the processes were audited by the research supervisor.  
• Confirmability:  conformability is reached when the research findings are 
derived from the raw data (Tobin & Begley, 2004). In other words, results 
are confirmed while using quotes and evidences from the transcripts and, 
according to Guba and Lincoln (1989), conformability is achieved when 
credibility, transferability, and dependability are achieved.  
• Audit Trails: audit trails were kept by the research supervisor to ensure 
evidence of the findings and conclusions, methodologies used while the 
analysis and transcribing the audio records, and rationale for the decisions 
were made.  
• Reflexivity: reflexivity has to do with consideration and documentation of the 
researcher’s opinions and biases (Nowell et al., 2017). In order to address 
reflexivity, consideration of the researcher’s own biases was reported, 
because the researcher was the person who collected the data and 
analysed it in the study. Reflexivity about the focus group and the qualitative 
analysis are addressed in Chapter 4. Additionally, reflexivity about the main 
trial, PPIE meetings and the PhD as a whole journey are covered in chapter 
7.  
 
3.5.15. Statistical analysis (quantitative data) 
Data from all measurements were analysed using SPSS (version 24) and Microsoft 
Excel (Microsoft Office 365). Data were assessed for normal distribution and 
equality of variances using Q-Q plots and histograms. As this was a feasibility 
study, no formal hypothesis tests were undertaken. All data analysis took place 
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using a database that had been copied after freezing the database, just before 
breaking the blinding of the assessor.  
 
In accordance with the CONSORT (2010) guidelines, baseline demographics of the 
two groups were recorded. The number of eligible patients who contacted the 
research team was included, and the number of people who dropped out at each 
visit was recorded. Means and standard deviations (SD) were calculated for 
normally distributed continuous data, and medians and interquartile range for 
ordinal data and data that were not normally distributed.  
 
As this was a feasibility study, no effectiveness analysis was conducted. However, 
any potential to change in CPET and PFT between the baseline and end of 
intervention session (8-week session) was assessed by mean difference or median 
difference and plotted in graphs. Assessing these differences could give an idea 
about the outcome measures and their potential for change, and if any changes are 
needed in terms of using the outcome measures to detect changes over time.  
 
To assess if similar outcome measures would be needed for the next trial, 
Pearson’s or Spearman’s correlations were calculated. This has been done to avoid 
collecting data from many outcome measures if they were measuring the same 
target (for example: the Barthel Index and the activity of Daily living domain in PDQ-
39 assess similar components).  Bar-graphs were used to illustrate frequencies and 
proportions. 
 
3.5.16. Adverse reactions and adverse events  
An adverse reaction is defined as “'A response to a drug / intervention which is 
noxious / unintended, and which occurs at doses normally used in man for the 
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prophylaxis, diagnosis, or therapy of disease, or for the modifications of 
physiological function”, whereas an adverse event is defined as “Medical 
occurrence temporally associated with the use of a medicinal product or 
intervention, but not necessarily causally related” (World Health Organisation, 
1972). Although the outcome measures used in this study are used in routine 
clinical practice (not in PLwP, but in the general population), the below are the 
expected adverse reactions that could happen while conducting the 
tests/intervention: 
• Risk of fall and fatigue during the aerobic exercise.  
 
During the CPET participants may experience adverse reactions in certain 
exceptional circumstances under intensive aerobic exercises, such as abnormal 
blood pressure, fainting, angina, and in rare instances, heart attack or stroke, which 
could lead to death. However, the intensity of the exercise anticipated in the study 
was restricted and limited by the fact that participants were PLwP (i.e: participants 
have done the CPET under the age predicted HR formulae, which could help in 
tailoring the intensity of cycling on individual basis). 
 
3.5.17. Trial management 
The supervisory team provided overall supervision of the study and ensured that it 
was conducted in accordance with the principles of Good Clinical Practice and the 
relevant regulations (Craig et al., 2012). Additionally, the assessor completed the 
Good Clinical Practice training (certified from the National Institute for Health 
Research in 2018) before staring any data collection. The supervisory team agreed 
the trial protocol and any protocol amendments and provided advice to the 
investigators on all aspects of the study. The supervisory team monitored the 
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progress of the study, including the recruitment, data completeness, analysis and 
ensured that there were no major deviations from the study protocol. 
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Chapter 4: Study 1 - Results  
This chapter presents the results of the EXoCARP feasibility study with findings 
related to each of the study objectives.  
 
4.1. Recruitment rate, attrition rate and included participants 
(objective 1a and 1b) 
Overall, 37 people contacted the researcher from online advertisements through the 
Parkinson’s UK website and through local Parkinson’s groups. Out of these, six said 
Keele was too far away for them to travel, three made contact during the first 
COVID-19 lockdown period (March/April 2020) so we could not recruit them or 
collect data, three were not eligible according to the inclusion criteria due to having 
respiratory or chronic cardiac diseases, and one was scheduled to attend the first 
assessment session at the first day of campus closure due to COVID-19 regulations 
and consequently no data were collected from the participant.  
 
Overall, 24 participants were eligible and consented and were included in the trial 
and completed the first assessment session, of which: one dropped out after the 
first assessment session due to a personal issue; another dropped out due to 
medical reasons (not Parkinson’s related); seven were part-way through the trial but 
could not attend the second visit due to COVID-19 lockdown; and one could not 
attend the third assessment visit due to the COVID-19 lockdown. In summary, 24 
participants completed the baseline assessments, 15 completed the outcome 
assessments at the end of the intervention period, and 14 completed the follow-up 
assessments. The information related to recruitment and attrition is summarised in 
the CONSORT diagram (Figure 13). Actual recruitment rate versus planned 
recruitment rate is represented in Figure 14.  
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Figure 13: The CONSORT diagram for the trial. 
Assessed for eligibility (n= 31) 
Excluded (n= 7): 
   Not meeting inclusion criteria 
(n= 3) 
   Contacted us during the 
COVID-19 pandemic (n= 3) 
   Scheduled just at the first day 
of the pandemic (n=1 ) 
Analysed (n= 7) 
 Excluded from analysis (n= 0) 
Lost to follow-up (n= 0) 
 
Allocated to the control group (n= 12) 
 Received allocated intervention 
(n=7) 
 Did not receive allocated 
intervention (n= 4): 
one participant due to personal 
issue; and three participants did 
not continue due to the 
pandemic. 
Lost to follow-up (n= 1): due to the 
pandemic.  
Allocated to the exercise group (n= 
12) 
 Received allocated intervention (n= 
8) 
 Did not receive allocated 
intervention (n= 5): one 
participant due to a medical 
condition; and four participants 
did not continue due to the 
pandemic.  
Analysed (n= 8) 




Randomised (n= 24) 
Enrolment 
Contacted us (n=37) 




























Recruitment to the EXoCARP trial over time  
Actul recruited rate Planned rate Start of COVID-19 pandemic Stafford visit Telford visit
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Recruitment rate (refers to the average number of participants recruited per month) 
was 1.92 participants per month (from mid-April 2019 until mid-March 2020). Figure 
14 represents the actual recruitment rate compared with the planned rate (between 
the period April 2019 until December 2020). As figure 14 shows, there was a boost 
in recruitment after two visits to Parkinson’s UK groups in Stafford (n=3) and Telford 
(n=5). The pattern shows that recruitment started similarly to what was planned, 
until the start of the COVID-19 pandemic that stopped continued recruitment due to 
the governmental regulation of social distancing, and suspension of face-to-face 
data collection at the university site to minimise the risk of infection of COVID-19 
virus. 
 
The proportion of participants recruited from the number of people who contacted 
the research team was 65% (24 out of 37 participants). Recruitment was 48% out of 
the targeted number (24 out of 50, from April 2019 to March 2020), and 80% out of 
the accepted sample size for pilot studies (24 out of 30). The achievement of the 
targeted number was not feasible due to the COVID-19 pandemic regulation in mid-
March 2020, and inability to recruit until the rest of the planned period (data 
recruitment was originally planned to continue until December 2020). Attrition was 
37% (9 out of the 24). Out of these, seven participants dropped out due to the 
COVID-19 pandemic (29%), and two dropped out due to other reasons as 
mentioned at the beginning of this section (8.3%). 
 
4.2. Baseline characteristics of participants  
The baseline characteristics for the groups are presented in table 12. The mean 
(SD) age for the two groups was similar (exercise group = 68.8 (11.1) years; control 
group = 65.55 (9.27) years). The proportion of males to females was similar in both 
groups with 75% males in each group. All participants who participated in the study 
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were Caucasian. There were slightly more people with higher H&Y scores in the 
exercise group (six participants with Hoehn and Yahr stage III in the exercise group) 
compared with four in the control group. This imbalance could be accounted for by 
the small sample size. Both groups were similar for mean (SD) years since 
diagnosis (exercise group = 6.17 (4.84) years; control group = 7.71 (7.53) years). 
Additionally, height and weight were similar in both groups (table 12).  
 
A total of 17 participants (71% of the sample) experienced tremor as the dominant 
symptom, and the remaining 7 (29%) experienced rigidity as the dominant 
symptom.  
 
Table 12: Baseline characteristics of the included participants. 
 
  







Age (years) Mean (SD) 68.8 (11.1) 65.55 (9.27) 67.25 (10.14) 








Height (cm) Mean (SD) 173.38 (10.50) 174.08 (7.35) 173.73 (8.87) 














Stage I (n) 
Stage 2 (n) 











4.3. Serious adverse reactions 
Submaximal exercise is considered low risk for adverse reactions and events. 
Within this feasibility study, there were no adverse reactions to report, indicating 
that no participant reported pain or fatigue related to the intervention. However, 
three participants reported pain in the knee after running the CPET. Pain was 
temporary and was reported to be relieved after a period of rest.  
 
There were two serious adverse events; however, neither of these was related to 
participation in the trial. One participant was investigated for an unrelated serious 
medical condition after the first assessment session and did not continue in the trial 
accordingly; another participant had a fall while on holiday, but that event was 
unrelated to the exercise intervention or tests.  
 
4.4. Success of blinding 
The blinded assessor correctly guessed the group randomization for seven 
participants (29.17%); table 13 represents the confidence level rated by the 
assessor when asked “How confident you are about in what group you think the 
participant was?”. The blinded assessor was not confident at all in five out of 16 
cases (31%). The blinded assessor accurately guessed the allocation of participants 
only in four participants.   
 





Description Assessors’ guess (number 
of participants) 




Not confident at all 5 
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4.5. Outcomes 
4.5.1. Physiological measures 
4.5.1.1.  Pulmonary function test (PFT) 
The PFT was conducted at the baseline session (n=24 participants), after 8 weeks 
(end of intervention, n=15 participants) and 4 weeks post intervention (12 weeks 
session, n=14 participants). The PFT was relatively a quick test (taking 
approximately 20 minutes to complete), with no adverse reactions reported or 
observed. When the PFT data were checked for normality using histograms and Q-
Q plots, all PFT outcomes data were normally distributed, and mean (SD) was 
reported (table 14). Mean (SD) FEV1 was 2.93 (0.83) L/min compared with a 
predicted value of 3.12 (0.67) L/min for healthy people of similar age, height, weight, 
sex, and ethnicity. Additionally, mean (SD) of FEV1/FVC (%) was found to be 72.48 
(7.21) % in the whole sample (n=24) (table 14).  
 
Results of the independent T-test showed that disease severity was significantly 
higher (p=0.03), and baseline physical activity level was significantly lower (p= 
0.003) in participants with abnormal pulmonary pattern (obstructive, restrictive and 
mixed patterns; n=13), than in participants with normal pulmonary pattern (n=11).  
 
With regard to pulmonary pattern, 54% of the included 24 participants showed 
abnormal pulmonary pattern (11 participants with obstructive pulmonary pattern, 
one with restrictive pattern and one with mixed obstructive and restrictive pattern) 
(Figure 15). Effectiveness of the intervention was not assessed; however, changes 
in PFT outcomes overtime in both groups were calculated and reported in table 16 
and figures 16 and 17. Differences in baseline characteristics between participants 
with abnormal pulmonary pattern vs participants with normal pulmonary pattern are 





Table 14: Baseline Pulmonary function test results for the whole sample (n=24) at baseline session, including 






















Minimum 1.31 1.77 64.86 2.11 2.34 70.95 59.95 





Table 15: Differences in baseline characteristics between participants with abnormal pulmonary pattern (n=13) vs participants with 
normal pulmonary pattern (n=11). 
 
 Age Sex Years since 
diagnosis 
Disease severity Physical activity 
t 1.05 -0.92 0.80 3.34 1.00 
p-value 0.08 0.37 0.54 0.003* 0.03* 




Figure 15: Bar chart representing pulmonary patterns for the included participants at baseline (n=24). 
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0.01 0.14 -2.53 
Control 
group 




























0.1 0.16 -0.25 
* Calculated as the difference between the two means. 
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Figure 17: FEV1/FVC results in both the exercise and the control groups.
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4.5.1.2  Cardiopulmonary Exercise test (CPET) 
The CPET was conducted with 19 participants out of the 24 at the baseline session. 
This is because five participants presented with high blood pressure during the 
baseline session (blood pressure >140/90 mm Hg according to the AHA/ACSM 
Health/Fitness Facility Pre-participation Screening Questionnaire) and we could not 
run the test according to the safety guidance mentioned in chapter three. Twelve 
participants completed the CPET at the end of the intervention session and the 
follow up session. In 21 participants, the test was terminated early before the full 
duration of the test was completed due to achieving 70% of the age-predicted 
HRmax. In three participants, the test was terminated due to fatigue, indicated by 
Borg scores above 5. No adverse reactions were reported or observed.  
 
As the data for CPET were not normally distributed, medians, IQRs and ranges 
were calculated and summarised in tables 17 and 18. Predicted median VO2Peak 
was 20.22 ml.kg-1.min-1 in the whole sample, compared with 19.39 ml.kg1.min-1 
predicted VO2Peak for healthy people above 65 years old (Loe et al., 2016). 
Effectiveness of the intervention was not assessed; however, changes in CPET 
outcomes over time points in both groups are reported in table 19 and plotted in 







Table 17: Cardiopulmonary exercise test results for the whole sample at baseline (n=19). 







































Minimum 17.00 45.00 51.00 78.00 60.00 0.75 1.00 4.00 
Maximu
m 
28.36 92.00 124.00 182.00 93.00 4.00 5.00 9.00 
VO2: oxygen uptake; HR: heart rate; SBP: systolic blood pressure; DBP: diastolic blood pressure; TD: test duration; IQR: inter 
quartile range.  
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 Predicted VO2Peak 
for the included sample 
(ml.kg-1.min-1) 
Predicted VO2Peak for 
healthy people above 




Median 20.23 40.20 
 
Females 
Median 19.39 31.10 
VO2: oxygen uptake  
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Table 19: Cardiopulmonary exercise test results in both groups at baseline (n=19), end of intervention (n=12) and the follow-up 

























































Minimum 17.00 18.27 17.64 51.00 95.00 95.00 4.00 5.00 4.00 













































Minimum 17.93 18.10 18.30 104.00 104.00 104.00 4.00 5.00 4.00 












-0.8 2.00 0.00 
VO2: oxygen uptake; HR: heart rate; IQR: inter quartile range.  




Figure 18: CPET changes in both groups in terms of VO2peak and heart 
rate for both the exercise group and the control group. 
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Figure 19: CPET changes in both groups in terms of test duration for both the 
exercise group and the control group. 
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4.5.2.  Analysis of the physical activity diary form and Activity monitors 
data  
All participants who were enrolled in the trial and completed the eight-week period 
(n=15) wore the activity monitors around their waists and completed the daily 
physical activities diaries. Mean (SD) of wearing days for the activity monitors was 
42.5 (8.8) days out of a maximum of 56 days. Adherence rate of wearing the activity 
monitors was 75.95%.  
 
All the physical activity data are reported as median (IQR) as they were not 
normally distributed. Table 20 represents the median (IQR) of minutes spent in 
exercise as reported by the physical activity diary and the Actigraph. From the daily 
diary sheets, participants in the exercise group reported doing 32.3 (28.9, 37.5) 
minutes of usual physical activity (without adding the extra amount of physical 
activity that they have been asked to do in the study) (figure 20A); of these minutes, 
only 3.7 (1.0, 8.9) were of MVPA intensity (figure 21A). The control group reported 
doing 21 (20, 51.3) minutes of usual physical activity (figure 18A), with only 3.0 (1.0, 
3.0) minutes as MVPA intensity (figure 22A).  
 
During the intervention phase of the study, participants in the exercise group 
increased time spent in MVPA up to 40.6 (22.3, 48.2) minutes per day, as recorded 
by the Actigraph (figure 21A). Of these minutes, 37.2 (27.1, 45.4) were the extra 
minutes that have been done on top of the 3.7 (1.0, 8.9) original minutes spent in 
MVPA as recorded by the Actigraph (figure 22B). Number of steps/day for each 
group is reported in Table 20 and figure 22B.  
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Table 20: Minutes spent in exercise as reported by the daily exercise diary and the Actigraph, including time spent in all intensities, and 
moderate to vigorous intensities specifically, as an extra minutes for the intervention, and as an original minutes without the intervention.  



























































Minimum 26.0 1.0 52.9 27.0 2073.7 
Maximum  39.2 12.5 89.3 52.4 10545.0 











Minimum 20.0 0.0 20.0  454.1 










Figure 20: A) Boxplot representing the total minutes of exercise per day without the 
extra minutes of intervention as reported by the exercise diary (including all the 
intensities) in both groups; B) Boxplot representing the total minutes of exercise per 
day in both groups. 
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Figure 21: A) Boxplot representing the total minutes spent in MVPA per day 
including the extra minutes of intervention by Actigraph in the exercise group; B) 
boxplot representing the extra minutes spent on MVPA as reported by the 










Figure 22: A) Boxplot representing the original MVPA per day (without the 
intervention extra minutes) by the Actigraph; B) boxplot representing steps per 




4.5.3. Subjective outcomes and questionnaires  
All of the questionnaires were completed at baseline (n=24) and at the end of 
intervention (n=15) by participants in both groups.  
 
4.5.3.1. Quality of life 
Participants in the exercise group increased their median (IQR) scores in the total 
PDQ-39 by 0.03 from baseline (0.27 (0.18, 0.37)) to end of intervention (0.30 (0.04, 
0.34)). Those in the control group increased their median (IQR) scores by 0.07, 
from baseline (0.22 (0.07, 0.32)) to end of intervention (0.29 (0.09, 0.32)).   
 
Results of the eight dimensions and the total score of the PDQ-39 are represented 
in Figures 23 - 27. The higher the PDQ-39 scores, the lower the quality of life. 
Lower scores (indication of better quality of life) were noticed in the exercise group 
in the following domains: ADL; emotion; stamina; social support; and bodily 
discomfort. In the control group, lower scores (indication of better quality of life) 
were noticed in the following domains: ADL; and stamina.  
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Figure 23: Parkinson's Disease Quality of Life Questionnaire results for: 
Mobility and Activity of Daily Life domains for both groups at baseline and at 
the end of intervention (after eight weeks).  
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Figure 24: Parkinson's Disease Quality of Life Questionnaire results 
for: Emotion; and Stigma domains for both groups at baseline and at 
















Figure 25: Parkinson's Disease Quality of Life Questionnaire results for: 
Stigma; Social support; and Cognition domains for both groups at baseline 
and at the end of intervention (after eight weeks).  
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Figure 26: Parkinson's Disease Quality of Life Questionnaire results for: 
Communication; and Bodily discomfort domains for both groups at 
baseline and at the end of intervention (after eight weeks). 
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Figure 27: Parkinson's Disease Quality of Life Questionnaire results for the total 
score of the questionnaire for both groups at baseline and at the end of 
intervention (after eight weeks). 
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4.5.3.2  Non-motor symptoms 
Median (IQR) total scores for the Non-Motor Symptoms Questionnaire (NMSQ) for 
the whole sample at baseline and at the end of intervention were the same (8), 
indicating mild symptoms (<10). However, the maximum score at baseline (18) and 
at end of intervention (17) indicate moderate symptoms. 
 
Participants who were in the exercise group showed a decrease in their median 
score, from 8.50 at baseline to 7.00 at end of intervention, indicating improvement in 
non-motor symptoms. Similarly, participants in the control group showed a slight 
decrease in their median score, from 9.00 at baseline to 8.00 at end of intervention 
(figure 28).  
 
4.5.3.3  Independence in activities of daily living   
There were no changes in total scores of the Barthel Index for either group between 
the baseline and the end of intervention (exercise group median (IQR) = 19 
(19,19.75) to 20 (19, 20); control group median (IQR) = 19 (19, 20) to 20 (19, 20)). 







Figure 29: Barthel Index results for intervention and control groups at baseline and 
end of intervention (after eight weeks). 
 
Figure 28:Results of the Non-Motor Symptoms Questionnaire (NMSQ) for both  
groups at baseline and at the end of intervention (after eight weeks). 
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4.5.3.4. Memory 
Median (IQR) prospective and retrospective memory questionnaire total scores 
increased for the exercise group by 3 points from baseline (25 (19.75, 38.75)) to 
end of intervention (28 (24.00, 46.00)), and for the control group by 5.5 points from 
baseline (28.5 (24.5, 38)) to end of intervention (34 (25.75, 47.75)). Similarly, the 
total PRMQ score increased in both groups from baseline to end of intervention 
(Figures 30 and 31). The higher the scores in PRMQ, the worse is the memory. 
 
Median (IQR) prospective memory scores decreased in the exercise group by 2 
points from baseline (15 (11, 20)) to end of intervention (13 (12, 24)), and 
retrospective memory increased by 3 points from baseline (12 (10, 19)) to end of 
intervention (15 (11, 25)).  Median (IQR) prospective memory increased by 3 points 
in the control group from baseline (15 (14.25, 21.5)) to end of intervention (18 (14, 
26.25)), and retrospective memory increased by 2.5 points from baseline (13 
(10.25, 16.5)) to end of intervention (15.5 (12.25, 22, 25)).  
 
4.5.3.5. Depression 
Median (IQR) GDS scores showed almost no changes in the exercise group from 
baseline (3.0 (0.5, 4.0) to end of intervention eight weeks later (3.0 (0.0, 6.0)). Slight 
improvement (decrease in score) was noticed in the control group scores from 
baseline (1.5 (1.0, 3.5) to end of intervention (1.0 (0.0, 1.8)) (figure 32). Median 









Figure 30: Prospective-Retrospective Memory Questionnaire results for both 
groups at baseline and at the end of intervention (after eight weeks). 
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Figure 32: The Geriatrics Depression Scale scores for exercise and 
control groups at baseline and end of intervention (after eight weeks). 
Figure 31: Total score of the Prospective-Retrospective Memory Questionnaire 
results for both groups at baseline and at the end of intervention (after eight 
weeks). 
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4.5.3.6. Baseline Physical activity (the Baseline Physical Activity 
Survey) 
Baseline physical activity survey data showed that most participants (22 out of 24) 
were already doing aerobic exercise regularly, with a range of 0 to 65 minutes per 
day for 0 to 7 days per week (figure 28). Stationary cycling, outdoor cycling, 
walking, jogging, running outdoors, taekwondo, dancing, swimming, and treadmill 
walking were reported as aerobic exercise that was regularly done before the trial.  
 
Nine participants (exercise group=4, control group=5) reported an average of 21-30 
minutes of exercise per day, three times per week. One participant (control group) 
reported more than 60 minutes per day, three times per week, and one participant 
reported zero minutes of exercise per day (control group) (figures 33 and 34).  
 
The baseline physical activity questionnaire revealed that 15 participants (exercise 
group=8, control group= 7) experienced dyspnoea while doing their regular 
exercise.  
 
4.5.4. Correlational analysis between outcome measures 
Spearman’s correlational analysis did not show any significant correlation between 
the GDS and the emotion dimension of the PDQ-39 (r=0.053, p=0.805). A 
significant, moderate correlation was found between the Barthel Index and the ADL 
dimension of PDQ-39 (r=-0.467, p=0.02).
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Figure 34: Average baseline minutes per day spent in aerobic exercise for the all participants as reported by the physical 
activity questionnaire, according to group. 
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4.6. Focus groups results  
All 12 participants in the exercise group were invited to attend a focus group, and 
nine accepted the invitation. Two focus groups were held, with four participants (all 
male) in the first focus group and five participants (three female, two male) in the 
second. In total, 75% of participants in the exercise group attended a focus group.  
The first focus group was held in the School of Allied Health Professions at Keele 
University, and the second focus group was held online using Google Meet Platform 
due to COVID-19 pandemic governmental restriction on face-to-face data collection. 
The researcher (AA) was the interviewer, and the research supervisor (SH) 
attended the focus groups as a facilitator to collect any non-verbal data. Both the 
researcher and the facilitator were female. The COREQ checklist had been used 
while writing up the focus groups results to ensure the quality of reporting. The 
completed COREQ checklist is in appendix 21. 
 
4.6.1. Results of the thematic analysis of the focus groups  
4.6.1.1. Summary of themes  
Themes were developed after coding. There were three main themes that 
developed and twelve sub-themes, which can be seen in table 21. These themes 
are related to the trial experience and are discussed with ideas supported by 
















4.6.1.2. Theme: Exercise intervention experience 
Participants found it easy to perform the exercise programme throughout the trial 
period when asked about their general experience. Their answers were mainly 
around intensity and ability to adapt to intensity of exercise with time:    
“I won’t show off, but I thought it was easy!” (P3 FG1) 
 
“I thought it was easy as well…” (P4 FG1) 
 
“Well, my initial exercise was the stationary bike, so for me it was just 
easier.” (P1 FG1) 
 
One participant reported difficulties at the beginning of the intervention and getting 
easier with time, and mixed his comment with conditioning to exercise over time; 
Theme Sub-themes  
Exercise intervention 
experience 
Dose of exercise 
Type of exercise (exercise mode) 
Perceived benefits 
Barriers / challenges 
 
General experience about 
the assessment tools/data 
collection tools 
Easy / difficult 
Comfort/ discomfort 
Preference of the test 
Problems with clothing 
Inconvenience  
Adherence to the actigraph 
Advice for the next trial Attraction of participants 
Multiple sites for data collection 
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“I must admit, it it always started off very easy but by the end of the er, 
session I was…I was fairly…tired! [light laugh]…I was trying to think of the 
word! It, as, as, as the sessions went on, it got easier.” (P2 FG1) 
 
4.6.1.2.1. Sub-theme: Dose of exercise  
Frequency 
When asked about frequency of exercise, participants’ answers varied, with some of 
them adhering to the prescribed frequency, three times per week, because that was 
what was expected of them:  
“Um…as to whether it was too much, I just fitted in three times because 
that’s what they said we should do.” (P1 FG1). 
 
Some participants suggested that the exercise frequency should be more than three 
times per week, and that they were able to do more. Others reported that they were 
already doing more than the required frequency: 
“I wonder whether three times a week is enough, and it should be four or five 
really. [all laughed]. It’s doing something that is more than you otherwise 
have normally have done, to put a little bit of effort into your body.” (P2 
FG2). 
 
“I go to the gym three times… on a Monday, Wednesday, Friday. I play 
badminton on a Tuesday night… and on a Thursday night I play basketball 
and five-a-side football…and then have a rest…[laugh]…Saturday and 




In terms of intensity, participants used different ways to monitor their exercise 
intensity, with some of them adhering to the instructions given by the researcher:  
“I was just going to say the way you phrase it, to work up a sweat, to do 
more than otherwise you normally do, is good. It’s making people exert 
themselves” (P2 FG2). 
 
Others used a machine monitored intensity, for example: HR measured by the cycle 
or the heart rate monitors:  
“Well, for me, the bike just indicated, the little, the little heart appeared and I 
sort of thought I probably should do less…” (P1 FG1). 
 
“Well I have a heart monitor with a watch to look at, yes, and that is quite 
useful. Because you can tell whether you are putting in enough effort or not.” 
(P1 FG1). 
 
Others adopted a pragmatic approach to intensity, increasing and decreasing the 
intensity either with no particular reason, or according to their physical ability and 
estimations:  
[Talking about the cycling] “I think, probably into the second week or so, I 
thought ’Oh, I don’t have to do the same speed all the time’, so I started 
doing a bit faster and then a bit slower, but with no particular purpose behind 
it.” (P2 FG2). 
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“I was cycling…I, I, I have a bike in the house…so I sort of did it my own little 
way. Jon Bon Jovi was good to cycle to! If I did a slow one, I couldn’t press 
the pedal so much, so I had something that was fairly…! So I did 5 minutes 
slow, then 5 minutes faster, and ten minutes faster still, then slowed it down 
and then slowed it down and…” (P2 FG1). 
 
Some participants used distance walked outside as a measure of intensity, by 
means of increasing what distance that they used to perform before the trial: 
“for me, its walking 200 yards rather than one.” (P1 FG2). 
 
“When I was walking, it was how long I walked for, not how fast I walked, so 
normally I, I tend to do my walking in 20-minute blocks, so I was extending 
that ... I am talking about distance more than speed” (P2 FG1).  
 
Others did not specify intensity, but used longer durations rather:  
“I was more, I’ve got, um, a particular route…which took exactly 20 
minutes…so…um, so I found I had to extend it a little bit to fill the thirty 
minutes” (P4 FG1).  
 
When asked about the preferred intensity prescription for future trials, participants 
agreed that it is very difficult to have one intensity prescribed for all cases, and this 
needs to be individualised:  
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“It is very difficult to sort of say “this is right for you, but it’s not right for you”. 
(P4 FG2). 
 
“Parkinson’s of course is a disease which is not sort of ‘one size fits all’. It’s a 
vague personal and individual thing, which makes it so very difficult even for 
the specialists, to say you’ve got it or you haven’t.” (P4 FG2). 
 
Participants also preferred to have an individualised exercise prescription that has 
an objective measure, such as heart rate intensity prescription:  
“I think that’s perhaps less subjective if you do that [using the heart rate 
monitors to monitor the intensity of exercise in the next trial]. I think asking 
somebody to, errrm, the way we did it this time was subjective, because 
what we think might be a fast pace for… isn’t always, you just perceive it to 
be. Whereas, actually if you are taking a measurement, of the heart rate or 
something that’s been this much more increased, um, it’s more factual.” (P3 
FG2). 
 
“I was going to say I think having a specific measurement to work towards is 
better.” (P1 FG2). 
 
Duration  
When asked about duration of the exercise intervention, how much they did perform 
and if that was suitable for them, participants reported varied answers, which 
ranged from 30 minutes to one hour and a half. However, the overall duration of 
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exercise did not necessarily include continuous high-intensity aerobic exercise. One 
participant reported exercising in the gym for an overall longer duration (90 minutes) 
than the intervention stipulated (30 minutes aerobic exercise), and some of those 90 
minutes involved running fast, and some involved walking at a slower pace: 
“So we…I mean, I was there for an hour and a half. But, obviously, I mean, 
what I was doing, if I was running fast, I’d slow it down to walking pace, just 
so, you know, you weren’t too tired at the end of it.” (P3 FG1).  
 
On the other hand, one participant followed the exercise intervention instructions 
and exercised for just an additional 30 minutes at the gym. Other comments related 
to “time” as a barrier are described in the following section.  
 
4.6.1.2.2. Sub-theme: Type/ mode of exercise   
Participants reported performing different types of exercises, with walking and 
cycling being the most reported. Other types include taekwondo, badminton, 
basketball, football, boxing, swimming, dancing, tennis and gardening.  
“I go to the gym three times…on a Monday, Wednesday, Friday. I play 
badminton on a Tuesday night…and on a Thursday night I play basketball 
and five-a-side football…and then have a rest…[laugh]…Saturday and 
Sunday! Well, I go to the match as well.” (P1 FG1). 
 
“with this stationary bike, I just decided to try it out on your terms and, er, 
and see whether it makes a difference; and then I may be comparing it in 
terms of time. We started a boxing class now in Derby…I never thought of 
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boxing in my life, but apparently, in the States, there’s research that says 
boxing’s good for you with Parkinson’s. Okay, so I’ll try that!” (P1 FG1). 
 
4.6.1.2.3. Sub-theme: Barriers to exercise 
Loss of balance was reported to be one of the main barriers to exercise: 
“I cannot cycle the proper cycle, I never have, I’ve got no sense of balance 
whatsoever. So I can only cycle on the fixed one. That’s the gym, or 
something like that.” (P1 FG2). 
 
“Well, in terms of balance. Um, to an extent stamina, which is getting 
better…but it, it's mainly my balance, and I, um, I, I, I was interested to see 
Billy Connelly on the television, saying that his wife has moved from New 
York to Florida because of these, the, the Parkinson's. I thought that was 
something to do with the heat…but it’s not, it’s to do with his balance when 
the weather gets bad.” (P2 FG1).  
 
Physical symptoms that are related to Parkinson’s were mentioned as barriers such 
as fatigue, stamina, and overall progression of the disease. Additionally, participants 
reported that more effort was needed to do exercise if a person has Parkinson’s:  




Breathing as a barrier to exercise was mentioned by participants. For example: 
breathing was reported to be an effort and one of the biggest problems experienced 
by one participant from focus group 2: 
“errm, well again, do other people have difficulty with breathing? That was 
one of my first symptoms I think. And so that is an effort for me. But I do try 
to push myself. Breathing is the, one of the biggest problems of my 
Parkinson’s.” (P5 FG2). 
 
Additionally, participants 2 and 4 from focus group 2 reported that they were 
breathing too fast (increased their respiratory rate) and puffing while cycling or 
walking: 
“There was sometimes, occasions that I was pedalling a little bit too fast on 
the bike, or was trying too much at the beginning that I struggled at the end 
of it, and sometimes I’ve overdone the walk, you go too far and you still have 
to go back again, and then the coming back became a little bit more difficult. 
Then I was puffing - Yes.” (P4 FG2).  
 
“To be fair, I did breathe a bit faster while cycling.”  (P2 FG2). 
 
The time at which the medication should be taken was mentioned as a barrier to 
exercise by one participant, who explained the importance of matching the time of 
exercise to work within the dose-effective time. In other words, the participants tried 
to explain the need to do exercise within the “on” period of the medication, and to 
avoid the “off” periods in which motor symptoms return or get worse:  
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“I find that the timing of the exercise was important to me. It was easier in 
the morning, it was nearer to medication time, or in the right slot, in 
connection with medications. In the afternoon, exercise was no good, or not 
as beneficial I think as it was, and easy to do, as it was in the morning. That 
may differ with other people with their medication levels.” (P4 FG2). 
 
Mood and motivation to exercise were reported as barriers to performing exercise. 
For example, participant 1 from focus group 2 and participant 1 from focus group 1 
reported the difficulty of finding self-motivation that could push them to start the 
exercise: 
“Self-motivation is sometimes difficult to find.” (P1 FG2). 
 
“The motivation before you start…I find it more difficult.” (P1 FG1). 
 
Participants reported that motivation in terms of the internal drive is a barrier  to 
performing exercise. For example, one participant reported that doing the exercise 
during the trial was because of the researcher and this motivation finished when 
finishing the trial. Another participant reported mood and described it as the “little 
inner devil” that need to be overcome:  
“only my mind sometimes, you know [all laugh]…you have to overcome that 
little devil! ... yeah. I frequently say you see this little inner devil that tells us 
‘Oh why bother!’” (P4 FG2). 
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“I would say I was more motivated during the trial because I felt I was doing 
it for a reason, for you, whereas when the trial had finished I guess my 
concern was that I had to be self-motivated.” (P3 FG2). 
 
During the COVID-19 pandemic, participants reported that their motivation to 
perform exercise was affected due to the circumstances of lockdown and 
governmental restrictions for face-to-face meetings:  
“I used to go to a class every week for balance and, called ‘Strictly no falls’, and 
of course that’s had to stop because the village hall isn’t available where we 
used to meet. All these things are sort of in limbo at the moment.  It is difficult, 
because the … something organised does help with the motivation.” (P1 FG2).  
 
“during the lockdown, motivation sort of dwindled more than little.” (P1 FG2).  
 
Weather and temperature were mentioned as barriers to performing exercise as 
well. Rainy weather was reported to be affecting participants’ exercise performance, 
by means of not to get wet, or affecting mood and motivation:  
“if it is rainy, I don’t go out. I don’t like getting wet.” (P3 FG2). 
 
“I think personal inclination and the weather, I think the weather” (P2 FG2). 
 
Fitting an extra 30-40 minutes of exercise was difficult for some participants and 
was mentioned as a barrier. For example, participant 1 in focus group 2 reported 
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that he was already doing exercise, and doing the extra 30 minutes of the trial 
exercise was difficult to fit in his diary. Additionally, participant 4 in focus group 1 
confirmed that her main problem was fitting the 30 minutes in her diaries, more than 
any physical barrier:  
“when I was doing it, I was already doing a lot of exercise and I found it 
difficult to even exercise the extra ones. I found it difficult to fit it in as well. 
There weren’t enough days in the week, and there weren’t enough hours in 
the day. I found it difficult but I managed it reasonably well. I am not doing so 
much now, I must admit. (P1 FG2). 
 
“It’s, er, picking a gap, actually fitting it in was a problem for me, the extra 
half hour... Yeah. Physically it wasn’t a problem…but just finding the time…” 
(P4 FG1).  
 
The second focus group was conducted online during the first COVID-19 lockdown 
period in the UK in the late Spring of 2020. Hence, some participants reflected on 
exercise being affected by the pandemic and the lockdown regulations that had 
been imposed by the government to reduce the rate of infection. Accordingly, the 
COVID-19 governmental regulation and the lockdown was reported as a barrier to 
exercise from the second focus group. For example, the governmental regulation 
prevented domestic help and this prevented participant 1 in focus group 2 from 
doing her usual exercise:  
“During the lockdown my exercise was quite different because, previous to that, 
I had had quite a lot of domestic help. And during the lockdown period I had 
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none…and I haven’t gone back to doing all the exercises I did before.” (P1 
FG2).  
 
Additionally, closure of Parkinson’s UK exercise groups and sport centres during the 
pandemic affected participants’ exercise. For instance, closure of swimming was 
reported: 
“In my case I missed one particular thing. Because walking is no problem, or 
with an exercise bike, the cycling, is no problem. But another exercise that I 
would have liked to have undertaken is swimming, which obviously, with the 
situation, is not possible any more …” (P4 FG2).  
 
4.6.1.2.4. Sub-theme: Perceived benefits 
Participants generally felt that they were getting physical benefits from incorporating 
the exercise intervention into their lives. They reported that they felt able to move 
better; for example, walking more in terms of distance, cycling more in terms of 
time, having better flexibility and muscle strength, and less tremor: 
“I just generally, generally felt better, as you know I couldn’t quantify 
whether…I mean, I was walking more, I was cycling…I, I, I have a bike in the 
house…so I sort of did it my own little way.” (P2 FG1). 
 
“I think I also find that, depending on the exercise, because it’s a resting 
tremor, when I’m exercising it doesn’t, it doesn’t, it goes away, not 
completely, but it reduces that symptom, so obviously that for me is a 
benefit.” (P3 FG2). 
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“I think, in terms of maintenance of your muscle, avoiding atrophy of your 
muscle ... I think definitely, making sure we use our muscles, to make sure 
they keep their strength up … and also flexibility” (P2 FG2). 
 
When they have been asked about any perceived breathing or respiratory related 
benefits, one participant reported that she felt her breathing pattern was better and 
wheezing was reduced: 
“I was probably…Because I took longer…erm…I don’t know! It’s hard to 
say…erm…yeah…erm…my lungs felt clear, if you like, and I could breathe 
easier…” (P5 FG2). 
 
“over the first two or three weeks, I was wheezing by the time, I don’t know if 
you noticed, but, erm, I couldn’t [demonstrated forced exhalation]…It was 
better by the time I got through to week eight. But it was…I’m not as fit as 
everybody else.” (P5 FG2).  
 
Other benefits included self-confidence, satisfaction and feeling better as a person: 
“I would say we did, I did personally, it made me do something more than I 
would otherwise have done.” (P2 FG2). 
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“There’s a satisfaction in knowing you have done the exercise. Very much 
our satisfaction, you feel you’re helping yourself. And I think that does 
motivate me to keep going when you feel benefit” (P1 FG2). 
 
4.6.1.3. Theme: General experience about the assessment tools/data 
collection tools 
Within this theme there were sub-themes of ‘easy / difficult’, ‘comfort / discomfort’, 
preference of the test’, problems with clothing’, ‘inconvenience’, and adherence to 
the Actigraph. 
 
4.6.1.3.1. Sub-theme: Easy / difficult  
CPET 
In general, the cardiopulmonary exercise test was considered to be an easy test for 
participants to perform, and some felt that they could have exceeded the level of 
effort required, for example by cycling at a faster pace:  
“I could have done…I could have gone faster than…” (P3 FG1). 
 
Pulmonary function test 
Spirometry, or pulmonary function test, was acceptable for the participants, and 
they found it easy to do, or they were familiar with it from previous tests or from 
language therapy sessions: 
“I was used to do those because I had asthma for many years, which I 
haven’t got any longer. It has gone away. So I was the accustomed to using 




“I do, um, speech and language therapy as well, and that’s all about 
breathing so, it was, er, it came easy really.”  (P1 FG1).  
 
However, for two participants, conducting the test was not easy for them, and they 
described it as being “a bit of an effort” (P5 FG2), or simply “difficult”. 
 
It was very hard to perform for another participant, who reported that in the first 
session it was harder. Also, he reported that the standardized motivational words 
that are used in the test were a nightmare for him: 
“I was just thinking, my, my problem wasn’t doing the test, it was surviving 
the test! ... you kept saying ‘Keep going! Keep going! Keep going!’ and I’d 
run out of breath and I was wheezing! ‘Keep going! Keep going!’ - and I just 
couldn’t keep going, you know! It was better towards the end, so that was, it 
was a mark of my improvement!... But, but for the first two or three weeks, I, 
I used to have nightmares about this voice saying ‘Keep going! Keep going!’ 
[all laugh]” (P2 FG1). 
 
Accordingly, the researcher asked him if saying these words was distressing for 
him, and he reported that it was not: 
“Oh! It wasn’t distressing! I just, you know, this thing through my head kept 
saying ‘I wish she’d say something other than ‘Keep going!’, and you’re like 
‘Stop!’ [all laugh] But I did find that, out of all the things, those last few 
seconds of that exercise the hardest…And I felt better as time went on…” 




Participants reported that being asked to complete the questionnaires was 
acceptable, and the questionnaires themselves were acceptable and inoffensive: 
“there was nothing in it was offensive, so no they were fine.” (P2 FG2). 
 
Some participants were familiar with these questionnaires from having participated 
in other trials, or just from having been asked to complete many questionnaires as 
part of the routine assessment processes for someone with Parkinson’s: 
“I always felt that it was a part and parcel of tests with Parkinson’s…every time 
you go to one of these things you get 1, 2, 3, 4, 5, ...” (P2 FG1).  
 
One participant reported that paper-based questionnaires that required a pen to 
complete them were difficult and suggested that the less handwriting the better for 
him, due to the Parkinson’s affecting his handwriting: 
“My only comment is it’s good to have as little hand-written space as 
possible, because with Parkinson’s the handwriting goes.” (P1 FG1).  
 
4.6.1.3.2. Sub-theme: Comfort / discomfort 
In general, participants reported that wearing the activity monitor around their waist 
was uncomfortable, and some of them reported that they would prefer to wear a 
physical activity monitor on their wrist or ankle: 
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“The belt, to wear it wasn’t uncomfortable, but to exercise and keep it in 
place, get dressed with it on, undress with it on, and things like that. Running 
24/7 as much as we can. I just found it awkward, I would prefer a wrist 
monitor. I mean, we have Fitbits these days, we’re used to those. I just 
found the chest one awkward.”  (P2 FG2). 
 
“well, I agree with [P2 FG2], I think around the waist is not ideal for me 
either. Although I wear my trousers with a belt, you know the additional one 
there, if it can be sorted differently probably would be better.” (P4 FG2). 
 
4.6.1.3.3. Sub-theme: Preference of the test  
When asked if they would have preferred to use a treadmill rather than the cycle for 
the CPET, most participants reported that they would prefer the cycle test due to 
balance issue, even if a harness was used with the treadmill.  However, they 
reported that the cycle saddle that was used for the cycle test was not comfortable 
for them: 
“no problem on the bike except for the saddle.” (P4 FG2).  
 
“The bike’s easier... Well, because of people who’ve got problems with 
walking erm… With balance – yes!” (P3 FG1). 
 
“The harness, you wouldn’t, erm, I mean, how can I put it…I , I , I get 
security by having my walking stick on the ground. If I was holding it up in 
the air, it would be like Mary Poppins, I wouldn’t have the same sort of 
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stability, you know. It’s getting some stability myself rather than, I just don’t 
think I’d have the security when the harness, in my head. I might be wrong, 
but in my head, I don’t think I’ll have the same security.” (P2 FG1).  
 
4.6.1.3.4. Sub-theme: Problems with clothing  
One male participant was quite happy about wearing the activity monitor under the 
clothes during the day:  
“It didn’t bother me during the day at all.” (P4 FG1). 
 
However, for another female participant, wearing it was an issue while wearing tight 
dresses: 
“it wasn’t so much uncomfortable for me, it was more, errrrm, if I was 
wearing a particular type of dress, and it was quite tight fitting, it was 
noticeable!” [All laughed]. (P3 FG2).  
 
4.6.1.3.5. Sub-theme: Inconvenience  
After explaining to participants during the focus group that wearing the device 
around the waist provides more accurate data for us than wearing it around the 
ankle or the wrist, in terms of detecting movements and steps, excluding tremor 
from the analysis, and including bradykinesia if the participant has this symptom, 
they accepted this explanation and understood the reasoning. However, they felt 
that this needed to be explained at the beginning of the trial so that participants 
understood the reasons for being asked to wear a waist monitor: 
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“I think it is feasible but as (P1 FG2) said you have to explain it far more, 
why it has to be on the waist” (P2 FG2). 
 
“Yeah, I think errm, it was a bit inconvenient. But had you explained that, 
had it gone on the arm or the leg, would maybe give a false reading, er, I 
would have understood a lot more. (P3 FG2).  
 
4.6.1.3.6. Sub-theme: Adherence to the Actigraph 
The participants reported that they did try to wear the monitor according to the 
protocol every day, and developed strategies to remind them to put it on after their 
morning shower, by placing it in a position that was accessible and visible, such as 
beside the bed or with the clothes they were planning to wear: 
“I had it by the side of the bed, so if I had a shower I just put it straight on.” 
(P2 FG2). 
 
“I…I always put my clothes for the next day out on the night before so the 
monitor last thing went on that.” (P2 FG1).  
 
However, there were some who forgot to put it on at the start of the day: 
“OK Yes, I think there was only one day when I lost a few hours, having not 
putting back on having been swimming but apart from that it’s tolerable. And 
as [1FG2] said, no, it was [3FG2], yeah, having it explained does help, but 
it’s logical. Logical and tolerable! (laugh).” (P5 FG2).  
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“I think I had about three days were I didn’t, and, err, kept putting it 
somewhere where, you know, it was mainly after a shower or something, 
and I’d forget. But most of the time I think I did.“ (P3 FG2).  
 
4.6.2. Advice for next trial 
4.6.2.1. Attracting participants  
Participants were asked to consider the recruitment procedures used in this pilot 
study to help us increase recruitment of more PLwP in future exercise trials. They 
made various suggestions, such as using social media for advertising the research, 
and changing the wording of the advert/invitation: 
“Have you tried the Facebook accounts? And there’s various other groups. I 
think you could use social media a bit wider. There are other groups, I 
guess, it depends on the demographics, doesn’t it? In terms of what people 
use. My children tell me that older people use Facebook these days [all 
laugh]. So, yeah, I don’t know whether work out what demographic you’re 
aiming for, how they interact. I guess, do you know how other trials are done 
and how they get volunteers? Are they getting more or less? Are they using 
different sort of options?” (P3 FG2). 
 
Two participants agreed that the initial information advertising the trial has to appeal 
to the PLwP receiving the information, as they receive many requests to participate 
in research and they can pick and choose the ones that they like the sound of: 
“4FG1: Yeah ‘cause when you see these, erm, you get emails through 
suggesting you might be suitable for this, you might be suitable for that, you 
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do, sort of, pick the ones that you… [talking to P2 FG1]. That you like!”  (P4 
FG1). 
 
Two participants from focus group 1 suggested that including the term ‘exercise’ in 
the trial information might be off-putting to some potential participants, and using 
words such as ‘activity’ instead of ‘exercise’ might make this type of study more 
accessible and less of a concern, and ultimately encourage those who are 
‘exercise-averse’ to take part: 
“Just something, a small point, I’d be careful about using exercise as a word. 
Maybe better to say activity or to not, erm, the word exercise is a red rag for 
quite a lot of people” (P1 FG1).  
 
4.6.2.2. Multiple sites for data collection 
Having only Keele University as the only site for data collection may have affected 
recruitment to the study: 
“I was fine from where I come. I don’t know where people were travelling from. 
It was fine and I had no issue with that. But I think you may get a wider network 
or audience, and more volunteers who are able to do it in other locations” (P3 
FG2).  
 
“it was quite a distance for me, I live near Matlock in Derbyshire” (P1 FG2). 
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Participants suggested that recruiting from multiple sites across the region might 
increase the number of participants as they would not have to travel so far, and a 
long journey might not be easy for some PLwP: 
“Keele was a nice trip out. So I don’t mind going to Keele, having said that, yes 
indeed I agree with the other comments made. Mainly if who you have is living 
locally, er, you might get wider audience or participation base for your studies to 
volunteer because other Parkinson’s sufferers might find the trip to Keele too 
cumbersome for them.” (P4 FG2). 
 
Indeed, some PLwP might not have the means or facilities to travel to Keele, and if 
recruiting from local Parkinson’s UK groups across the region, taking the testing out 
in to the community to do local testing might be preferable to local group members: 
“They might not have the opportunity to do that travelling at all. Whereas if you 
do something with a local group where they are used to meeting regularly, that 
might be, er, you would have to do the travelling then Aseel!  [laugh]” (P1 FG2). 
 
4.7. Summary  
Table 22 summarises the main key findings of the mixed methods results and 
relating them to study objectives. 
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Table 22: summary of the EXoCARP study findings. 
Objective Quantitative results related to the objective Qualitative results related to the objective 
1a: assess if 
recruitment methods 
were effective, by 
calculating the 
recruitment rate, 
number of people 
who contacted the 
research team, and 
number of people 




• Recruitment rate (refers to the average 
number of participants recruited per month) 
was 1.92 participants per month. 
• Proportion of participants recruited from the 
number of people who contacted the 
research team was 65% (24 out of 37 
participants). 
• Recruitment was 48% out of the targeted 
number (24 out of 50, from April 2019 to 
March 2020), and 80% out of the accepted 
sample size for pilot studies (24 out of 30). 
• Recruitment was boosted by two visits to 
Parkinson’s UK groups in Stafford and 
Telford. 
• Participants suggested that the 
researcher and equipment might need to 
go out to local Parkinson’s UK groups and 
to collect data there to increase the 
recruitment. 
• Participants suggested to use social 
media to recruit participants in the next 
trial.  
• Participants suggested changing the 
wording of the advert/invitation from 
“exercise” to “activity” to attract more 
people. 
1b: calculate the 





• Attrition was 37% (9 out of the 24) mainly 
due to the COVID-19 pandemic. 
• Without accounting for COVID-19 related 
attrition, only two participants dropped out 
(8.3%). The attrition was less than the 
originally planned criteria for feasibility 
(<15% of the sample). 
Not addressed 
1c: evaluate the 
screening tool and 
inclusion/exclusion 
criteria. 
• Screening tests used to assess the 
EXoCARP participants were easy to 
conduct, and effective in identifying 
participants who are not eligible to do the 
intervention or the outcome measures/tests. 
• Undiagnosed high blood pressure, albeit 
transitory / short-term, should be considered 
in the screening, leading to exclusion from 






practicalities of using 
the outcome 
measures. 
• Adherence rate (calculated as number of 
days participants wore the Actigraph, divided 
over the required number to wear) of 
wearing the activity monitors was 75.95% 
• All participants completed all the outcome 
measures at the sessions, except for five 
participants who had undiagnosed high 
blood pressure before running the tests (at 
the baseline session).  
• Focus groups results indicate no 
problems with most of the participants, 
and some of them were already familiar 
with the spirometry from language 
therapy sessions. 
• Participants reported no problems in 
conducting the CPET when asked about 
that in the focus groups, except for the 
saddle of the cycle used. 
• Participants reported difficulties in filling 
the questionnaires by handwriting.  
1e: explore feasibility 
of delivering the 
exercise intervention. 
• Participants in the exercise group have done 
around 30 minutes per day on top of their 
usual physical activity, similar to what they 
were instructed to do.  
 
• Participants reported that it was easy, or it 
starts difficult and with time became 
easier. 
• The frequency, intensity and duration of 
exercise were found to be acceptable to 
the participants but need more guidance 
in terms of the intensity. 
1f: explore 
participants’ 
experiences and the 
acceptability and 




and adherence to the 
intervention. 
• The plot graphs indicate changes in PFT 
values. FEV1, FVC, and FEV1/FVC values 
were increased with time in the exercise 
group, and decreased with time in the 
control group. 
• Plot graph for the CPET results show that 
almost no changes in term of peak HR, 
predicted VO2 peak, or test duration. 
• Participants reported physical benefit and 
self-confidence after the intervention.  
• Physical ability, motivation, and mood, 
time, weather, and COVID lockdown 
regulations were reported to be barrier 
exercise. 
• Participants reported doing range of 
exercise types including stationary 
cycling, outdoor cycling, walking, jogging, 
running outdoors, taekwondo, dancing, 
swimming and treadmill walking 
2. to assess 
pulmonary function in 
people with mild to 
moderate 
Parkinson’s. 
• 54% of participants were found to have 
abnormal pulmonary pattern: 11 obstructive; 
1 restrictive; 1 mixed pattern; and 1 normal 
pattern. 
• Two participants reported dyspnoea and 
difficulties to do the spirometry (FVC).  
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Chapter 5: Study 1 - Discussion 
In chapter one, the motor and non-motor symptoms of Parkinson’s, pulmonary 
function, obstructive and restrictive pulmonary diseases were introduced; and in 
chapter two, a review of the literature relating to pulmonary function in Parkinson’s, 
cardiorespiratory response to exercise testing in Parkinson’s, and the effects of 
aerobic exercise on cardiopulmonary function in Parkinson’s were reviewed, 
summarised and discussed. The aims and objectives of this pilot and feasibility 
study were introduced at the beginning of chapter three. Chapter three presented 
the detailed methodology used in the study, and chapter four reported the results of 
the EXoCARP pilot and feasibility study.  
 
This chapter involves a discussion concerning findings of the EXoCARP pilot and 
feasibility study in line with the findings of the systematic review in chapter two. 
Strengths and limitations of the study methodologies will be highlighted, along with 
pertinent findings. Finally, suggestions, recommendations and aspects to address 
for future research trials will be made. 
 
5.1. The pilot and feasibility trial findings (Objective 1) 
5.1.1. Recruitment and attrition (objective 1a and 1b) 
Recruitment of the planned 50 participants was not achieved, with the trial recruiting 
48% of the target number (24 out of 50), and 80% out of the accepted sample size 
for pilot studies (24 out of 30) (Lancaster et al., 2004). Recruitment was significantly 
affected by the COVID-19 pandemic in 2020, as recruitment to the trial was planned 
between April 2019 until December 2020. However, recruitment to the trial was 
stopped in March 2020 due to the COVID-19 pandemic and UK governmental 
regulations and University access and research restrictions during the first COVID-
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19 lockdown. Thus, a period of nine months of recruitment was lost from the 
originally planned 20 months.  
 
Although recruitment was not limited to a specific ethnic group, all participants were 
Caucasian. Parkinson’s UK include members who live in the UK and have 
Parkinson’s from different ethnicities. Thus, in the next study, the use of recruitment 
advertisements in different languages might help in recruiting more participants from 
ethnic minorities to be involved in the trial. However, the costing of translators may 
also need to be considered.  
 
Attrition rate was 37% (9 out of the 24) mainly due to the COVID-19 pandemic, as 
seven participants were lost to follow-up because of University access and research 
restrictions during the COVID-19 lockdown. However, without accounting for 
COVID-19 related attrition, only two participants dropped out (8.3%). The attrition 
rate was less than the originally planned criteria for feasibility (<15% of the sample).  
 
Recruitment was boosted by visits to two Parkinson’s UK groups in Stafford and 
Telford, following which five participants were recruited after the Telford visit and 
three participants after the Stafford visit. This might give an indication about the 
importance of visiting Parkinson’s UK groups to present the research idea, and not 
to fully depend on the online Parkinson’s UK website and emails.  
 
In the focus group, participants addressed that wording of the advertisement need 
to be changed from “exercise” to “physical activity” to attract more people. 
Additionally, they have reported that Keele University location as the only data 
collection site might be a reason for people who live far to not participate in the trial, 
and suggested mutli-site data collection.  
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5.1.1.1. Comparison of recruitment with other trials  
The recruitment of the EXoCARP trial compares well with other exercise trials in 
PLwP. It has been pointed out that the main obstacle to the implementation of 
clinical trials in PLwP is recruitment (Valadas et al., 2011). For example, in a high-
intensity exercise trial, recruitment was 68.8% of their targeted sample size (Harvey 
et al., 2019), while it was around 11% in another exercise trial over a period of eight 
months (Lima and Rodrigues-de-Paula, 2013), and 45% in another feasibility trial 
that assessed the effects of dancing on motor function (Shanahan et al., 2017).  
 
Keele University’s location was one factor that affected recruitment of participants, 
as suggested by participants in the focus groups: the researcher and equipment 
might need to go out into to local Parkinson’s UK groups in the community to collect 
data there to increase the recruitment rate. The location for data collection and 
availability of transportation of participants need to be considered for the next trial. 
This is supported by the number of participants who contacted the researcher but 
could not travel to Keele University to attend the assessment sessions (n=6). 
 
The COVID-19 pandemic was another factor that limited recruitment of participants 
for the EXoCARP trial. The UK governmental instructions to “Stay at home” and 
“Stay alert”, in addition to PLwP being a high-risk group, affected the continuation of 
recruitment. Further details about how the COVID-19 pandemic affected PLwP’s 
physical activity level are addressed in detail in the following chapter (Chapter 6). 
 
Other reasons reported in the literature regarding factors that might affect 
recruitment while designing trials for PLwP include: fear of adverse reactions such 
as falls and balance impairments; fear of aggressiveness of the intervention or the 
outcome measures; and fear of the results (Valadas et al., 2011). 
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5.1.1.2. Implications for future trials 
A total of 11 months was not enough to recruit the target sample size of 50. The 
original plan was 20 months (from April 2019 to December 2020) but the 
unexpected circumstances due to COVID-19 pandemic affected the trial data 
collection. Multi-site data collection is highly encouraged to improve data collection. 
However, this will have an impact in terms of cost of location (room/hall rent), 
movement of equipment, and the assessor’s time. One assessor might not be 
enough in case of multi-site data collection. Additionally, in the case of multi-site 
data collection, piloting of the centres/locations that will be identified need to be 
assessed, and inter-rater reliability (the degree of agreement among assessors) in 
relation to the outcome measures and objective tests need to be conducted. 
Moreover, it is recommended to conduct more information-giving visits to 
Parkinson’s UK groups to promote the research and boost recruitment in the next 
trial.  
 
5.1.2. Evaluating screening tools of inclusion and exclusion criteria 
used in the EXoCARP trial (objective 1c) 
5.1.2.1. Findings of the EXoCARP study  
The screening tests used to assess the EXoCARP participants were quick, easy to 
conduct, and effective in identifying participants who were not eligible to complete 
the intervention or the outcome measures/tests. The AHA/ACSM Health/Fitness 
Facility Pre-Participation Questionnaire (Appendix 8) was found to be helpful in 
identifying those participants who could not be included in the trial, generally, and in 
the CPET specifically. However, the assessor (AA: a physiotherapist) took the 
clinical decision to not perform the CPET for five participants who had high blood 
pressure during the baseline session. These participants were not diagnosed with 
hypertension, but this decision was taken as a precautionary measure, to prevent or 
minimise risk of adverse events.  
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The findings indicate that the screening tools are appropriate for future trials. 
However, undiagnosed high blood pressure, albeit transitory / short-term, should be 
considered in the screening, leading to exclusion from performing the CPET.  
 
5.1.3. Feasibility of the intervention and perceived benefits (objective 
1e and 1f) 
Adherence to the intervention 
It was important to explore whether the intervention was feasible for PLwP. The 
success of the intervention was noticed by the number of extra minutes (median 
(IQR) = 37.2 (27.1, 45.4) minutes) that participants in the exercise group spent on 
doing the intervention on top of their usual MVPA (usual time spent on MVPA was 
3.7(1.0, 8.9)), as recorded by the Actigraph.  
 
Taking into consideration that participants in the exercise group reported doing a 
median (IQR) of 32.3 (28.9, 37.5) minutes of usual physical activity (i.e. not 
including the additional intervention exercise programme), with only 3.7 (1.0, 8.9) 
minutes within the MVPA intensity, the addition of 37.2 (27.1, 45.4) minutes per day 
for three days per week of MVPA during the intervention period is considered a 
success of the intervention.  
 
It is important to mention that, originally, all participants in both groups were 
engaging in daily physical activities. This is confirmed by the physical activity 
survey, which showed that most participants, in both groups, were already doing 
between 21-30 minutes of aerobic exercise per day, three days per week, prior to 
enrolling in the study. Examples of regular physical activity included stationary 
cycling, outdoor cycling, walking, jogging, running outdoors, taekwondo, dancing, 
swimming and treadmill walking.  
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The intervention was selected based on aerobic exercise training studies that have 
resulted in improvements in cardiorespiratory fitness and maximal oxygen uptake 
(VO2max) in PLwP (Burini et al., 2006; Fernández-del-Olmo et al., 2014; Mavrommati 
et al., 2017; Ridgel et al., 2016; Schenkman et al., 2012; Shulman et al., 2013). The 
intervention in most of these studies has involved exercise durations of 30 to 40 
minutes per session, for two to five days per week. The eight -week period of the 
intervention in the EXOCARP trial had been chosen according to the 
recommendations in the British Thoracic Society (BTS) guidelines about the need of 
at least eight weeks of aerobic exercise to induce changes in pulmonary function or 
to improve quality of life in respiratory patients (British Thoracic Society, 2001).  
 
The intervention was chosen to be an unsupervised community-based intervention, 
aiming towards a sustainable intervention. Unsupervised interventions have 
advantages and disadvantages. For example, participants might overestimate or 
underestimate their exercise level and ability to work at a specific intensity, or might 
conduct unsafe or incorrect exercise that is not suitable to their individual cases. 
However, to manage monitoring of the intensity, accelerometers were used, and 
participants were educated and instructed to conduct exercise in a safe manner to 
reduce/minimise side effects. The advantage of community-based unsupervised 
interventions is that they help people to change their exercise and physical activity 
culture, and to continue doing exercises after trials (sustainability) as the 
interventions do not require specific equipment or facilities.  
 
Effectiveness of the intervention was not assessed as this was only a feasibility trial. 
However, changes in pulmonary function and CPET results were plotted in graphs. 
The figures could give an idea about how the outcome measures used might detect 
changes over time, and if any changes are needed to the outcome measures for 
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future trials. The graphs (figure 16) show that at the end of the intervention period 
there was an increase in pulmonary function outcomes (FEV1, FVC and FEV1/FVC) 
in the intervention group but not in the control group. However, minimal changes 
were seen when plotting the VO2peak results over time in both groups (changes are 
<3.5 ml.kg.min-1, which is less than one metabolic equivalent). Additionally, 
minimum changes were noticed in HR and test duration as well (refer to table 19). If 
the aim will be to assess the effectiveness of aerobic exercise on cardiac fitness, 
measured by CPET, then the intervention dose and prescription might need to be 
changed and tailored to each individual according to each participant’s results in the 
baseline CPET. In this case, it is recommended that HR monitors are provided for 
participants to wear and aerobic exercise is prescribed within a specific HR window, 
in future trials. 
  
The feasibility of the intervention was affected in participants who were engaged in 
the trial and then stopped doing the exercise due to the COVID-19 pandemic, as 
has been addressed in the second focus group. Thus, it is crucial to adapt the 
intervention for home-based or alternative exercise choices that could be used in 
unexpected circumstances, such as the COVID-19 pandemic, or any other future 
events. Subsequently, understanding the preferences of PLwP in terms of home-
based or unsupervised exercise choices is important for future trials.  
 
Acceptability of the intervention  
Focus group participants confirmed that the intervention was acceptable from their 
point of view. For example, they reported that it was easy, or it started as difficult 
and with time became easier. The intervention dose (frequency, intensity and 
duration) was found to be acceptable. Regarding the mode/type of exercise, 
participants referred to different types of exercises used as “aerobic exercise” that 
have been chosen depending on either their preference, or availability of 
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equipment. This helped them not to be limited by one type of exercise, and to 
choose the preferred type according to their interests. However, participants 
suggested that they would prefer to be prescribed a more tailored/individualised 
intensity, which could be measured objectively (for example: measuring intensity by 
HR monitors to make sure that they are exercising to a consistent level/ within a 
specific window). Prescribing exercise using HR windows will have the advantage of 
working within the needed intensity for aerobic training even after adaptations 
(Manley, 1996, Chapter 3, Page 70). This is because the cardiovascular and 
respiratory system will attain tolerance with training (i.e. HR will decrease with 
training), and subsequently the person needs to increase the intensity of exercise 
(for example: speed of walking or cycling) to achieve the required HR window 
(Manley, 1996, Chapter 3, Page 70). In other words, using the HR as a method or 
prescribing the intensity of the intervention could help participants not to stay in their 
“comfort zone” or to exceed their “moderate intensity”, and to progress the exercise 
intensity according to their improved capacity. Costing of heart rate monitors needs 
to be considered while planning for the next trial. 
 
The development of the intervention in EXoCARP was not based on a behavioural 
change model. It has been reported previously that using behavioural change 
models could help to improve adherence to physical activity interventions (Samdal, 
2017). For example: the use of goal setting and self-monitoring of behaviour when 
counselling overweight and exercise in adults and the use of a person-centred and 
autonomy supportive counselling approach were found to be important in order to 
maintain behaviour over time (Samdal, 2017). However, participants showed good 
adherence to the intervention in EXoCARP, so the use of a behavioural change 
model, such as goal setting, might not be needed in the next trial.  
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5.1.4. Acceptability and use of the selected outcome measures 
(objective 1d) 
As part of the research objectives, acceptability of the outcome measures to 
participants was assessed. The outcome measures that were used in the 
EXoCARP study were chosen carefully in terms of validity, reliability, clinical usage 
in practice and responsiveness to change (Sim and Wright, 2000). In the following 
sub-sections, these issues will be discussed for each outcome measure and 
limitations of in each outcome measure will be summarised. At the end of this 
section, the impact on designing the next trial in terms of these outcome measures 
will be discussed.  
 
5.1.4.1. Pulmonary function test (spirometry) 
Spirometry is the gold-standard method to assess pulmonary function (Miller et al., 
2005). The assessor used the standardised procedure, described in Chapter 3, 
according to the ATS/ERS guidelines for conducting spirometry.  
 
All participants completed the pulmonary function test (spirometry) at baseline, with 
no exclusions. Focus group participants’ results indicated acceptability of this test, 
and some of them were already familiar with the spirometry from speech and 
language therapy sessions. This perhaps helped to run the spirometry more easily. 
However, two participants found the test to be effortful while performing the forced 
expiratory volume test. The assessor did not find any difficulties in conducting the 
test with the included participants. One of these, who was in the exercise group, 
reported that he could not keep going with the test in the first session, and found the 
standardised motivational instructions to be stressful. But he reported an 
improvement in the experience during subsequent sessions and could notice an 
improvement in acceptability difference over time. 
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Although disposable paper mouthpieces were used, the assessor was sterilising the 
spirometry transducer in the time between each participant and the next one, while 
the next participant was completing the other tests. This took extra time and the 
more expensive disposable mouthpieces that have a filter inside might save the 
time used for sterilisation. However, the cost implications of this would need to be 
considered when planning the next trial. 
 
Although assessing effectiveness was not an objective of this feasibility study, the 
plotted data indicated an increase in FEV1, FVC, and FEV1/FVC values over time in 
the exercise group and decrease over time in the control group. Additionally, the 
same participant, who reported difficulties in conducting the test at baseline, 
reported improvement in her breathing pattern and decrease in wheezing at the end 
of intervention and the follow up sessions.  
 
Aerobic exercise refers to the use of oxygen to adequately meet energy demands 
during physical exercise (Kisner et al., 2017). In the general population, heart rate 
(HR) and respiratory rate increase during aerobic exercise to fulfil demands of the 
exercising skeletal muscles (Manley, 1996). Additionally, it has been found that 
regular aerobic exercise, such as walking, cycling, or swimming, of 30–60 minutes 
three times per week can improve lung function, improve oxygen consumption, and 
decrease shortness of breath in the general population (Myers, 2003). However, 
these effects have not been widely explored in PLwP.  
 
Baseline findings of the pulmonary function test, and pulmonary impairments in the 
early stages of Parkinson’s (Stages I, II and III in Hoehn and Yahr) will be discussed 
in detail in section 5.2 (objective 2 of the EXoCARP trial).   
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5.1.4.2. Cardiopulmonary Exercise Test (CPET) 
CPET is the gold standard method to measure cardiac fitness and response to 
physical stress. The assessor did not find any difficulties while running the CPET, 
and the American Heart Association/American College of Sport Medicine guidelines 
were followed in the sessions.  
 
The CPET was not, however, conducted with all the included participants. The 
assessor, an HCPC-registered physiotherapist, took the decision to exclude the 
CPET from the assessment tests for five participants due to them presenting with 
high blood pressure during the session, although they were not diagnosed with 
hypertension, in order to reduce/minimise potential adverse events. Missing this 
data was a loss for the study; however, safety of participants was prioritized. The 
researcher kept in mind the potential of undiagnosed, or even undeclared, 
hypertension.  
 
Participants reported no problems in conducting the CPET when asked about that in 
the focus groups, except for the saddle used on the cycle, as some participants 
reported that the saddle was not comfortable. Accordingly, if the same cycle were to 
be used in the next trial, the saddle needs to be changed, and perhaps there should 
be more than one type with different sizes and designs to suit different people. This 
needs to be considered in the costing for the next trial.  
 
Although this feasibility trial was not testing effectiveness of the intervention, or 
differences between PLwP and healthy people at the same ages, the plotted data 
for the CPET results showed almost no changes in terms of peak HR, predicted 
VO2peak, or test duration. This raises the question of whether the protocol used, with 
70% of the age predicted HR as the endpoint of the test, was challenging the 
cardiorespiratory system enough for the included sample. Taking into consideration 
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that most of the included participants were already physically active at the start of 
the study, subsequently, using the same CPET protocol in the following trials will 
need to be reviewed. The use of protocols with a higher sub-maximal level than 
70%, or the use of a maximal CPET, need to be considered. However, if a maximal 
CPET is to be conducted for PLwP, a hospital-based environment with a 
cardiologist present will be needed as risk management for older adults with 
comorbidities, according to the ACSM recommendations (American College of 
Sports Medicine, 2013). This needs to be considered when planning the next trial. 
Alternatively, other maximal forms of tests could be considered, such as the 
incremental shuttle walk test. The incremental shuttle walk test has the advantages 
of being simple, cost-effective, and relevant to functional activities (American 
College of Sports Medicine, 2013). However, the incremental shuttle walk test might 
not be the best as well for people with gait and balance impairments such as PLwP, 
and might be challenging. Additionally, the CPET remains the golden standard test 
for measuring cardiac fitness, and the most accurate in estimating maximum 
oxygen consumption (American College of Sports Medicine, 2013). 
 
5.1.4.3. Activity monitors acceptability  
Adherence to wearing the activity monitors was 75.95% (mean (SD) 42.5 (8.8) days 
out of a maximum of 56 days). This was confirmed by the focus group participants 
when asked about their adherence. However, at the same time, they reported that 
wearing the monitors around the waist was uncomfortable, or the monitor did not fit 
with their clothes. Yet, after explaining that the data are more accurate when the 
monitor is worn around the waist compared to the wrist or ankle, participants agreed 
that it is feasible to wear them around the waist despite the potential discomfort. 
Perhaps more explanation about why the device needs to be worn on the waist 
needs to be given and discussed with participants at the first session in the next 
trial. This is important to address in the next study, because Actigraph data for 
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PLwP is not considered to be accurate when worn around the wrist, due to tremor 
and bradykinesia (Kim et al., 2019). Previous research recommended using 
accelerometers around the waist for PLwP (Kim et al., 2019; Nero et al., 2015; 
Wendel et al., 2018).  
 
Median (IQR) number of steps per day for participants in the exercise group was 
6021.6 (3522.7, 7001.0), and for the control group was 5568.3 (2089.5, 7178.3). 
This is in the middle of the average range of steps per day for healthy people who 
are above 65 years old (3,000-7,000 steps per day) (Bohannon, 2007). Results of 
the Actigraph was discussed previously in section 5.1.3. 
 
5.1.4.4. Subjective outcome measures (questionnaires)  
This trial did not set out to assess the effectiveness of the intervention using 
subjective outcome measures. However, an insight into the results are summarized 
below with comparison to previous exercise trials, where possible. Additionally, 
acceptability of the subjective outcome measures is discussed in this section.  
 
The PDQ-39 results showed a similar level of quality of life for PLwP in all the 
dimensions, and in the median (IQR) total score at baseline of  0.27 (0.18, 0.37) in 
the exercise group, and 0.22 (0.07, 0.32) in the control group, compared to other 
exercise trials at baseline  (Park et al., 2014; Rafferty et al., 2017). Participants in 
the exercise group showed an increase in the domains of ADL, Emotions, Stigma, 
Cognition, Communication, Bodily Discomfort, and the total score, as can be noted 
from the bar charts, with lower scores indicating better QOL (for more details see 
section 4.5.2.1.1 in Chapter four).  
 
Participants who were in the exercise group showed a decrease (indicating 
improvement of the non-motor symptoms) in their NMSQ median score from 8.50 at 
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baseline to 7.00 at end of intervention. Baseline results of both groups indicate mild 
to moderate non-motor impairments. The potential improvement in NMSQ supports 
previous literature about the effects of exercise on non-motor symptoms (Amara 
and Memon, 2018; Dashtipour et al., 2015). 
 
The Barthel Index was shown to be correlated with the ADL dimension of the PDQ-
39 (r=-0.467, p=0.02). Subsequently, the Barthel Index could be removed from the 
battery of outcome measures used in the next trial, and assessing independence in 
ADL through the PDQ-39 might help to decrease the time needed to complete 
subjective outcomes. Although the Barthel Index has been used widely clinically, 
other scales and questionnaires have been found to have better sensitivity and 
specificity in PLwP. For example, the Hoehn and Yahr scale was found to have 98% 
specificity and 80% sensitivity in detecting dependency in ADL compared with 67% 
sensitivity and 78% specificity in the Barthel Index when assessed in PLwP 
(Bjornestad et al., 2016). 
 
The PRMQ prospective memory results showed an improvement after the eight-
week intervention period for participants who were in the exercise group, with no 
changes in the control group. Retrospective memory showed an increase in scores 
for both groups after the eight weeks. These results are very similar to results of a 
previous study that assessed the effects of aerobic exercise on prospective and 
retrospective memory in the healthy people (p<0.05) (Shamsipour Dehkordi et al., 
2018). However, the effects of aerobic exercise on prospective and retrospective 
memory in PLwP was not assessed previously, and this could be an addition to the 
next trial to further investigate the benefits of aerobic exercise in Parkinson’s.   
 
Focus group participants reported that the questionnaires were acceptable, and 
some were familiar to participants either from previous trials or from routine clinical 
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assessments. However, reported difficulties in terms of handwriting due to 
Parkinson’s symptoms suggest that, perhaps for the next trial, the use of an 
electronic device, such as an iPad or a smart tablet, to complete questionnaires, 
could be preferable and solve this handwriting problem associated with completing 
of paper and pen questionnaires. 
 
5.1.5. Adverse reactions 
No adverse reactions were reported in the EXoCARP trial. Although one participant 
reported the accelerometer to be uncomfortable, no adverse reactions were 
reported as a result of wearing it. Moreover, expected adverse reactions such as 
dizziness, imbalance, falls, pain, and depression from the outcome measures or 
from the intervention were not reported. Therefore, safety issues have not been 
identified as a concern and the same protocol could be repeated.  
 
5.2. Pulmonary function in PLwP (Objective 2) 
Assessing the prevalence of pulmonary impairment in PLwP in the early stages of 
the disease (H&Y stages I, II and III) was one of the objectives of this work. 
Interestingly, 54% of the included 24 participants showed an abnormal pulmonary 
pattern (11 participants with obstructive pulmonary pattern, one with restrictive 
pattern and one with mixed obstructive and restrictive pattern). However, these 
participants had not been diagnosed as having an abnormal pulmonary pattern 
through routine screening of lung function in PLwP, by the National Health Services 
(NHS), and were not aware about their lung impairment. As has been addressed in 
Chapter Two (section 2.3 Pulmonary Function in Parkinson’s), the systematic 




Results of the current study also showed that participants who have abnormal 
pulmonary pattern (obstructive, restrictive or mixed pattern) have higher disease 
severity and are less active physically than participants who have normal pulmonary 
pattern. Motor symptoms worsen with progression of the disease; including rigidity, 
stiffness, bradykinesia and walking impairments; and respiratory impairments might 
be linked to these symptoms. Thus, respiratory impairments might be affected by 
both physical activity level and disease severity. These results, however, need to be 
confirmed in a larger study with an appropriate sample size. 
 
There is no clear or definite cause for the abnormal lung patterns in PLwP, but 
factors such as kyphoscoliosis, chest wall rigidity and weakness of respiratory 
muscles lead to a decrease in the lung’s recoil ability, loss of elasticity, decreased 
lung volumes, affect V/Q mismatch and lead to dynamic hyperinflation of the lungs 
(Baille et al., 2016; Black and Hyatt, 1971; Estenne et al., 1984; Sabaté et al., 1996; 
Santos et al., 2019). Rigidity of chest wall muscles might lead to a reduction in chest 
wall compliance due to stiffening of tendons and ligaments and ankylosis of 
costosternal and thoraco-vertebral joints (Shill and Stacy, 2002). Furthermore, 
postural instability in Parkinson’s (Bloem, 1992) might also affect the mechanics of 
ventilation by affecting the diaphragm and, subsequently, reduction in the generated 
force by the diaphragm. Moreover, low level of physical activity due to the motor 
symptoms might lead to alveolar collapse and, subsequently, atelectasis, which 
might result in reduced lung volume and decreased lung compliance, and increase 
the elastic load (Dargaville et al. 2010). These factors can contribute to the 
abnormal pulmonary patterns in Parkinson’s. Other factors that might lead to the 
abnormal pattern include: environmental factors (e.g. dust, weather and smoke) 
(Berry and Wise, 2010); immunological factors that could affect the defence of the 
respiratory system against foreign bodies and subsequently destroy the normal 
defence mechanism in the airways (e.g. destroying the mucocilliary escalator 
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system by viral and bacterial infections) (Wanner et al., 1996); or neurological 
reasons that might affect the respiratory drive in the medulla oblongata or 
impairment to the respiratory afferent or efferent neurons (Pyatigorskaya et al., 
2016). It should be noted, however, that these factors are hypotheses for pulmonary 
impairment in Parkinson’s, but have not yet been fully investigated.  
 
These different factors that might contribute to pulmonary impairment in Parkinson’s 
highlight the importance of targeting appropriate physiotherapy management 
according to the factors that could be assessed individually. For example, if chest 
wall rigidity is the main cause, then chest expansion exercise might need to be 
embedded in a pulmonary rehabilitation programme. Similarly, if kyphoscoliosis is 
the main cause, then postural training needs to be addressed. In all cases, aerobic 
exercise is the essential main element within pulmonary rehabilitation for long-term 
respiratory conditions (Cooper, 2001), on top of other individualised exercises such 
as postural training, chest expansion exercises, or respiratory training exercises. 
Furthermore, if PLwP started to report complications or symptoms such as 
dyspnoea or secretion retention, management of those symptoms in the earlier 
stages of Parkinson’s is recommended to avoid further complications.  
 
The findings of this study suggest two main changes to current practice in the 
management of PLwP: 1) routine screening of pulmonary function in the earlier 
stages of Parkinson’s; 2) individualised physiotherapy programmes that include 
aerobic exercise in addition to other exercises, to address factors that could be 
causing abnormal pulmonary patterns. Management of pulmonary impairment in the 
earlier stages of Parkinson’s might help to reduce or delay the impairment, and 
subsequently, reduce or delay the respiratory complications that occur in the end 
stages of the disease, which are considered to be the main cause of mortality in 
Parkinson’s (Ebmeier et al., 1990). 
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It should be highlighted, however, that these findings about pulmonary function in 
PLwP are limited due to not assessing the full spirometry profile, and perhaps a 
plethysmography assessment is needed. Furthermore, assessment of respiratory 
muscles by means of a mouth pressure test might be needed to highlight respiratory 
muscle strength. This study lacked some external validity as smokers were 
excluded, and it would be interesting to explore the differences in characteristics 
(such as age, physical activity level, disease severity and dominant symptom)  
between those with and those without an abnormal pulmonary pattern in a wider 
sample size. 
 
5.3. Summary and aspects to take forward to a future study 
This pilot study investigated the feasibility of conducting a larger clinical trial to 
investigate the effects of aerobic exercise on cardiopulmonary function in the earlier 
stages of Parkinson’s (H&Y Stages I, II and III).  
 
Before finalizing plans for the next trial, consideration needs to be given to the 
challenges related to recruitment, assessment and screening, the intervention itself 
and the outcome measures. Results of the current feasibility trial reflect the need for 
further planning prior to the next trial, especially since this feasibility trial did not 
achieve the target sample size due to COVID-19 related issues. In particular, these 
include: 
• The use of multiple recruitment sites to collect data is recommended to 
boost the recruitment rate, although with resolution of the COVID-19 
pandemic and removal of restrictions to data collection experienced in this 
trial as a result of the pandemic, recruitment from a single-site in a future trial 
in the absence of a pandemic is likely to be more successful. However, it is 
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anticipated that data collection would be more challenging when multiple 
sites are used due to access to standardised equipment. 
• Further piloting would provide better understanding of and insights into the 
use and potential effects of an individualised, intensive aerobic exercise 
programme, rather than a general exercise prescription.  
 
In general, the outcome measures used in this trial were found to be acceptable to 
participants and, therefore, feasible to be used in the next trial.  
• Objective assessments including the spirometry (PFT) and the CPET are 
recommended to be used in the next trial. However, one-way filter 
mouthpieces are recommended to be used for spirometry to save time spent 
in sterilising the transducer. 
• If a maximal CPET will be conducted in the next trial, the presence of a 
cardiologist will be needed, if that is considered to be more appropriate. 
Alternatively, a maximal shuttle walk test could be used. Also, if the same 
cycle is going to be used for the next trial, more comfortable saddles with 
different types and designs are recommended to be there.  
• Subjective assessment measures used in this trial were found to be 
acceptable and easy to administer. However, the Barthel Index could be 
removed, and ADL dimension of the PDQ-39 could be used instead to save 
time because the PDQ-39 is being used anyway to collect information for the 
other domains, and collecting the ADL data using it will help in saving more 
time for both the assessor and the participants.  
• An electronic method of data collection for the questionnaires is 
recommended to avoid the need of fine movements needed for handwriting 
in Parkinson’s.  
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In order to summarize the study recommendations to improve the quality for the 
future trial, a traffic light system has been used (Sheron et al., 2012; van Meijel et 
al., 2014). Table 23 shows the aspects of this feasibility study that are not 
recommended to be continued (in red), are recommended to be continued but some 
changes are required (in yellow), or are recommended to be continued without 
changes (in green). 
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Table 23: Aspects of the trial to consider for the next trial, presented using the traffic light system (where red denotes areas that should 
not continue in the next trial, yellow denotes area that need to continue but with some changes/modifications, and green denotes areas 
that should continue as it is). 
Traffic light colour  Aspect of 
feasibility 
Considerations/changes if needed/aspects to continue or not 
continue  
 Devices Cycle: Do not use the same saddle for CPET. Need to have different 
sizes/designs to suit different people.  
Outcome measure  Do not use the Barthel Index. 
Do not use the age-predicted maximal HR formula. Use a maximal 
CPET in a hospital-based setting with a cardiologist present, or use a 




Need to continue with using Parkinson’s UK website, Parkinson’s UK 
email address and Parkinson’s UK local groups. However, using social 
media (Facebook, Twitter, etc) is recommended. Recruitment from NHS 
clinics for PLwP is also recommended. Aim to include a less-biased 
sample by marketing the trial to more sedentary PLwP and referring to 
‘activity’ rather than ‘exercise’ in the marketing resources. 
Settings  Continue collecting data from Keele. But need to add other local areas 
to boost the recruitment rate. 






Continue with the same inclusion/exclusion criteria and screening 
methods. However, another point is recommended to be added 
regarding high undiagnosed blood pressure and inclusion in the CPET.  
Intervention  Use the same intervention (community-based aerobic exercise 
programme), but with a tailored / individualised exercise prescription 
depending on results of the CPET at the first exercise session. Use 
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heart rate monitors to help participants to monitor their exercise 
intensity within the prescribed window.  
Devices and tools 
used  
Use the same spirometer devices but use disposable mouthpieces that 
have a filter inside to save time used in sterilisation. 
Use the same accelerometers but give more explanation about 
sensitivity of waist-worn devices data compared to wrist or ankle worn 
devices.  
Need a Tablet or an iPad for questionnaires data collection. 
 Outcome 
measures 
Use the same standardised pulmonary function test protocol.  
Continue using the Actigraph. 
Continue using the PDQ-39, PRMQ, NMSQ, physical activity survey 
and the GDS. 
Continue using daily exercise diaries.  
Continue conducting focus groups after the intervention and use 
thematic analysis to collect information about participant’s experiences 
about the trial. 
Blinded assessor Use the same method for blinding.   
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5.4. Strengths of the study  
The EXoCARP trial was a single-blinded mixed-methods randomised controlled 
feasibility trial. The randomization process was set up in advance by a chartered 
statistician from Keele University (Professor Julius Sim), and the blinding was 
conducted and maintained by the research supervisor (Dr Sue Hunter) who 
delivered instructions to participants according to their allocated groups, to keep the 
assessor (Aseel Aburub) blinded. The research team had reviewed the trial protocol 
and the trial was registered in the ISRCTN registry (ISRCTN14167992; 
https://doi.org/10.1186/ISRCTN14167992). 
 
The assessor was trained to conduct pulmonary function tests and spirometry 
analysis, and was certified as such by the British Thoracic Society. The training 
aimed to conduct the test according to the standards and regulations of the 
American Thoracis Society/ European Respiratory Society (ATS/ERS) in order to 
assure the quality of testing lung function.  
 
The use of a mixed-methods design helped to explore in more depth participants’ 
experiences of the trial. The combination of the quantitative and qualitative data 
provided richer insights into feasibility of planning and conducting a larger clinical 
trial in the future.  
 
PPIE meetings helped to inform the study protocol prior to conducting the study. For 
example, people in the PPIE meetings considered whether they would be happy to 
wear a facemask during the CPET, and reflected that they would prefer not to, with 
many reporting that it might make them feel claustrophobic. Accordingly, the VO2peak 
was estimated using the HR formula rather than direct measure by means of the 
oxygen consumption mask.  
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Finally, this is the first study of PLwP that has included aerobic exercise and 
pulmonary function tests. Cardiopulmonary function is often neglected in 
rehabilitation of PLwP and its routine assessment over time would be interesting to 
further expand knowledge about potential secondary complications of Parkinson’s 
and their long-term management. This is to fill the gap that is in the European 
Physiotherapy Guidelines for Parkinson’s Disease (2018), the National Institute for 
Health & Care Excellence (NICE) guidelines for Parkinson’s disease (2019), and the 
Association of Chartered Physiotherapists in Respiratory Care guidelines (Bott, 
2009) which included interventions for management of secretion retention, weak 
cough, and respiratory muscles training. However, these guidelines do not 
recommend interventions, such as aerobic exercise, to improve lung volumes in the 
early stages of Parkinson’s. Thus, if aerobic exercise is found to be an effective 
intervention to improve lung function in the early stages of Parkinson’s from a 
subsequent clinical trial, this evidence will contribute to filling the gap in these 
guidelines.  
 
5.5. Limitations of the study  
This feasibility trial is not without limitations. The COVID-19 pandemic severely 
limited recruitment to the trial and data collection; the national lockdown period 
began in March 2020, resulted in a smaller sample size (n=24) than was originally 
planned (n=50). Although we had some participants willing to travel from other 
regions, recruitment was limited to the local areas around Keele University, as the 
only assessment site was at the University. This affected recruitment to the study. 
Also, recruitment was conducted through Parkinson’s UK email groups and was not 
conducted through larger recruitment possibilities, such as the NHS or Parkinson’s 
social media groups. Furthermore, recruitment for the study attracted people who 
were relatively physically active and routinely engaged in regular exercise. The 
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advertisement should perhaps be re-worded to attract people with different exercise 
levels.  
 
Furthermore, the intervention was not prescribed based on CPET results and, 
consequently, the intensity of exercise might not have been sufficiently high to result 
in improved cardiopulmonary function and changes in the CPET from baseline. 
Participants needed more guidance in terms of intensity and exercise prescription. 
Additionally, the CPET itself was conducted as a peak test using 70% of 
participants’ maximal age-predicted HR, rather than a maximal exercise test. This is 
due to the need for a cardiologist to be on site if the maximal CPET is to be 
conducted. 
 
Another limitation in this study is that there was no participants from other ethnic 
groups than Caucasians, although recruitment was not limited to a specific gender, 
ethnic group or age group (except for being an adult). Furthermore, the first focus 
group included four males with no females, although invitations to participate in the 
focus group were sent to all participants in the exercise group from any gender. The 
resultant demographic of the focus group participants was dependent on who 
responded and agreed to participate. 
 
The development of the intervention in EXoCARP was not based on a behaviour 
change model. The objectives of the EXoCARP study were not seeking to change 
behaviour, but to see whether participants would adhere to the intervention (as part 
of the feasibility assessment). It so happened that this group of PLwP were all 
active prior to enrolling in EXoCARP; the sample was biased, and the study failed to 
recruit PLwP who were sedentary. Thus, in a future study or trial that aims to also 
recruit a more sedentary sample of PLwP, it might be beneficial to consider the 
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Social Cognitive Theory, using goal setting and self-efficacy models, in order to 
improve adherence to the exercise intervention. 
 
Due to the limitation in recruitment, and inability of the participants to continue with 
their intervention during COVID-19 pandemic, there was a need to assess how the 
pandemic affected PLwP physical activity, and other questions arose about exercise 
during the pandemic in PLwP. This led the researcher to start Study 2 of this thesis 
(Chapter 6) which is about a survey questionnaire that assessed physical activity 
levels during the pandemic, exercise limitations, and people’s preferences in term of 
indoor exercises. 
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Chapter 6: Study 2 - Physical activity during COVID-
19 period: a survey questionnaire study  
6.1. Exercise during COVID-19 questionnaire: Justification and 
brief introduction  
The EXOCARP trial (ISRCTN14167992), at Keele University has been recruiting 
participants with Parkinson’s from the community since April 2019. Participants 
were attending the exercise laboratory in the School of Allied Health Professions at 
Keele University to undertake pulmonary function tests (spirometry) and a 
cardiopulmonary exercise test on a cycle ergometer, with the researcher present 
and in close proximity during the tests. In March 2020, all research activities at 
Keele that involved face-to-face interaction were suspended temporarily, due to the 
COVID-19 pandemic and the social distancing measures implemented by the 
government. This has been the case for many similar research studies that have 
been suspended around the world.  
 
COVID‐19 caused a global pandemic as a results of severe acute respiratory 
distress syndrome coronavirus 2 (SARS‐CoV‐2) (Lu et al., 2020). COVID-19 
patients usually present with fever, pain, respiratory symptoms and sometimes 
digestive symptoms (Zhou et al., 2020). Being an older adult is one of the risk 
factors that are associated with aggressive COVID-19 symptoms leading to acute 
respiratory distress syndrome (ARDS) and, sometimes, death (Zhou et al., 2020). 
Because Parkinson's is a common neurodegenerative disease, the prevalence of 
which increases in older adults, PLwP are considered as a vulnerable group for 
COVID-19 (Tipton and Wszolek, 2020).  Additionally, motor and non-motor 
symptoms have been noted to have significantly worsened in PLwP who have been 
infected by COVID-19, ending with ARDS and, unfortunately, death (Hainque, 
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2020). Although it may be too early to understand how COVID-19 has affected 
Parkinson’s symptoms in the long-term, the danger is that COVID-19 acute 
symptoms, including loss of smell, dyspnoea, and sore throat, are hidden as they 
are already affected in Parkinson’s, making it start silently and progress until the 
appearance of chronic symptoms and development of ARDS (Cilia et al., 2020). 
Thus, it is important to consider precautionary measures for this population.  
 
One of the measures that have been put in place to protect people from COVID-19 
infection was social distancing, and the government recommendation to, initially, 
“Stay at home”, and then, subsequently, “Stay alert”. However, the initial “Stay at 
home” message placed restrictions on the number of times people could go outside 
to exercise, with just one outing for exercise per day. Thus, limiting outdoor physical 
activities and mobility for people who are normally more active than this could result 
in them leading a more sedentary lifestyle for some people, potentially leading to 
worsening of their symptoms (Helmich and Bloem, 2020). The most recent physical 
activity recommendation for older adults is to perform 150 minutes of moderate 
exercise per week (UK Chief Medical Officers' Physical Activity Guidelines, 2019), 
and the research team were interested to explore whether PLwP were actually 
achieving this level of physical activity before the quarantine, and to understand 
how the COVID-19 lockdown had affected their physical activity and exercise. 
Additionally, it is important for future research to find out if PLwP are performing any 
indoor physical exercises, and if so, what type of physical activity that is, how often 
and for how long they are performing it, and whether they have engaged in any 
indoor group exercises, such as virtual exercise/fitness groups online, DVD 
exercises groups, or videogames that involve exercise and physical activity. This is 
important especially if the lockdown was to continue, or return, to help advise and 
support people to meet the target of 150 minutes of moderate exercise per week. 
This knowledge of current practice for PLwP at home will be helpful in the 
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development of future exercise trials that need to consider indoor exercises and 
self-management approaches. Furthermore, this could also help to implement the 
recommendations published recently regarding the importance of running self-
management trials for Parkinson’s at the moment (Helmich and Bloem, 2020). 
Thus, study 2 of this thesis aimed to understand how COVID-19 has affected PLwP 
in their ability to achieve the recommended dose and intensity of exercise per week 
to maintain health. Additionally, this study aimed to understand the preferences of 
PLwP in terms of self-management exercise programmes, so that these 
preferences can be considered and used to inform the design of future studies. 
 
6.2. Objectives of the study 
The primary objective of this study was to:  
1. Understand how the COVID-19 quarantine affected physical activity and 
exercising in PLwP. 
The secondary objectives of the study were to: 
2. Find out whether PLwP are aware of the recommendation of the UK 
Chief Medical Officer’s guidelines for older adults (Gibson‐Moore, 2019), 
and if they were following these recommendations before and 
subsequently during the COVID-19 pandemic. 
3. Investigate what methods or modes of exercise were used by PLwP to 
keep exercising during the COVID-19 restrictions.  
4. Explore preferences of PLwP in terms of self-management and methods 




6.3.1. Ethical approval  
Ethical approval was received from Keele University Ethical Review Panel (ERP) 
(Appendix 22), approved 09/09/2020, Faculty of Medicine and Health Sciences 
Research Ethics Committee (FREC) (School of Medicine, Keele University, Staffs, 
ST5 6JQ; 01782 734673; k.m.adams@keele.ac.uk) ref: MH- MH-200139. 
 
6.3.2. Design 
In order to answer the research questions and achieve study objectives, an online 
self-administered questionnaire was used. Self-administered questionnaires are the 
most common method of data collection in healthcare research (Bowling, 2009). 
Designing a questionnaire should include steps that could help achieve a high-
quality, test-retest reliable and unbiased questionnaire. Thus, the process and steps 
recommended by Bowling (2009) were used while designing this questionnaire, 
which included:   
1. Determine the target and study population and sample size 
2. Decide the method of data collection and channel of questionnaire 
presentation 
3. Designing the questions  
o Developing the items and the scales 
o Memory and timeframes  
o Wording and questions  
o Order of questions  
4. Pilot and check reliability 
5. Minimise bias 
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6.3.2.1. Determine the target and study population 
The study population was PLwP, sampled from the 6000 members of Parkinson’s 
UK Research Support Network. 
 
6.3.2.1.1. Inclusion criteria 
Adults who have been diagnosed with Parkinson’s and receiving emails from 
Parkinson’s UK Research Support Network or follows Parkinson’s UK social media 
platforms were eligible to participate. Inclusion was not limited to a specific ethnic 
group, gender or age group. 
 
6.3.2.1.2. Sample Size 
Following a sample size calculation, based on the 6000 PLwP who are members in 
Parkinson’s UK Research Support Network that receive research emails, with 95% 
confidence interval (CI) and 5% marginal error, the target sample size was 362 (Hill, 
1998). 




Where: N = population size; e = Margin of error (percentage in decimal form); p 
=0.5; z = z-score. The z-score is the number of standard deviations a given 
proportion is away from the mean. With 95% CI, z-score was set as 1.96: 
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Sample size= 362 
 
6.3.2.2. Deciding the method of data collection and questionnaire 
presentation 
The method of questionnaire presentation (e.g. aural, visual, text) affects the 
cognitive and physical burden placed on respondents (Bowling, 2009). Additionally, 
the mode of delivery (for example: paper-based, online, oral interviews) imposes 
different cognitive requirements and can affect the process of responding to 
questions, and subsequently the quality of the data (Bowling, 2009). 
 
PLwP might suffer from tremor, and this could affect their ability to complete a paper 
copy of the questionnaire, and limit the numbers responding. Additionally, PLwP 
might have speech and language disorders, making it difficult to conduct a 
telephone interview questionnaire. Thus, an electronic questionnaire was distributed 
online, using Microsoft forms, via Parkinson’s UK email (invitation letter in appendix 
23).  Using Parkinson’s UK email invitations as the first point of recruitment would 
help to minimise completion of the questionnaire by people who might not have 
Parkinson’s. However, if the sample size was not achieved by email invitations and 
subsequent reminders by the deadline, then the questionnaire would be circulated 
via Parkinson’s UK social media to increase the sample size. However, we did not 
have any control over participants passing the questionnaire on to other people, 
with or without Parkinson’s, even if they were instructed not to do so, though we 
explicitly asked them not to do so.  
 
 211 
6.3.2.3. Designing the questions 
6.3.2.3.1. Developing the items and the scales  
In the process of planning and developing the items (questions) of the survey, it was 
crucial to list the research questions, create questions that could help in gathering 
information that could answer the research questions, think about the items and add 
more items, refine the questions and remove questions that were not essential, and 
finally relate the questions again to the research questions and study goals 
(Bowling, 2009). 
 
While developing the items, the researcher consulted other researchers to discuss 
the points/items, looked at similar studies that assessed physical activity during the 
pandemic in other populations (Ammar et al., 2020; Schuch et al., 2020; Yamada et 
al., 2020), and piloted the questions with a group of PLwP that were participants in 
Study -1 (EXoCARP).  
 
6.3.2.3.2. Memory and timeframes  
Some points were taken into consideration while developing the survey items for 
this population, especially that PLwP might suffer from memory impairment. Bowling 
(2009) reported that there are four steps involved in answering questions in a 
survey:  
• Comprehension of the question 
• Recall of requested information from memory 
• Evaluation of the link between the retrieved information and the 
question 
• Communication of the response/ choosing the answers. 
 
Thus, cognitive impairment was taken into consideration, specifically because the 
survey asks about the period during the quarantine. Accordingly, time-framed recall 
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bias (memory bias) was taken into consideration by following the recommendations 
to not ask about a period beyond the past six months, specifically for questionnaires 
targeting older adults (Crawley and Pring, 2000). Thus, the survey data collection 
period was between 7th of September 2020 and 22nd of October 2020, because the 
national lockdown in the UK started on 23rd of March 2020 and ended on the 22nd 
of April 2020. 
 
6.3.2.3.3. Wording and questions 
The form and wording of the items could affect answers and responses (Bowling, 
2009). Thus, it was essential to consider using simple words, short phrases and 
simple sentences. Additionally, leading questions were avoided. Leading questions 
could direct participants to answers that are biased (Jackson and Furnham, 2000). 
For example: if the researcher asked a question like “When would you like to 
participate in our study?”, this might coerce people to give a date to participate 
rather than having the choice of not registering such as when asking “Would you 
like to participate in our study?”. Additionally, closed questions were avoided, where 
possible, and open questions were used such as the second example used above. 
This is because closed questions might limit participants’ choices / answers (Sim 
and Wright, 2000). However, in some items, it was crucial to use a closed question 
depending on the purpose of the question, but filtered questions were used 
subsequently in that case. Filtered questions were used in order to further 
investigate after asking closed questions. For example, when asked about 
familiarisation of participants with the physical activity guidelines and 
recommendations, the question was: 
The physical activity guidelines and recommendations are for people with 
Parkinson’s to do 150 minutes of exercise per week. Are you familiar with 
these recommendations and were you doing exercise according to the 
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recommendations before the quarantine? (please select one statement from 
below) 
• Yes, I am familiar with the physical activity recommendations and 
guidelines, and I was doing the recommended amount of 
exercise (150 minutes per week) before the lockdown. 
• Yes, I am familiar with the physical activity recommendations and 
guidelines, but I was not doing the recommended amount of 
exercise (150 minutes per week) before the lockdown  
• No I am not familiar with the physical activity recommendations 
and guidelines, but I was doing the recommended amount of 
exercise (150 minutes per week) before the lockdown. 
• No, I am not familiar with the recommendations, but I was not 
doing the recommended amount of exercise (150 minutes per 
week) before the lockdown. 
 
However, this question was immediately followed by another question for people 
who were familiar with physical activity guidelines, in order to know how they were 
following it, and how many minutes of exercise they were performing: 
How many minutes of exercise per week you were performing, on average, 
before the COVID-19 period?  
• Please write the number of minutes here …………….. 
 
Where possible, a Likert scale or adverbial rating scale were used. A Likert scale 
consists of a statement with a number of agreement/disagreement options. An 
adverbial rating scale consists of a question with a number of options that are 
framed as adverbs (e.g. very often, often, sometimes, occasionally...). Bowling 
(2009) advises developing an odd number of options for such scales (preferably 
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five- or seven-point scales) to have a choice in the middle as an equilibrium item. 
Below is an example of an adverbial question: 
How much did you feel that the advice for everybody to “Stay at Home” 
affected your physical activity?:   
• Completely restricted my physical activity  
• Somewhat restricted my physical activity  
• Minimally restricted my physical activity  
• Did not change my physical activity at all 
• Minimally increased my physical activity 
• Somewhat enabled me to increase my physical activity 
• Significantly increased my physical activity  
 
6.3.2.3.4. Order of questions 
Bowling (2009) recommended that ordering of questions is very important in the 
process of answering and could help in avoiding distraction of the reader. It is 
recommended that researchers do not keep changing the topic of the questions and 
then return back to it (Bowling, 2009). Accordingly, the questionnaire was 
developed in a way that it included the following sections in the following order:  
• A question to understand what PLwP do to protect themselves 
from COVID-19. 
• Questions about familiarity of physical activity recommendations. 
• Questions about physical activity level and mode (type of 
exercise) before the quarantine, during the “Stay at home” 
regulations, and during the “Stay alert” recommendations during 
COVID-19 pandemic. 
• A question about their preference in terms of future self-
management mode of exercise. 
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• Questions about Parkinson’s UK exercise groups. 
• Questions about any Parkinson’s symptoms (if found) that 
deteriorated during the COVID-19 period. 
• A final question if they have any comments about the study.  
 
The final full questionnaire is in Appendix 24. 
 
6.3.2.4. Piloting and reliability 
Before distributing the questionnaire online through Parkinson’s UK, the 
questionnaire was piloted by sending it to PLwP who were participants in a previous 
trial and who had provided written consent, with preferred contact details, to be 
contacted in relation to further research studies. This was to make sure that they 
were happy with the wording, could understand it easily, think that this is 
appropriate to share it through Parkinson’s UK, and to suggest any changes (if 
needed). According to Bowling (2009), a sample size of at least 12 participants is 
recommended for piloting questionnaires. Thus, for piloting issues, the 
questionnaire was sent by email to participants of the study 1 in this thesis (the 
EXOCARP trial) who provided written consent to be contacted by email for future 
studies (n=24).   
 
In order to assess test-retest reliability, participants who piloted the questionnaire 
were asked to complete it again after one week. The one-week gap was considered 
between sessions to minimize potential recall bias (Portney, 2020), but for the test-
retest reliability check, each participant had a different Microsoft Forms link from the 
others. Figure 35 shows the different links that has been send to each participant. 
This is because we needed to check for agreement in the answers for the same 






Figure 35: Screenshot showing a different link (form) for each responder in the pilot 
phase of the questionnaire to ensure that answers of each responder will be 
compared by his/her answers after one week, and not by answers of any other 
responders. 
 
6.3.2.5. Minimising bias (non-response and recall bias) 
The questionnaire was sent to Parkinson’s UK members through Parkinson’s UK 
email groups. This did not limit the non-response bias (Portney, 2020), which may 
be caused by the following: people might forget to complete and return the survey; 
people might be busy and not have time to complete it; the survey may be too long 
for them; people might not have internet internet/IT access; or people might be 
concerned about security and data integrity (Atif et al., 2012). Non-response bias is 
the bias that exists in the data because respondents to a survey are different from 
those who did not respond or responded late (Atif et al., 2012). Several techniques 
have been suggested to reduce non-response bias such as an attractive cover 
letter, clear instructions on how to answer the questions, gentle emails as 
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reminders, emphasizing the confidentiality of the material, reducing the number of 
questions, and flexible scheduling (Atif et al., 2012). Accordingly, while planning for 
data collection, minimising non-response bias was taken into consideration, and the 
survey questionnaire included clear instructions, with a total of 26 questions, and 
two gentle reminders were sent (appendix 25) by the Research Participation Lead in 
Parkinson’s UK. However, all of these techniques will not fully prevent non-
response bias, and the possibility of such bias should be acknowledged whenever 
there are missing returns.  
 
6.3.3. Statistical analysis 
Data were analysed using the SPSS, Version 21 (SPSS, Chicago)). Test-retest 
reliability assessment was conducted for questions that included numbers as an 
answer (for example: number of minutes), or questions that included choosing one 
answer only. These include questions number 2, 3, 4, 5, 7, 8, 11, 12, 15, 16, 18, 
and 19. Data reported for the test-retest reliability included medians and Kappa 
coefficient (indications of Kappa results: 0.0 – 0.20 slight agreement; 0.21 – 0.40 
fair agreement; 0.41 – 0.60; moderate agreement; 0.61 – 0.80; substantial 
agreement; 0.81 – 1.00 almost perfect agreement) (Landis and Koch, 1977).  
 
For the main study, no total scores were calculated, and only descriptive statistics 
including frequencies, proportions, counts and medians/modes of answers were 
recorded (for example: 105 participants answered that they use a stationary cycle, 
etc.). Figures for the answers were created using Microsoft Excel.  
 
6.3.4. Thematic analysis of question 26 
Answers to question number 26: “If you would like to, please add any additional 
comments about how the COVID-19 period and social distancing regulations have 
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affected your life”, contained qualitative data. Thus, simple thematic analysis was 
used to analyse the responses to this question (for more details about thematic 
analysis, refer to section 3.5.12 in Study 1). Thematic analysis is a flexible method 
of analysis of qualitative data that is not restricted to a particular epistemological or 
theoretical perspective (Braun and Clarke, 2006).  
 
6.4. Results 
6.4.1. Pilot study 
Twelve responders completed the questionnaire at day one, and re-filled it again 
after one week for the test-retest piloting without having access to their previous 
responses. Table 24 represents the test-retest reliability of the questions tested. As 
seen from table 24, the kappa coefficient=1 in most questions indicating almost 
perfect agreement. Medians of questions’ scores at the test and the retest are 
reported in table 24.  
 
Two participants spotted a repetition in a phrase (a typographical error) in the online 
questionnaire and contacted the research team to advise them of this while piloting 
the questionnaire. Accordingly, the repeated phrase was removed. No other 
comments were received from participants in the pilot phase.  
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Table 24: Results of the test retest reliability for the questionnaire. 
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6.4.2. Results of the main study 
In total, 441 participants submitted the online questionnaire, which was 121.8% of 
the targeted sample size, and 7.35% of the population sampled. Out of these, 25 
responders only completed the consent section but did not complete any of the 
subsequent questions. Thus, 416 questionnaires were included in the analysis, 
which was 114.9% of the targeted sample size and 6.93% of the population 
sampled. Average time to complete the questionnaire was 14 minutes.  
 
6.4.2.1. Demographics 
Mean (SD) age was 70.43 (7.26) years, and time since diagnosis was 6.22 (5.05) 
years (table 25). A total of 191 participants described their gender as male, 221 as 
female, and 4 as “other”. Information about ethnicity was not requested and 
therefore not reported. 
 
6.4.2.2. Usual physical activity 
Most participants (n=329, 79%) reported that they could walk independently without 
the need for walking aids, and for more than one mile (n=209, 50%) (figure 36). The 
mean (SD) time per week spent exercising was 203.83 (175.54) minutes (table 25).  
 
 
Table 25: answers for questions 6, 10 and 13. 




Average time spent 
performing aerobic 
exercise per week before 
the COVID-19 period 
(minutes) 
Mean (SD) 70.43 (7.26) 6.22 (5.05)  
 
203.83 (175.54)  
Minimum 55.00 2 months 0.00  





Figure 36: Answers to questions 8 and 9. 
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6.4.2.3. Precautionary acts to protect from COVID-19 
Responders reported practising social distancing, hand washing, using hand 
sanitizer, staying at home, eating healthy food, getting some rest and sleep and 
shielding at home, respectively, as precautionary acts to protect themselves from 
getting the virus (figure 37). Other comments included practising exercise at home 
and taking vitamin D.   
 
6.4.2.4. Usual physical activity before the pandemic 
Prior to the pandemic, 343 (82%) responders reported that they were “walking 
outdoors” and 234 (56%) reported that “gardening” was their main exercise; 130 
(31%) responders reported that they do not have any of the exercise equipment that 
were mentioned in the choices for that question (figure 38).  Other types of usual 
exercise included yoga, table tennis, aqua-aerobic exercises, golf, Zumba, 
taekwondo, boxing, Pilates, and dancing. 
 
6.4.2.5. COVID-19 pandemic effect on physical activity 
A total of 170 (41%) responders reported that the instructions “Stay at Home” 
somewhat restricted their physical activity while 159 responders (38%) reported no 
change to their physical activity level with the instructions “Stay alert” (figure 39). A 
total of 40 responders reported strong negative experiences of the restrictive effects 
that the COVID-19 pandemic had not only on their physical activity but also on their 
life: 
'Completely destroyed my life' 
'Restricted everything in my life' 
However, some activities such as gardening, which were done at home, were not 
affected: 
'restricted everything except gardening'.  
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Figure 37: results of question 11. 
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Figure 38: answers to questions 14 and 15. 
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Figure 39: Answers to questions 16 and 17. 
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6.4.2.6. Adapting exercise during the pandemic 
During the COVID-19 period, 181 (44%) responders reported using web-based 
virtual exercise classes, 52 (13%) were using a web-information portal for 
exercising, 51 (12%) engaged with TV exercises, and 36 (9%) reported using DVD 
exercises (figure 35). Gardening, followed by web-based virtual classes, were 
reported as activities that might help to exercise more at home (figure 40).  Other 
comments included golf, Xbox, Wii fit, PlayStation, yoga and dog walking.  
 
6.4.2.7. Parkinson’s UK exercise groups 
A total of 211 responders (51%) reported that they were not attending Parkinson’s 
UK exercise fitness group at all before the COVID-19 period, 90  (22%) reported 
that they were attending regularly on a basis of once per week, and 76 (18%) 
reported attending more than once per week before the COVID-19 period (figure 
36). For 219 (53%) responders, the question “Because of COVID-19 social 
distancing regulation, have you missed attending your Parkinson’s UK exercise 
group?” was not applicable, whereas 174 (41%) responded with “Yes” and 23 (6%) 
responded with “No” (figure 41). Social contact and communication with other group 
members was the most frequent aspect that they missed from the Parkinson’s UK 
groups, followed by the exercise itself and the physical activity, and the getting out 
of the house (figure 36). When asked about returning to Parkinson’s UK groups, 
158 responders (38%) reported that it was too risky at that time, and 130 (13%) 
reported that they felt that they would need to get back to the Parkinson’s UK 
groups, while the others (n=130, 31%) chose “Not applicable” (figure 42). 
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  Figure 42: Answers to questions 23 and 24. 
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6.4.2.8. COVID-19 pandemic and Parkinson’s symptoms 
Bradykinesia, stiffness, tremor and fatigue were the symptoms that were most frequently 
reported to have worsened since the start of COVID-19 period (figure 43). One participant 
reported that worsening of symptoms is not always obvious, as it occurs slowly and perhaps 
without the person realising it is happening:  
“I can't say that I've noticed any quantum worsening, but then it's an  
 insidious enemy - it creeps up on you”.  
 
6.4.2.9. Effects of the COVID-19 period and social distancing regulations on the 
lives of PLwP (question 26) 
Three main themes (exercise, symptoms affected and social contact), and eleven 
subthemes arose from the thematic analysis. Table 26 represents the themes identified from 
the question 26 of the questionnaire. 
 
Table 26: Topics and themes identified from Question 26 in the questionnaire. 
Themes Sub-themes 
Exercise  Affected negatively (restricted exercise level). 
Exercise groups and sport centres. 
Factors that limited exercise participation. 
Affected positively (improved exercise level). 
 
Symptoms affected  Worsening of mental, cognitive and physical symptoms  
Social contact  Loss of social contact and isolation  
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Figure 43: Answers to question 25. 
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6.4.2.9.1. Theme: Exercise 
Sub-theme: Affected negatively (restricted exercise level) 
In response to question 26, “If you would like to, please add any additional 
comments about how the COVID-19 period and social distancing regulations have 
affected your life”, comments highlighted that the types of exercise available and the 
restrictions on where people were allowed to exercise, due to the lockdown and 
social distancing regulations, was limiting their ability to undertake physical activity: 
“The social distancing regs are restricting the range and location where 
exercise can be taken and being unable to exercise”.  
 
One comment suggested that this restriction on choice was affecting their mental 
health: 
“The lack of freedom of choice to choose when you want to do any activity is 
very restrictive and can be depressing”.  
 
Sub-theme: Exercise groups and sport centres 
Some reported that the closure of Parkinson’s UK exercise groups, fitness clubs 
and sport centres as the reason why they did not do exercise during the COVID-19 
period: 
“Closure of swimming pools for several months; closure of Parkrun on 
Saturday mornings; both of those reduced my exercise since March”  
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“Reduced my attending my local sports centre for several months as it was 
closed my aerobics class cancelled. My yoga class closed and will not be 
restarting!” 
 
“unable to attend the fortnightly Parkinson’s group meetings (they still have 
not restarted)” 
 
Furthermore, some classes were just no longer available due to funding issues to 
charity centres for Parkinson’s during the pandemic, thus further limiting 
opportunities to continue to exercise during this period of time:  
“I cannot return to dance classes as funding has been withdrawn”.  
 
The benefits of group exercise and peer support were also highlighted in some 
comments as effects of the pandemic restrictions on the lives of PLwP: 
“Exercising in a group is not only good physically but also gives great 
support for each other”,   
 
“Prevented participation in regular club events i.e. group cycle rides, table 






Sub-theme: Factors that limited exercise participation  
The decreased physical activity and exercise level also was attributed to the lack of 
social contact with their peers, which they used to get while exercising in a group 
setting:  
“I realise how important the ballet and exercise classes have become to me 
since losing them. Also now aware of importance of social contact of work, 
generally going out and even group therapy - Exercise *much* easier when 
done in a group”. 
 
Some comments included environmental factors that affected their exercise level. 
These included lack of space to exercise at home,  
“I have a very small studio flat, so I cannot exercise at home, by Youtube, or 
Zoom” 
anxiety about becoming infected with COVID-19 when exercising outdoors where 
there are many other people,  
“I have missed being able to go out walking as freely as I was used to. We 
usually walk along a canal towpath not far away (because it is flat) but it has 
not felt safe to do so - too many people” 
and lack of motivation:  
“Also difficult to motivate to do exercise even though I know the importance 
of exercise”  
 
“am completely demotivated regarding exercise”  
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“Very restrictive . Exercise almost stopped and difficult to motivate myself to 
do on my own”. 
 
Exercising at the gym was another factor that responders highlighted as offering a 
structured routine and time that can be dedicated to exercise, providing equipment, 
instructors and motivation:  
“I find attending my normal gym gives me the discipline of having a set time 
to myself to exercise & my instructors enthusiasm and personal knowledge 
of my health and family circumstances keeps me motivated and addresses 
any issues that I have the social contact“ 
 
The trend for on-line exercise classes during the pandemic lockdown, using Zoom 
for example, was beneficial for some, but there was still difficulty accessing the 
equipment that had been previously used use during these exercise classes: 
“Parkinson’s exercise class went on-line (Zoom) which has been very helpful 
but the equipment we used to use (rowing machine, punch ball etc) in the 
village hall was obviously unavailable”  
 
Sub-theme: Affected positively (improved exercise level) 
On the other hand, some people were benefiting from time at home and increased 
their physical activity during lockdown period:  
“I got far more exercise during lockdown -- approx 25 miles on bike (nearly 3 
hrs) per week”  
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“I have discovered “reach your peak online”, with that 5 times a week plus lots 
of stretch routines they provide, plus cycling, badminton, online live Zumba, 
walking hillwalking basketball training, I have a lot to do”.  
 
Mainly, online or virtual exercise classes were reported to be ‘better than nothing’, 
and featured in comments of those who reported to have increased their exercise 
level:  
“During lockdown, I got into the routine of starting the day with exercise: PD 
Warrior warm up and Joe Wicks for seniors on Youtube”  
 
“I have added Pilates and Tai Chi to my exercise regime as they are taught 
by my PD Dance teacher through Zoom. I walk with a friend once”,  
 
Online classes were also beneficial for some people who could not be included in 
exercise group before COVID-19 period due to location/travel issues:   
“Stopped live dance classes but enabled Zoom live PD warrior with 
Hallamshire Physiotherapy. I live near Hertford and searched in vain for 
three years for a local pd warrior class. Lockdown enabled me to join the 
Sheffield based Zoom classes which greatly benefited and improved my 
symptoms”  
 
“I feel that the COVID crisis has actually meant that there are more 
opportunities to exercise from home and there is wonderful new market in 
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terms of exercise opportunities. Apart from regular, brilliant PD Warrior 
classes run by some trainers in Bristol (I'm in London), I've participated in 
Yoga classes from Bridlington and weight bearing training from the States”.  
 
6.4.2.9.2. Theme: Symptoms affected 
Sub-theme: Worsening of mental, cognitive and physical symptoms  
Beside physical activity level and exercise, responders reported other effects of the 
COVID-19 period on their life, symptoms, and disease progression, such as:  
• Anxiety, depression, fear and mental wellbeing:  
“The threat of catching COVID-19 did, however, cause some anxiety” 
“I found it very distressing at times. Anxiety levels rose significantly” 
“The main impact has been my mental wellbeing” 
“Increased sense of isolation and loneliness from not being able to 
meet friends and family and other group participants in person” 
“My panic attacks have been worse” 
“Very anxious prescribed propananol. Low mood under more stress 
not sleeping” 
“Fear of contracting deadly virus meant less time spent outdoors”  
“I am alive, but not living!”.  
• Fatigue and lack of energy:  
“I feel weaker with a lack of energy and fatigued. I sometimes feel a bit 
lethargic”.  
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• Progression of the disease: 
“I found that my progression of Parkinson’s caused me to ask for an 
urgent appointment to start medication”,  
 
“my Parkinson's became much worse, very quickly. I was surprised at 
this as it is supposed to be a slowly progressing disease”.  
• Back pain:  
“As I exercised less my walking became harder and my backaches 
became worse. A vicious circle!!” 
• Stiffness and flexibility  
“Stiffness and flexibility affected”. 
 
6.4.2.9.3. Theme: Social contact   
Sub-theme: Loss of social contact and isolation 
In addition to exercise limitation, social contact was affected, resulting in social 
isolation and loneliness in some cases, and this loss of social contact reported very 
frequently in the comments:  
“I also have family abroad and can not see them due to risk and restrictions” 
 
“Increased sense of isolation and loneliness from not being able to meet 
friends and family and other group participants in person”  
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“I miss not being able to hug my children and grandsons and other members 
of my family”  
 
“Serious illness of my sister which led to her death. Contact with her was 
affected both during her illness and at her subsequent funeral”.  
 
6.5. Discussion 
This is the first study reporting how the COVID-19 pandemic affected exercise and 
physical activity in PLwP. During the COVID-19 outbreak, the proportion of 
responders who decreased their duration of intensity of exercise or did not exercise 
at all increased, and the proportion of responders continuing exercise at sports 
facilities decreased. This survey on PLwP showed that the COVID-19 outbreak, and 
its subsequent restrictions, had a significant impact on the lives of PLwP in general, 
including social, physical and mental effects. Furthermore, this survey helps to 
complement findings of the feasibility study (EXoCARP), in terms of the intervention 
design; including interventions in a larger clinical trial in the future that could not be 
affected by further outbreaks of COVID-19 and the resultant restrictions on activity, 
or by other crises or pandemics, is important. 
 
Exercise was affected mainly during the COVID-19 period with the government’s 
instructions “Stay at home”. This could be explained by answers of 343 people 
(82% of the sample) who reported outdoor walking as the main aerobic exercise 
that they were performing before the pandemic. Subsequently, because the 
instruction was to 'Stay at home', people who were previously walking outdoors, 
cycling outdoor or doing any form of outdoor exercise stopped doing so. 
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Additionally, comments about the closure of sport/fitness clubs, and exercise groups 
might be another reason for the decrease or restriction of their physical activity 
levels. This was also confirmed by comments about lack of freedom to choose the 
exercise mode, location, space and time. As has been noted previously in the 
literature, freedom to choose the preferred type of exercise is a major factor that 
affects adherence and compliance to physical activity and physiotherapy 
programmes (Iso-Ahola, 2009). Subsequently, this factor was hugely affected by the 
restrictions during the pandemic.  
 
The sample that participated in the study revealed that most of them were familiar 
with the physical activity recommendations for PLwP to perform 150 minutes of 
exercise, with a median of 203 minutes per week reported. This indicates a good 
level of awareness and health education about the importance of exercise for this 
population. However, 135 responders (32%) did not know about the 
recommendations and were not familiar with the physical activity guidelines. 
Subsequently, further education from clinicians and Parkinson’s organisations 
needs to be disseminated as much as possible, to promote physical activity and 
exercise to PLwP.  
 
People who performed exercise during the pandemic reported that they have 
engaged most frequently with web-based and virtual exercise classes as their 
indoor activity during the pandemic. In the comments of the last question of the 
questionnaire (question 26), people reported many websites and online groups 
(anonymised here) with which they have engaged, as well as television 
programmes. 
 
When asked about their preference for exercise that could be conducted at home, 
respondents reported gardening and web-based exercise as number one, followed 
 241 
by stationary cycling and treadmill walking and DVD exercises. These preferences 
are important and should be considered for future exercise trials, self-management 
programmes, and physiotherapy management for PLwP, to enhance opportunity for 
exercise and adherence to any trial intervention protocols. It is highly recommended 
that future research considers self-managed and minimally-supervised exercise 
programmes for PLwP, to encourage sustainability and continuation of the exercise 
programme beyond the trial (Estabrooks et al., 2011). This is particularly important 
for the implementation of findings where the trial exercise programme is found to be 
effective. However, the benefits of developing exercise habits are well-documented, 
and any such behaviour change that can be sustained and reflects the 
recommended guidance for exercise frequency and intensity is likely to be of benefit 
to PLwP (Estabrooks et al., 2011). Furthermore, with many hospitals and outpatient 
centres limiting their face-to-face sessions, sustainable solutions and platforms for 
interventions to shift the current model of care for physiotherapy programmes for 
this population are needed, to overcome any pandemics or future circumstances. 
However, few points for these solutions need to be taken into consideration while 
planning for these types of interventions in future trials, including access to 
internet/telehealth, training for both patients and physiotherapists, and safety 
measures for minimally supervised or unsupervised exercise sessions.  
 
Recent studies are implementing new minimally supervised interventions to 
increase physical activity and exercise levels in older adults such as using virtual 
reality avatars to enhance exercise (Horne et al., 2020), video games including Wii 
and Xbox (Carrasco et al., 2020), and peer-support online physical activity groups 
(Crozier et al., 2020). These interventions are needed in such circumstances, and 
results of the survey support the urge of developing such interventions for PLwP.  
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This survey revealed many comments about the issue of social contact and how the 
COVID-19 pandemic affected responders’ social life with their families, friends, and 
other PLwP. This also was reported by several comments about depression and 
loss of confidence due to the decrease in social contact with other people. Some 
comments indicated great sadness and feelings of depression, and some indicated 
how PLwP feel lonely and isolated while in home. Additionally, anxiety and mental 
health disorders might be hugely affected, according to the questionnaire results. 
These results are consistent with studies that assessed mental and sleep health 
during the pandemic (Helmich and Bloem, 2020). Perhaps physical inactivity during 
the pandemic contributed to worsening in these symptoms, because it was reported 
previously that exercise helps to reduce anxiety, depression, cognitive impairment 
and improve sleep quality in PLwP (Amara and Memon, 2018; Memarian et al., 
2017; Wassom et al., 2015). 
 
It was reported previously, long before the pandemic, that PLwP suffer from 
isolation and decrease in their social activity and quality of life (Forsaa et al., 2008; 
Karlsen et al., 2000). The social isolation was attributed to the feeling of shame 
about their speech impairments, slowness of movement, freezing of gait, tremor or 
the lack of facial expressions that is covered by the Parkinson’s Mask Face life 
(Forsaa et al., 2008; Karlsen et al., 2000). While in the coronavirus months, the self-
isolation, shielding at home or social distancing regulations imposed further 
loneliness and social effects on top of their pre-COVID-19 isolation. With the 
uncertainty brought about by the current pandemic, it is advantageous to start 
thinking about altering the current model of care for psychological health and mental 
health for PLwP. 
 
Furthermore, most PLwP who were attending Parkinson’s UK exercise groups 
(77%) reported that they missed attending the groups; specifically, they indicated 
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that they were missing the social contact and the exercise classes. This finding 
indicates the importance of Parkinson’s UK peer support group for PLwP. These 
groups usually offer social support and physical exercise that is usually conducted 
by an exercise specialist or a physiotherapist. However, around half of those 
thought it too risky to return to the groups now, whilst the other half thought that 
they did need to return to the groups. The threat of potential closure of Parkinson’s 
UK groups,  making them no longer available to PLwP, due to lack of funding 
(through non-attendance), would limit the opportunity for peer support, social 
contact, and regular exercise developed specifically for PLwP. 
 
While the main focus of this survey was about exercise and physical activity during 
the pandemic, rather than mental health, understanding mental and social effects of 
the pandemic could help to improve exercise duration or intensity for this 
population. For example, trials that used group-exercise interventions reported 
higher exercise engagement and adherence than self-exercise trials (Hackney et 
al., 2007; Mitchell et al., 1987). These results are important in terms of building 
future studies. For example, a virtual online group exercise trial, with a space for 
social contact, might be a suggestion for consideration.  
 
Bradykinesia, stiffness, tremor and fatigue were at the top of the list of symptoms 
that were reported as having worsened since the start of the COVID-19 period. The 
progression of these symptoms was previously reported to be less in people who 
perform aerobic exercise and physical activity interventions (Dashtipour et al., 2015; 
dos Santos Delabary et al., 2018; Fox et al., 2018; Schmitz‐Hübsch et al., 2006). 
Subsequently, these results support the importance of our recommendations to start 
remote exercise trials to reduce symptoms, improve quality of life and continue 
care-management while in confined environments or restricted circumstances.  
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Strengths and limitations  
This is the first study to report how the COVID-19 pandemic affected exercise and 
physical activity in PLwP. Additionally, this study has provided knowledge about 
exercise preferences in PLwP in terms of indoor exercises. Findings of this study 
are important while planning for future research that include exercise in PLwP. 
 
This study is not without any limitations. The study could not address the non-
response bias in full. The survey was sent to participants by email. The 
disadvantage of using emails includes: the potential for participants not to open the 
email; the potential for the email to be received into another folder other than the 
main inbox (for example, junk folders, advertisements and spams); people might not 
have internet connection or internet connection might be disrupted during the time 
period set aside for completion of the online survey; some participants might have 
changed their email address and not informed Parkinson’s UK, who sent the 
questionnaire to those on their email list; or some participants might have difficulties 
completing the whole survey online, maybe due to cognitive or visual reasons, or 
maybe due to lack of technological skills. These factors might have limited 
recruitment, response rate, and data collection. Not requesting ethnicity from the 
participants was a limitation as there might be important differences between ethnic 
groups in terms of their usual physical activity levels and their preference for 
exercise (e.g. DVD, groups, at home or at Parkinson’s UK groups) and this should 
be considered in future surveys. 
 
Summary 
This survey questionnaire revealed a decrease in physical activity in PLwP while in 
the COVID-19 pandemic. This might be due to the restricted freedom to choose 
exercise mode and type, or due to the closure of Parkinson’s UK exercise groups or 
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sport clubs and facilities. Additionally, the survey showed that the social aspect of 
exercise was hugely affected, and people were missing the social contact mostly in 
exercise groups.  
 
Furthermore, the survey summarizes that people prefer online virtual exercise 
classes, stationary cycling and treadmill running, and DVD exercises as 
remote/indoor exercise methods, and think they might help them during the 
pandemic.  
 
Accordingly, the results of this survey indicate the importance of designing remote 
or minimally supervised exercise trial interventions, taking into consideration 
people’s preferences regarding mode of exercise, and social contact. This finding 
complements the findings of the mixed-methods feasibility study (EXoCARP), 
highlighting that an exercise intervention for a future clinical trial needs to be 







Chapter 7: Reflexivity  
Reflexivity is often regarded as a crucial element within qualitative research 
(Clissett, 2008). This is mainly because qualitative researchers do not regard 
themselves as objective observers, but as participants in a dynamic relationship 
with their research (Colaizzi, 1978; Ryan and Golden, 2006). Thus, reflexivity could 
be one of the methods to increase the credibility of qualitative research to enhance 
quality and to increase the transparency of the researcher’s position (Patton, 2002; 
Walker et al., 2013). Additionally, the researcher’s personal and professional factors 
might affect the results, and it is recommended that these factors are reported in 
qualitative research (Mannix et al., 2015). For example, the researchers’ gender, 
age, and experience (including clinical experience) might affect the interpretation 
and analysis of the qualitative data. Thus, this section will include my own 
reflections on aspects of the research, including PPIE meetings and group visits, 
focus groups, COVID-19 pandemic restrictions, and recruitment through 
Parkinson’s UK.  
 
7.1. PPIE meetings and group visits’ reflections and 
observations 
In this PhD, I spent time facilitating the PPIE meetings (three groups) and visiting 
Parkinson’s UK local groups (four groups) for recruitment. These visits improved my 
confidence towards the research idea and methodology. PPIE meetings were very 
helpful in confirming the choice of method of assessment regarding using the cycle 
rather than the treadmill for the CPET, and shaped our methodology by group 
members reporting claustrophobia and being uncomfortable to exercise while 
wearing a mask. The PPIE meetings gave me confidence about the project idea 
and methods before submitting the ethical committee application, and before 
starting data collection.  
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During Parkinson’s UK local groups visits, we were sometimes invited to attend their 
own exercise sessions before presenting our research project for recruitment. Thus, 
I had the opportunity to observe two exercise sessions and to reflect on them. I 
noticed that the physiotherapists who ran both sessions played an important role in 
motivating group members to exercise, understand what is helpful and what is 
needed for the members, and understanding the meaning of aerobic exercise. I 
observed that one physiotherapist acted as an assertive person for her group 
members, choosing motivational music from previous decades while running 
aerobic exercise, and showing an understanding of different disease severity levels 
by choosing an alternative for each movement for those who were unable to do it. In 
contrast, the other physiotherapist was asking PLwP to perform flexibility exercises, 
but calling the session an “aerobic exercise session”, and without considering 
different disease severity levels. There is no guidance about not performing 
flexibility exercise for PLwP. However, flexibility exercises are prescribed to reduce 
rigidity, stiffness and kyphoscoliosis, and to improve gait in PLwP (Gobbi et al., 
2009; Reuter et al., 2011; Schenkman et al., 1998). There is no literature to support  
the use of flexibility exercises as an alternative to aerobic exercise for PLwP. 
Although there is no specific guidance in the literature about a specific exercise limit 
for PLwP as a “threshold” to hit aerobic exercise and not to stay in the “comfort 
zone”, but through the observations of that visit (the second visit) and through my 
previous experience, I felt that PLwP with different disease severity might have 
different “aerobic thresholds”. This observation led me to think about future research 
about aerobic thresholds in different disease severities in PLwP. Also, while thinking 
about the two sessions, I would support the use of an assessment tool (for example: 
Borg RPE scale or heart rate monitors) to make sure that PLwP are exercising at 
the required level of intensity and hitting their aerobic threshold individually.  
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7.2. Focus groups reflection 
As a PhD student and a researcher, this was the first time I have conducted 
exploratory research collecting and analysing qualitative data, since all my previous 
research studies involved the collection and analysis of only quantitative data. 
When I first sent the proposal of EXoCARP trial and discussed it with my 
supervisor, the supervisor suggested adding the focus group. I did not feel confident 
that time, and I was trying to avoid adding the qualitative part to my PhD. I did not 
realise the importance of qualitative research on that day, until I read more about 
mixed methods trials. When I conducted the first focus group, I realised how 
qualitative data could add value to the trial, and how participants’ opinions could be 
important when planning for the future trial. Subsequently, I became “in love” with 
qualitative studies, and I think using it in my future work will lead me to learn more 
and to get more knowledge needed in the studies.  
 
Thus, I have considered the first focus group to be a trial for myself, to reflect and to 
be well-equipped for the following focus groups and any following qualitative 
research. Additionally, the PhD supervisor guided me to register in a workshop 
entitled “Running a Focus Group” at Keele University, beside the regular 
supervisory meetings and advice on running focus groups. The workshop was good 
for beginners to understand how to run focus groups, how to manage discussions 
while running the interviews, how to get the most out of participants in interviews, 
and how to perform a simple thematic analysis. I have learnt from it how to 
transcribe a record, identify codes and themes for qualitative data.  
 
An important dimension in reflexivity for this study was my professional background 
as a physiotherapist and as a researcher of neurodegenerative diseases 
(Parkinson’s and Multiple Sclerosis), which could influence data collection and 
analysis (Finlay and Ballinger, 2006). My interest in this area of research stemmed 
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from my research background working with PLwP, in addition to lecturing on both 
cardiopulmonary and neurological rehabilitation. This might have influenced the 
focus group questions and my unconscious perception of the anticipated answers. 
For example, I was anticipating that participants would mention balance impairment, 
vision impairment, fatigue, shortness of breath, freezing of gait, and rigidity as 
answers to the question about barriers that limited participants to exercise.  
 
However, I did not anticipate an answer such as “time” as a barrier for them to do 
exercise, taking into consideration that most of them were retired. Anticipating the 
answers might have affected data collection in the first focus group. This is because 
I was waiting to hear these specific answers and might not have dug deep enough 
in relation to other factors. While asking the questions, I may have subconsciously 
asked them if there were any other factors and moved on to the next question 
without investigating or asking participants to expand their responses in more detail. 
Moreover, I was trying to avoid the use of any professional jargon, or words that 
participants may not understand, and focused on using lay language instead. This 
put an extra effort on myself as an international student whose first language is not 
English. Additionally, if participants had speech problems, it required an extra effort 
for me during the focus groups and again while transcribing the audio records. 
Speech disorders that some participants had was one of the issues that I need to 
reflect on. For some sentences, I was asking the same participant to repeat the 
sentence (two times), after which I avoided asking for it to be to repeated again. I 
felt that asking the participant to repeat too many times might embarrass the 
participant and might lead the participant to avoid discussing with the group. 
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7.3. COVID-19 pandemic restrictions: concerns from a PhD 
student point of view 
The pandemic governmental regulations affected higher education in different 
degrees (diplomas, bachelor’s, master’s or PhD). However, undergraduates were 
lucky to have alternatives and solutions to minimise any changes in their studies. 
Master’s degree students as well had opportunities to adapt their studies according 
to the governmental regulations during the pandemic. However, PhD students, 
specifically those with face-to-face data collection projects, were very limited in 
terms of alternatives and had to wait for months hoping that this crisis would end! 
From a PhD student view, I was very concerned and stressed about Study – 1 
(EXoCARP) data collection in the first two months of the pandemic. I was afraid that 
the data that was collected would  not be enough, or the results might not be 
publishable! However, after thinking about physical activity of PLwP during the 
pandemic, I started discussing my supervisor about Study 2 to understand if there is 
a pandemic inside the pandemic, that is physical inactivity! Subsequently, my 
concerns were relieved after developing the online survey and I was happy with the 
fast data-collection of it.  
 
7.4. Ethnic diversity   
One of the issues that I could not achieve through EXoCARP was to collect data for 
people from diverse ethnicities. When the recruitment invitation was sent to 
members of Parkinson’s UK, it was not limited to only Caucasians, but those who 
responded were only Caucasian. This led me to think about the importance of 
translating the advertisements of my future studies to more than one language. 
Perhaps the translation of the advertisement might attract other ethnicities. I have 
worked as a physiotherapy lecturer and clinical tutor in Jordan and in United Arab 
Emirates (both countries are in the Middle East), and from my experience, majority 
of the people from the Middle East do not consider exercise as an important need 
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that need to be conducted regularly. Perhaps cultural perception of exercise is 
different from a region to another. Furthermore, I have noticed that females in the 
Middle East might be much more sedentary than females in the UK. Even myself, 
as a Jordanian woman, I consider myself as a “sedentary” person, as I do not do 
exercise regularly. I believe this matter is related to how exercise is introduced and 
included in people’s lives since childhood. 
 
7.5. Recruitment through Parkinson’s UK  
Recruitment of participants in both Study 1 and Study 2 was conducted by using 
Parkinson’s UK email groups. I would reflect how happy I was about the prompt 
response a researcher could get from Parkinson’s UK research team, and how 
cooperative they were in circulating, and recirculating the invitation letters in both 
studies. I would say: recruitment through Parkinson’s UK made my life easier 
through both studies! I Tweeted this reflection on my Twitter profile to help other 
researchers by using Parkinson’s UK research help in data collection.  
 
7.5. Summary 
In summary, I would recommend running PPIE meetings while planning for future 
studies, to ensure the interests of people, and to gain knowledge about people’s 
views to confirm the choice of methods to be used in future studies. Additionally, 
observing exercise/ interventions sessions of people before running trials might give 
the researcher ideas about the importance of managing the intervention to get the 
best outcomes. Moreover, qualitative data adds value to quantitative data to give a 
more comprehensive picture, and subsequently, pragmatism is recommended for 
my future work. 
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Chapter 8: General discussion  
This thesis studied the feasibility of conducting a trial about aerobic exercise 
intervention and cardiopulmonary function in PLwP. The thesis included: an 
introduction about Parkinson’s, its symptoms, and a brief introduction about 
pulmonary impairment (Chapter 1); reviews about pulmonary function and 
cardiopulmonary fitness in Parkinson’s and a systematic review of the effects of 
aerobic exercise on cardiopulmonary function in Parkinson’s (Chapter 2). Chapters 
3—5 reported the methodology, method, findings and discussion of Study 1, the 
EXoCARP trial; and Chapter 6 reported, in full, study 2, an online questionnaire 
study. A personal reflection about the PPIE meetings, focus groups and qualitative 
research (Chapter 7). This final Chapter 8, offers a discussion about the work 
presented in the whole thesis, and recommendations for future research and clinical 
practice. 
 
The two reviews (Chapter 2) showed variations in evidence about cardiopulmonary 
impairment in the early stages of Parkinson’s. Both reviews have shown that only a 
small number of studies have investigated impaired pulmonary function and cardiac 
fitness in the early stages of Parkinson’s. The first review revealed that pulmonary 
function might worsen with the progression of Parkinson’s. Findings of the first 
review could be explained by an increase in rigidity of chest wall muscles with 
progression of Parkinson’s, which may result in kyphoscoliosis (Baille et al., 2016; 
Santos et al., 2019); this may, in turn, lead to decrease in lung volume (Black and 
Hyatt, 1971; Sabaté et al., 1996), decrease in lung elasticity, stretching and 
recoiling ability (Estenne et al., 1984). EXoCARP (Study 1) included assessment of 
pulmonary function and revealed that PLwP have obstructive, restrictive, mixed or 
normal pulmonary patterns at the early stages of Parkinson’s. Thus, it is 
recommended that NHS needs to conduct spirometry as a routine test for PLwP at 
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different stages of Parkinson’s to avoid any complication out of respiratory 
impairments.  
 
The second review in this thesis showed that studies that assessed cardiovascular 
response to exercise in Parkinson’s have reported contradictory results, with some 
reporting lower and insufficient cardiovascular response to exercise and some 
reporting normal profiles. These variations in findings might be attributed to the 
sample size, gender differences or CPET protocols used in the studies. Therefore, 
there was a need to assess cardiovascular response to exercise in EXoCARP to 
establish the feasibility of conducting the test before moving to the next trial. In 
addition, there is a need to investigate rehabilitation programs that could improve 
cardiovascular response to exercise in Parkinson’s.  
 
The third review revealed positive effects of aerobic exercise on cardiopulmonary 
function in Parkinson’s. The review showed that the studies used similar intensities 
and frequencies recommended by the World Health Organization (WHO) (30–
45 minutes of moderate intensity, three times per week) (World Health Organization, 
2020). However, the review revealed that no studies were conducted to assess the 
effects of aerobic exercise on pulmonary function in Parkinson’s. Taking into 
consideration that respiratory impairments are the main cause of mortality and 
morbidity in the advanced stages (stages IV and V in Hoehn and Yahr) of 
Parkinson’s, it is important to find an intervention that improves pulmonary function 
in the early stages, rather than waiting for the progression of the disease and 
progression of the impairment. Thus, it was crucial to assess the effects of aerobic 
exercise on pulmonary function in the early stages of Parkinson’s. However, before 
conducting a large trial, a feasibility trial was needed to assess the practicalities of 
conducting the assessment tests, the intervention and study design. Subsequently, 
Study  1 (the EXoCARP) was conducted.  
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The primary purpose of the EXoCARP trial was to pilot and establish feasibility of 
recruitment to, and delivery of, a clinical trial of an eight-week community-based and 
patient-led aerobic exercise programme compared with usual care to improve 
pulmonary function and cardiovascular response to exercise in PLwP. The 
EXoCARP trial was a mixed methods pilot and feasibility study of an aerobic 
exercise programme compared with usual care, involving focus group interviews to 
explore acceptability and feasibility of the exercise intervention and the outcome 
measures. However, while conducting the trial, COVID-19 pandemic governmental 
regulations in 2020 led to suspension of the trial and any face-to-face data 
collection, to minimise the infection rate of the virus. Subsequently, recruitment to 
the trial was affected by the pandemic. Although EXoCARP data collection was 
affected by the pandemic, recruitment rate was 80% out of the accepted sample 
size for pilot studies (24 out of 30) (Lancaster et al., 2004). Compared with 45% 
(Shanahan et al., 2017), and 11% (Lima and Rodrigues-de-Paula, 2013) in other 
feasibility trials that included exercise in PLwP. The trial results revealed the need 
for multiple recruitment sites to collect data and boost the recruitment, and to re-
wording the invitation letter to attract more people.  
 
Assessment tools used in EXoCARP were found to be easy and effective, but there 
is a need to exclude undiagnosed high blood pressure to avoid any adverse events 
while conducting the CPET in the future study. The aerobic exercise intervention 
used in EXoCARP was found to be feasible and acceptable to the participants, and 
this was confirmed with the activity monitors results (participants in the exercise 
group conducted the required duration and intensity of exercise as asked to do 
(median (IQR) = 37.2 (27.1, 45.4) minutes of MVPA per day). However, participants 
asked for an individualised prescription of intensity of exercise. Prescribing intensity 
based on HR baseline CPET results, and using HR monitors to assure that 
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participants are doing the correct intensity might be helpful in the following trial. 
Although participants in both groups reported doing 21-30 minutes of exercise, 
these minutes were light physical activity not MVPA. This might suggest the need of 
monitoring intensity in clinical practice for PLwP, not only in research. This study 
suggests using the same intensity and duration in the next trial (30-40 minutes for 2-
5 times per week) similar to previous studies (Burini et al., 2006; Fernández-del-
Olmo et al., 2014; Mavrommati et al., 2017; Ridgel et al., 2016; Schenkman et al., 
2012; Shulman et al., 2013). Using a community-based exercise intervention could 
help in terms of sustainability of the intervention rather than clinical-based exercise 
settings (Estabrooks et al., 2011). 
 
The outcome measures used in the trial were found to be acceptable to participants 
and feasible to be used in the next trial. However, a maximal CPET with the 
presence of a cardiologist might be needed to challenge the cardiopulmonary 
fitness in PLwP in the next trial. Also, PLwP might prefer to use tablets / IPADs to fill 
the questionnaires in the next trial, rather than hand writing due to tremor and 
bradykinesia.  
 
The suspension of the EXoCARP trial during the pandemic led to limitations in 
recruitment, and inability of the participants to continue with their intervention during 
the COVID-19 pandemic. Therefore, there was a need to assess how the pandemic 
affected engaging in physical activity for PLwP, and other questions arose about 
exercise undertaken by PLwP during the pandemic. This led to Study 2 of this 
thesis (Chapter 6), an online survey questionnaire that explored physical activity 
during the pandemic, exercise limitations and people’s preference in term of indoor 
exercises.  Study 2 revealed that PLwP had a decrease in physical activity while in 
the COVID-19 pandemic. This might be due to the restricted freedom to choose 
exercise type, and/ or due to the closure of Parkinson’s UK exercise groups or sport 
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clubs. Moreover, the survey results showed that people prefer online virtual 
exercise classes, stationary cycling and treadmill running, and DVD exercises as 
remote/indoor exercise methods and think they might help them during the 
pandemic.  
 
Recommendations for future research 
Overall, the work reported in this thesis recommends that future clinical trials need 
to include an aerobic exercise intervention that meets the preferences of PLwP, that 
is flexible to accommodate any sudden changes in circumstances, such as 
pandemics and restrictions on social contact and outdoor activity, by including 
indoor exercises (for example: internet-based exercises and DVDs). The thesis 
recommends using community-based aerobic exercise 30 minutes per day for 3-5 
days per week on a moderate to vigorous intensity. Monitoring intensity is 
recommended by giving participants HR monitors to assure exercising at the 
required intensity. Additionally, the thesis results recommend using the same 
assessment tools, but to exclude undiagnosed high blood pressure. Moreover, 
using the same outcome measures in the next trial is recommended but with a 
maximal intensity in CPET, and tablets / iPad for questionnaires filling (Section 5.3 
includes a summary for the recommendations using the traffic light system).  
 
Clinical recommendation  
Results of the thesis suggests the need for a routine assessment of pulmonary 
function in the early stages of Parkinson’s. Additionally, we recommend including 
people’s preference in term of exercise in their usual physiotherapy/exercise 
interventions, as an alternative plan to any unexpected circumstances such as 
pandemics.  
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Planned publications out of the thesis 
The following manuscripts are planned to be published: 
 
Aburub, A., Ledger, S. J., Sim, J., & Hunter, S. M. Cardiopulmonary response to 
exercise in early staged of Parkinson’s. To be published in the Movement Disorders 
Clinical Practice.  
 
Aburub, A., Sim, J., & Hunter, S. M. A pandemic within the pandemic! Physical 
activity challenges in Parkinson’s during COVID-19 ages: an online survey study. 
To be published in the Movement Disorders Clinical Practice. 
 
Aburub, A., Ledger, S. J., Sim, J., & Hunter, S. M. Aerobic exercise and 
cardiopulmonary function in early stages of Parkinson’s: a feasibility trial. To be 
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Title of Project:  The effects of aerobic exercise on cardiopulmonary function 
in people with Parkinson’s disease.  
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 Aseel Aburub 
 School of Health and Rehabilitation Sciences, Keele University, Staffordshire, 
United Kingdom 01782733809 
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Re: The effects of aerobic exercise on cardiopulmonary function in 
people with Parkinson’s disease. 
I am a PhD student in the School of Health and Rehabilitation at Keele 
University, supervised by Dr Sue Hunter, a physiotherapist and researcher. I am 
undertaking a research project to evaluate cardiopulmonary (heart and lung) 
function in people who are diagnosed with Parkinson’s and investigate the effects of 
aerobic exercise on their cardiopulmonary function. This will ultimately help to 
provide an improved standard of care for people with Parkinson’s. You are invited to 
consider taking part in this study. Before you decide, it is important for you to 
understand why the research is being done and what you would have to do.  
Please take the time to read the information on the following pages carefully 
and, if you wish, discuss it with relatives and friends. If you would like more 
information, or would like to volunteer to take part, please contact me using the 
contact details below and let me know how you would like me to get in touch with you. 
Please take your time to decide whether or not you wish to take part and feel free to 
ask any questions you may have. 
Remember that you do not have to participate in this study. Furthermore, if 
you do volunteer and then change your mind, you would be free to leave the study at 
any time and there would be no need for you to give a reason. Your routine medical 
care would not be affected in any way. 
I suggest that you keep this letter so that you can show it to anyone concerned 
with your medical care. If you have any questions or queries, please do not hesitate 
to contact Aseel Aburub by email at a.a.m.aburub@keele.ac.uk  or Dr Sue Hunter by 












Appendix 10 (Information sheet) 
 
 
Study Title: The effects of aerobic exercise on cardiopulmonary function in people 
with Parkinson’s disease. 
 
Invitation 
You are being invited to consider taking part in the research study “The effects 
of aerobic exercise on cardiopulmonary function in people with Parkinson’s disease”. 
This project is being undertaken by Aseel Aburub, a PhD student at Keele University, 
supervised by Dr. Sue Hunter, Dr. Sean Ledger, Professor Nicola Edelstyn and 
Professor Julius Sim. 
 
Before you decide whether or not you wish to take part, it is important for you 
to understand why this research is being done and what it will involve. Please take 
time to read this information carefully and discuss it with friends and relatives if you 
wish. Ask us if there is anything that is unclear or if you would like more information.  
 
Aims of the Research 
 
Respiratory (breathing) impairment is considered to be the main cause of 
death in the later stages of Parkinson’s. Although there is evidence of respiratory 
impairment in the early stages of the disease, these symptoms do not appear until 
the end-stage. Aerobic exercise has been shown to improve respiratory function in 
asthmatic patients and in healthy people, but effects of aerobic training on respiratory 
function in people with Parkinson’s have not been investigated. If aerobic exercise 
could decrease or delay respiratory impairment in Parkinson’s, this might reduce 
respiratory complications, improve quality of life, and reduce treatment costs. Thus, 
this study will investigate the effects of an eight-week program of aerobic walking on 
respiratory function in people with Parkinson’s. 
 
Why have I been invited? 
 
You have been invited to take part because you are a member of a 
Parkinson’s support group. Permission has been granted from your group lead for 
me to approach all members to invite them to take part in this study, which will 
recruit 34 people with Parkinson’s. 
 
Do I have to take part? 
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You are free to decide whether you wish to take part or not.  If you do decide 
to take part, you will be asked to sign a consent form. You will be given a copy of this 
participant information sheet and your signed consent form to keep. You are free to 
withdraw from this study at any time and without giving reasons. If you decide to 
withdraw from the study, we will destroy securely any documentation that contains 
personal identifiable information, but we will need to use other data collected up to 
the point of your withdrawal. You are free to withdraw from the study at any time and 
this will not affect your continuing medical care. 
 
What will happen if I take part? 
 
If you would like to take part, we will agree with you and arrange a suitable 
time for you to attend an appointment at Keele University for your assessment. There, 
you will be asked to sign a written consent form indicating that you are happy to take 
part in the study. We will collect some information about you, including name, gender, 
age, height, weight, and medical history; and you will then be asked to complete the 
following tests: 
1. An exercise test (which will be repeated on three subsequent occasions 
during the trial, at weeks 4, 8 and 12):  
You will perform an exercise test on a static bike (cycle ergometer). The 
exercise intensity will begin at a low level and will be advanced in stages, 
depending on your fitness level, but will not exceed an intensity that raises 
your heart rate to more than 70% of your maximum heart rate (calculated by 
220 minus your age), estimated to be between 84 (for a 100-year-old person) 
and 119 (for a 50-year-old person), depending on your age (the average 
resting heart rate is 72 beats per minute). The test can be stopped at any time 
if we observe or you report any signs of fatigue or any type of discomfort. 
However, these symptoms are not anticipated and are considered to be 
unlikely. Heart rate, breathing rate and the amount of oxygen that you 
consume will be measured during the test. The test may take approximately 
8-15 minutes to be completed. Before the test you will be asked to have a rest 
for 30 minutes. Thus, we allocate one hour for this test to be done.   
 
2. A breathing (lung function) test: 
You will be asked to do a lung function test by using a nosepiece and 
mouthpiece that is connected to a device; this is called spirometry. You will 
be asked to simply breath in and out quickly, and the device will record the 
amount of air you breath in and out, and the force of your breathing. This test 
will take approximately 30 minutes.  
 
3. Completion of questionnaires.  
As part of the assessment you will be asked to complete a questionnaire about 
your general physical functionality, memory, sleep and general health 
perception.  
 
After these tests, you will be randomly allocated to one of two groups: one group will 
be given an 8-week exercise program to do at home, on top of your usual care; the 
other group will receive usual care. Participants in both groups will be asked to wear 
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a physical activity monitor. You will be given devices that record your physical activity 
level. You will be asked to wear it around your waist during the day except for 
swimming of showering. At the end of a 12 week period, you will be asked to 
participate in a discussion (focus group) to discuss any feedback you have about the 
study. The discussion will be audio recorded. In preparing the data from the process 
evaluation for analysis, all the audio tapes will be transcribed in full into text.  
 
What are the benefits (if any) of taking part? 
 
The results obtained from the tests may help in quantifying your exercise capacity 
and may be helpful in evaluating what type of physical activities are appropriate and 
safe for you. Participating in this pilot study will help us to find out whether the 
exercise programme improves fitness and function, is an acceptable programme 
that people with Parkinson’s can do at home, and will help us to plan a larger trial.  
 
What are the risks (if any) of taking part? 
 
During the exercise test, participants may in certain exceptional circumstances, e.g. 
under intensive aerobic exercise, experience abnormal changes to blood pressure, 
fainting, angina, and in rare instances heart attack or stroke. However, in this study, 
the anticipated and planned intensity of the exercise will be restricted and limited to 
the fact that people have Parkinson’s disease, are older adults, and therefore will not 
be exercising at an intensive aerobic level. The level of exercise intensity will be 
closely monitored throughout and will be limited by the calculated 70% of maximum 
age-related heart rate. For example, for a 50-year-old person, the estimated 
maximum age-related heart rate would be calculated as 220 – 50 years = 170 beats 
per minute (bpm). The 70% levels would be 170 x 0.70 = 119 beats per minute. 
Similarly, for an 80-year-old person, the estimated 70% maximum heart rate would 
be 220 – 80 = 140 x 0.70 = 98 beats per minute. The exercise intensity would be 
monitored so that these heart rates (according to age) were not exceeded throughout 
the test. It is worthy of note that the average adult resting heart rate is around 70 
beats per minute, e.g. when sitting in a chair.  
 
How will information about me be used? 
 
All personal information collected about you will be treated as confidential and 
privileged. It will not to be accessible to anyone except the research team members. 
The information and data, however, may be used for statistical analysis or scientific 
purposes with your right of privacy maintained. For example, we will want to 
calculate the average age and the male:female ratio of people in the study. Your 
height and weight will be used to help us to interpret the data from the exercise, 
breathing and walking tests. 
 
Who will have access to information about me? 
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We would like to reassure you that your personal details would be kept strictly 
confidential. No one, except the named investigators involved in the collection of data 
(Aseel Aburub, Dr. Sue Hunter, and Dr. Sean Ledger), will have access to these 
details and no identifying details will appear in our published results according to 
Keele University confidentiality guidelines.  
 
Who is funding and organising the research? 
This research is not being funded externally and is part of Aseel Aburub’s PhD 
studies, organised and overseen by Keele University.  
 
What if there is a problem? 
If you have a concern about any aspect of this study, you may wish to speak to the 
researchers who will do their best to answer your questions.  You should contact 
Aseel Aburub on a.a.m.aburub@keele.ac.uk. Alternatively, if you do not wish to 
contact the researchers you may contact Dr. Sue hunter on s.m.hunter@keele.ac.uk  
 
If you remain unhappy about the research and/or wish to raise a complaint about any 
aspect of the way that you have been approached or treated during the course of the 
study please write to [name to be inserted when confirmed] who is the University’s 
contact for complaints regarding research at the following address:- 
 
Research Governance Officer 
Directorate of Engagement and Partnerships 
IC2 Building  
Keele University  
ST5 5NH 
E-mail: [to be confirmed] 
Tel: 01782 733306 
Contact for further information 
Aseel Aburub or Dr. Sue Hunter  
a.a.m.aburub@keele.ac.uk  or s.m.hunter@keele.ac.uk 
01782733809 

















Appendix 12 (Parkinson’s Disease Quality of Life Questionnaire 
PDQ-39) 
Due to having Parkinson’s disease,  
how often during the last month have you… 
Please tick one box for each question 
 
Never Occasionally Sometimes Often Always  
1. 
Had difficulty doing the leisure 
activities which you would like  
to do? 
 
     
2. 
Had difficulty looking after your home, 
e.g. DIY, housework, cooking? 
 
     
3. 
Had difficulty carrying bags of 
shopping? 
 
     
4. Had problems walking half a mile? 
 
     
5. Had problems walking 100 yards? 
 
     
6. 
Had problems getting around the 
house as easily as you would like? 
 
     
7. 
Had difficulty getting around in 
public? 
 
     
8. 
Needed someone else to accompany 
you when you went out? 
 
     
 
Please check that you have ticked one box for each question before going onto 
the next page. 
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Due to having Parkinson’s disease,  
how often during the last month have you… 
Please tick one box for each question 
 
Never Occasionally Sometimes Often Always  
9. 
Felt frightened or worried about 
falling over in public? 
 
     
10. 
Been confined to the house 
more than you would like? 
 
     
11. Had difficulty washing yourself? 
 
     
12. Had difficulty dressing yourself? 
 
     
13. 
Had problems doing up buttons  
or shoe laces? 
 
     
14. Had problems writing clearly? 
 
     
15. 
Had difficulty cutting up your 
food? 
 
     
16. 
Had difficulty holding a drink 
without spilling it? 
 
     
17. Felt depressed? 
 
     
18. Felt isolated and lonely? 
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Due to having Parkinson’s disease,  
how often during the last month have you… 






s Often Always 
19. Felt weepy or tearful? 
 
     
20. Felt angry or bitter? 
 
     
21. Felt anxious? 
 
     
22. Felt worried about your future? 
 
     
23. 
Felt you had to conceal your 
Parkinson’s from people? 
 
     
24. 
Avoided situations which 
involve eating or drinking in 
public? 
 
     
25. 
Felt embarrassed in public due 
to having Parkinson’s disease? 
 
     
26. 
Felt worried by other people’s 
reaction to you? 
 
     
27. 
Had problems with your close 
personal relationships? 
 




Due to having Parkinson’s disease,  
how often during the last month have you… 






s Often Always 
28. 
Lacked support in the ways you 
need from your spouse or 
partner? 
If you do not have a spouse  
or partner, please tick here   
 
     
29. 
Lacked support in the ways you 
need from your family or close 
friends? 
 
     
30. 
Unexpectedly fallen asleep 
during the day? 
 
     
31. 
Had problems with your 
concentration, e.g. when 
reading  
or watching TV? 
 
     
32. Felt your memory was bad? 
 
     
33. 
Had distressing dreams or 
hallucinations? 
 
     
34. Had difficulty with your speech? 
 
     
35. 
Felt unable to communicate 
with people properly? 
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Due to having Parkinson’s disease,  
how often during the last month have you… 






s Often Always 
36. Felt ignored by people? 
 
     
37. 
Had painful muscle cramps or 
spasms? 
 
     
38. 
Had aches and pains in your 
joints or body? 
 
     
39. Felt unpleasantly hot or cold? 
 
     
 
 
Please check that you have ticked one box for each question. 
 






























Appendix 16 (Geriatric Depression Scale) 
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Appendix 17 (Physical activity survey questionnaire) 
Survey questionnaire  
 
The following is a survey questionnaire that aims to seek information about your 
physical activity level. The answers you give will be used in the development of a 
study that will assess the effects of aerobic training on cardiopulmonary function in 
Parkinson’s. All the information will be used with confidentiality and privacy. Please 
note that you will not be asked to add your name or contact number in the survey, 
and you will not be identifiable from the survey. If you agreed to participate in the 
survey, please answer the next 10 questions.  
 
1. Please state your current medication for Parkinson’s.  
 
 
2. At what time do you usually take your medication? Please select one 
answer: 
a. From 7:00 a.m. to 9:00 a.m. 
b. From 9:01 a.m. to 11:00 a.m. 
c. From 11:01 a.m. to 12:00 p.m. 
d. From 12:01 p.m. to 2:00 p.m 
e. Other (please specify in the space below) 
 
3. ’Aerobic’ exercise includes physical activity that makes you breathe harder 
or makes your heart beat faster, such as walking, running, swimming, 
cycling, rowing, cross trainer). Do you do any aerobic exercise? Please 
select as many as apply from the list below: 
a. No – I don’t do aerobic exercise 
b. Yes - walking outdoors 
c. Yes – walking on a treadmill 
d. Yes - cycling outdoors 
e. Yes - cycling indoors on stationary cycle using just legs 
f. Yes - indoors on stationary cycle using just arms 
g. Yes - rowing outdoors 
h. Yes – rowing on a row machine indoors 
i. Yes – running outdoors 
j. Yes – running on a treadmill 
k. Yes - using a cross trainer 
l. Yes – swimming  
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4. Please state how many minutes per day you do the aerobic exercise. Please 
select one answer from the list below: 
a. I don’t do aerobic exercise  
b. 10-20 minutes  
c. 21-30 minutes  
d. 31-40 minutes  
e. 41-50 minutes 
f. More than 50 minutes  
 
5. Please state how many days per week you do the aerobic exercise. Please 
select one answer from the list below: 
a. I don’t do aerobic exercise 
b. One day per week 
c. Two days per week 
d. Three days per week 
e. Four days per week 
f. Five days per week 
g. Six days per week 
h. Seven days per week 
 
6. Do you experience shortness of breath, and if so, when do you feel it? 
Please select as many answers from the list below that apply to you: 
a. No, I don’t feel shortness of breath 
b. Yes, I feel short of breath when climbing stairs 
c. Yes, I feel short of breath when walking short distances e.g. around the 
house 
d. Yes, I feel short of breath walking longer distances e.g. outdoors walking 
to the shop 
e. Yes, I feel short of breath during aerobic exercise (as in question 3) 
f. Yes, I feel short of breath during gym exercises 
g. Yes, I feel short of breath when lying down 
h. Yes, I feel short of breath all the time 
i. Other (please describe in the space below) 
 
7. Are you a smoker?  
a. Yes – I smoke cigarettes 
b. Yes – I smoke a pipe 
c. No, I don’t smoke 
 
8. If you currently smoke, please state below how many cigarettes / how much 




9. Do you have the ability to get on and off a stationary cycle / exercise bike? 
Please select one answer from the list below: 
a. Yes, I could do this easily by myself 
b. Yes, I could do this by myself but with a struggle 
c. Yes, I could do this with assistance 
d. No, I would be scared to try 
e. No, I have tried and I can’t  
f. I don’t know  
g. Other  
10. Do you have the ability to walk independently (without assistance)? Please 
select one answer from the list below: 
a. Yes, I can walk independently without any walking aid or other form of 
external support 
b. Yes, I can walk independently but with a walking aid 
c. No, I need physical assistance or support from one other person to walk 
d. No, I need physical assistance or support from more than one other 
person to walk 
e. I am unable to walk 
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Appendix 18 (Physical activity diary) 
Aerobic exercise diary  
 
Participant number:  
 
Week  Date Duration of 
exercise 
Aerobic exercise type (for example: 
walking, cycling, rowing … etc) 
1    
   
   
   
   
   
   
2    
   
   
   
   
   
   
3    
   
   
   
   
   
   
4    
   
   
   
   
   
   
5    
   
   
   
   
   
   
6    
   
   
   
   
   
   
7    
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8    
   
   
   
   
   
   




Appendix 19 (The first draft of the focus group questions) 
 
                                   a priori topic  
 
How did you find the aerobic exercise? 
Was the aerobic exercise programme suitable for you?  
What do you think about the overall aerobic exercise 
 programme? 
How often you were exercising? 
Prompt questions: 
Was the aerobic exercise easy?  




Did you have difficulty in performing the aerobic exercise 
 program?  
Can you explain?  
 Prompt question:  
Can you please specify any difficulties (if found)?  
 
 
Was the exercise programme useful? 
What benefits you achieved after doing the 
 aerobic exercises? 
 
 
Suitability of the 




Did you find any difficulties while wearing the activity  
monitors? Explain 




Were the tests done during the four assessments 
 sessions difficult? Could you explain, please? 
 
 
Have any other comments about the project? 
Outcome measures  
Activity monitors 
 324 
Appendix 20 (The final version of the Focus group questions) 
 
 
Focus group questions 
 
Date:  
Name of Facilitator: Aseel Aburub 
Name of Note taker:  
Introduction to the process 
I would like to welcome and thank you for agreeing to attend a focus group discussion regarding 
participation in the study “Aerobic exercise to improve cardiopulmonary function in people with 
Parkinson’s: a mixed method pilot study”.. Before starting, I’m providing you a copy of the consent 
form which has previously been completed and a copy from the questions that we are going to 
discuss now. Please, answer any questions that may arise as comprehensively as possible. Please 
note that: 
 
• The Focus Group interview will take no longer than one and a half hours. 
• The interview will be audiotaped by two devices. 
• The information that is collected about you during the course of the study and the audio-
records will be kept strictly confidential. Everyone needs to respect this please.  
• You are going to be anonymous in any dissemination work undertaken external or internal 
to the University, and quotations that will be used in any work will be completely 
anonymous. 
• The information provided by you during this interview will be used to inform a future study 
looking at aerobic exercise and cardiorespiratory function in Parkinson’s. 
• If you do not want to participate or if you want to leave, you are entitled to do so, but please 
let me know. 
 
Please let me know if you have any questions or if you need any clarifications. I would gently ask if it 
is OK to turn on the tape recorder now to conduct the interview. I would like to remind you that 
there is no right or wrong answer and you can just give your honest opinion. I would be grateful if 
you can speak clearly and only one person at a time. 
Now I am going to start the audio-recording. 
 
 
Interview schedule  
Questions: a priori topics  
                     
I would like to hear from you about your experiences of  
doing the aerobic exercise programme.  
 
1. How did you find the aerobic exercise? 
Prompt questions: 
• Was the aerobic exercise programme suitable for you?  
• What do you think about the overall aerobic exercise 
programme? 
• Was the aerobic exercise easy?  
• Did you enjoy doing the aerobic exercise? 
• Prompt question: How often you were exercising? 
 
Suitability of the exercise 







1. Did you have difficulty in performing the aerobic  
exercise program? 
 
Prompt question:  
• Can you explain?  
• Can you please specify any difficulties (if found)?  
• Was there anything that stopped you being  
able to exercise? 
 
 
2. Was the exercise programme useful? 
Prompt question: 
• Do you feel there were any benefits for you  
in doing the aerobic exercise programme? 
 
3. Did you find any difficulties while wearing the 
 activity monitors?  
Prompt questions: 
• Please can you explain that a little more 
 
4. Did you remember to wear the activity monitor  
every day? 
Prompt questions: 
• Why do you think you forgot to wear it? 
• Is there anything we could have done / you could have done 




5. I am interested in your experience of the tests that  
were done during the four assessments sessions.  
Did you find any of them particularly difficult or  
unpleasant, or were there any problems for you?  
Prompt questions: 
• Could you explain this a little more, please?  








I would like to thank you for your time today. Now I am going to stop the audio-recording.  
Barriers 




Appendix 21 (answers to the COREQ checklist for the focus groups). 
 
No.  Item  Guide 
questions/description 
Answers 
Domain 1: Research 
team and reflexivity  
  
Personal Characteristics    
1. Inter viewer/facilitator Which author/s conducted the 
interview or focus group?  
Aseel Aburub (AAb: 
interviewer)  
Dr Sue Hunter (SH: 
observer) 
2. Credentials What were the researcher’s 
credentials? E.g. PhD, MD  
AAb: PhD student, 
MSc, BSc (PT).  
SH: PhD, BSc (PT) 
3. Occupation What was their occupation at 
the time of the study?  
AAb: PhD student 
and physiotherapy 
lecturer. 
SH: Senior lecturer 
4. Gender Was the researcher male or 
female?  
AAb: Female 
SH: Female  
5. Experience and 
training 
What experience or training 
did the researcher have?  
AAb: research 
teaching and clinical 
experience 
SH: Research 
teaching and clinical 
experience  





Was a relationship 
established prior to study 
commencement?  
N/A 
7. Participant knowledge 
of the interviewer  
What did the participants 
know about the researcher? 
e.g. personal goals, reasons 




What characteristics were 
reported about the 
interviewer/facilitator? e.g. 
Bias, assumptions, reasons 
and interests in the research 
topic  
AAb: had the 
assumption that 
PLwP have time to 
fit in exercise in their 
diaries, not as active 
as needed. 
Domain 2: study 
design  
  
Theoretical framework    
9. Methodological 
orientation and Theory  
What methodological 
orientation was stated to 
underpin the study? e.g. 





Participant selection    
10. Sampling How were participants 
selected? e.g. purposive, 
All participants who 




group were invited 
to the focus groups 
without any 
exemption  
11. Method of approach How were participants 
approached? e.g. face-to-
face, telephone, mail, email  
Invited by email 
12. Sample size How many participants were 
in the study?  
Focus group 1=4 
Focus group 2=5 
13. Non-participation How many people refused to 
participate or dropped out? 
Reasons?  
3 did not respond 
Setting   
14. Setting of data 
collection 
Where was the data 
collected? e.g. home, clinic, 
workplace  
Focus group 1: at 
Keele University 
(School of Allied 
Health Sciences 
meeting room).  
Focus group 2: 
online using Google 
Meet app. 
15. Presence of non-
participants 
Was anyone else present 
besides the participants and 
researchers?  
In focus group 1: 
one partner of a 
participant 
16. Description of 
sample 
What are the important 
characteristics of the sample? 
e.g. demographic data 
Focus group1: four 
males (>63 years 
old). 
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Focus group 2: 
2males and 3 
females (>55 years 
old).  
Data collection    
17. Interview guide Were questions, prompts, 
guides provided by the 
authors?  
Yes 
18. Repeat interviews Were repeat interviews 





Did the research use audio or 
visual recording to collect the 
data?  
Audio 
20. Field notes Were field notes made during 
and/or after the inter view or 
focus group? 
During the interview 
by the observer (SH) 
21. Duration What was the duration of the 
interviews or focus group?  
Focus group 1: one 
and a half hour 
Focus group 2: One 
hour  
22. Transcripts returned Were transcripts returned to 
participants for comment 
and/or correction?  
No 
Domain 3: analysis and 
findings  
  
Data analysis    
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23. Number of data 
coders 
How many data coders coded 
the data?  
Two 
24. Description of the 
coding tree 
Did authors provide a 
description of the coding 
tree?  
N/A 
25. Derivation of themes Were themes identified in 




advance, and two 
more themes were 
added after 
observing the focus 
groups  
26. Software What software, if applicable, 
was used to manage the 
data?  
NVivo 
Reporting    
27. Quotations presented Were participant quotations 
presented to illustrate the 
themes/findings? Was each 
quotation identified? e.g. 
participant number  
Yes 
28. Data and findings 
consistent 
Was there consistency 
between the data presented 
and the findings?  
N/A 
39. Clarity of major 
themes 
Were major themes clearly 
presented in the findings?  
Yes 
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30. Clarity of minor 
themes 
Is there a description of 
diverse cases or discussion 






Appendix 22 (Ethical approval letter for the physical activity during 




Appendix 23 (invitation email to the physical activity during COVID-




Re: Physical activity during COVID-19 period in Parkinson’s: a survey 
questionnaire pilot study  
I am a PhD student in the School of Health and Rehabilitation at Keele University, supervised by 
Dr Sue Hunter, a physiotherapist and researcher. I am undertaking a research study to explore the 
effects of COVID-19 period on physical activity in people with Parkinson’s.  This will ultimately help to 
provide an understanding of the physical activity levels of people with Parkinson’s, and whether they are 
achieving the recommended physical activity level; and to explore their views and opinions about types 
of exercise that could be done as part of a self-management exercise programme. The study will collect 
answers through an online questionnaire.  
However, before we send the questionnaire through Parkinson’s UK, we need to check that it is 
of a good quality, well structured, easily administered and well-worded. Thus, you are invited to 
consider taking part in this study (piloting the questionnaire as part of the study design, before we share 
it).  Also, we need to check the reliability of the questionnaire. Thus, we are going to re-send it again 
after one week from your reply. This could help us to understand if the answers to the survey are 
consistent over time.  
If you would like more information please do email the researcher at the email address below. If 
you would like to volunteer to take part, please fill the attached questionnaire and send it back to me 
using the contact details below. Please take your time to decide whether or not you wish to take part and 
feel free to ask any questions you may have. 
Remember that you do not have to participate in this study. Furthermore, if you do volunteer and 
then change your mind, you would be free to leave the study at any time and there would be no need for 
you to give a reason. Your routine medical care would not be affected in any way. 
I suggest that you keep this letter so that you can show it to anyone concerned with your medical 
care. If you have any questions or queries, please do not hesitate to contact Aseel Aburub by email at 
a.a.m.aburub@keele.ac.uk   or Dr Sue Hunter by email at s.m.hunter@keele.ac.uk .  
 
Yours Sincerely, 
Aseel Aburub (Physiotherapist) 
a.a.m.aburub@keele.ac.uk  
01782 733809 






Appendix 24 (The physical activity during COVID-19 period in 
Parkinson’s questionnaire) 
Physical activity during COVID-19 period in Parkinson’s 
This questionnaire asks about physical activity in people with Parkinson’s before 
and during the COVID-19 period of lockdown, social distancing and shielding. Data 
collected from this questionnaire will be used anonymously in a research study 
which aims to explore changes in physical activity level during that COVID-19 
period from March 20th 2020 to September 20th 2020. There is no need to provide 
any personal information such as your name or contact information.  
If you have any comments or queries, please contact a.a.m.aburub@keele.ac.uk 
If you need to know more about the study, please read the detailed information 
sheet from the below link: 
https://drive.google.com/file/d/1y7U3pT7PNndq2XOmFFF6Tg6DV3piwpTS/view?us
p=sharing 
By answering the online questionnaire, you are agreeing to be part of the study. No 
need to write any personal information such as your name or contact details. 
 
Section 1: Consent 
Before you consent to participating in the research, please read the participant 
information sheet and then choose yes if you agree on the first 5 questions, or 
choose no if you do not agree to go to the end of the form.  If you have any 
questions or queries before signing the consent form please speak to the 
researcher. 
1. I have read and understood the research information sheet dated 
02/07/2020 (version 1.0) or the project has been fully explained to me.  (If 
you will answer No to this question please do not proceed with this consent 
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form until you are fully aware of what your participation in the project will 
mean). 
• • Yes 
No 
 
2. I have been given the opportunity to ask questions about the project, ask 




3. I understand that my taking part is voluntary. I also understand that I can 
discontinue participation at any point and I can also withdraw myself and my 
data from the research at anytime before submitting the questionnaire. I do 
not have to give any reasons for why I no longer want to take part and there 




4. I understand that data collected during this research will be processed in 









Section 2:  
6. What is your age in years? 
• Please type your answer here:  
7. What is your gender? 
• Male 
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• Female  
• Other 
8. Please tell us about your level of mobility: 
• I can walk independently without walking aids 
• I can walk independently, but I use walking aids (for example: stick or 
walker/stroller) 
• I need a person to assist me while walking 
• I need a walking aid and a person to assist me while walking 
• I am on a wheelchair 
If the answer of Question 3 was 1, 2, 3 or 4 then go to Question 4. If the answer 
was 5, then go to Question 5.  
9. How far can you walk? 
• Less than 10 metres  
• More than 10 metres but less than a mile 
• More than a mile 
 
10. How long have you been diagnosed with Parkinson’s? 
• Please type your answer here: 
…………………… years 
…………………… Months  
 
11. What precautions did you use to protect yourself from getting the 
Coronavirus? (you can tick more than one choice): 
• Practicing social distancing (to stay at least 6 feet away from other 
people). 
• Practicing good hand washing technique (to wash your hands with 
soap and warm water for at least 20 seconds by rubbing your palms 
together, tips of your fingers, including your thumb, and the back of 
your hand). 
• Using hand sanitizer with at least 60% alcohol if soap and water are 
not available. 
• Staying at home and avoiding unnecessary exposure to crowds. 
• Shielding at home.  
• Eating healthy food that strengthen your immune system, such as 
whole food, like fruits and vegetables. 
• Getting some rest and sleep. 
• Other …..     
 
12. The physical activity guidelines and recommendations are for people with 
Parkinson’s to do 150 minutes of aerobic exercise per week. ’Aerobic’ 
exercise includes physical activity that makes you breathe harder or makes 
your heart beat faster. Are you familiar with these recommendations and 
were you doing exercise according to the recommendations before the 
quarantine? (Please select one statement from below) 
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• Yes, I am familiar with the physical activity recommendations and 
guidelines, and I was doing the recommended amount of exercise 
(150 minutes per week) before the lockdown. 
• Yes, I am familiar with the physical activity recommendations and 
guidelines, but I was not doing the recommended amount of exercise 
(150 minutes per week) before the lockdown. 
• No I am not familiar with the physical activity recommendations and 
guidelines, but I was doing the recommended amount of exercise 
(150 minutes per week) before the lockdown. 
• No, I am not familiar with the recommendations, but I was not doing 
the recommended amount of exercise (150 minutes per week) before 
the lockdown. 
 
13. How many minutes of aerobic exercise per week you were performing, on 
average, before the COVID-19 period?  
• Please write the number of minutes here …………….. 
 
14. Please state the types of aerobic exercise you were performing before the 
COVID-19 period (for example: walking in the community, cycling, jogging, 
running …etc.):  
• I don’t do aerobic exercise 
• walking outdoors 
• walking on a treadmill 
• cycling outdoors 
• cycling indoors on stationary cycle using just legs 
• indoors on stationary cycle using just arms 
• rowing outdoors 
• rowing on a row machine indoors 
• running outdoors 
• running on a treadmill 
• using a cross trainer 
• swimming 
• other (please specify)…………………………….. 
 
15. Did you use any of the following devices/machines normally for indoor 
aerobic exercise, before the COVID-19 period?  
• Stationary cycling using a stationary cycle at home 
• Stepping exercise using stepping machine at home 
• Walking or running using a treadmill machine at home 
• Gardening 
• Other: …….. 





16. How much did you feel that the advice for everybody to “Stay at Home” 
affected your physical activity :   
• Completely restricted my physical activity  
• Somewhat restricted my physical activity  
• Minimally restricted my physical activity  
• Did not change my physical activity at all 
• Minimally increased my physical activity 
• Somewhat enabled me to increase my physical activity 
• Significantly increased my physical activity  
• Explain: ………………………………… 
 
 
17. How much did you feel that the advice for everybody to “Stay Alert” 
affected your physical activity :   
• Completely restricted my physical activity  
• Somewhat restricted my physical activity  
• Minimally restricted my physical activity  
• Did not change my physical activity at all 
• Minimally increased my physical activity 
• Somewhat enabled me to increase my physical activity 
• Significantly increased my physical activity  
• Explain: ………………………………… 
 
18. Have you used any of the following to undertake physical activity level 
during the COVID-19 period? (You can choose more than one choice if 
applicable): 
• Telemedicine clinics 
• Web-based information portal 
• Virtual reality exercise games (video games, for example: Xbox, Wii 
or PlayStation) 
• Television (TV) exercise programmes 
• DVD exercise programmes  
• Web-based or virtual classes 
• Other (Please type here)…………………. 
• I did not do any form of physical activity at all 
 
19. Which of the following might help you to exercise at home?   
• Telemedicine clinics 
• Web-based information portal 
• Virtual reality exercise games (video games, for example: Xbox, Wii 
or PlayStation) 
• DVD exercise programmes  
• Web-based or virtual classes 
• Stationary cycling using a stationary cycle at home 
• Stepping exercise using stepping machine at home 
 340 
• Walking or running using a treadmill machine at home 
• Gardening 
• Other (Please type here)…………………. 
• None of the above 
 
20. Before the COVID-19 period, how regularly were you attending a 
Parkinson’s UK exercise or fitness groups on a regular basis? 
• I was attending regularly more than once per week  
• I was attending regularly once per week 
• I was attending regularly more than once every two weeks 
• I was attending regularly once every two weeks 
• I was attending regularly once every three weeks 
• I was attending regularly once every month 
• I was attending but not on a regular basis  
• No, I was not attending at all.  
 
21. Because of COVID-19 social distancing regulation, have you missed 
attending your Parkinson’s UK exercise group?  
• No, I did not miss it.  
• Yes I missed attending. 
 
If answered yes, move to Q17, if answered no move to Q18 
 
22. What did you miss exactly by not attending your Parkinson’s UK exercise 
group? You can choose more than one answer if you wish: 
• The social contact and communication with other group members. 
• The exercise itself and the physical activity. 
• Getting out of the house. 
• The journey from my house to the group location 
• Other points, please specify: …………… 
 
23. How do you feel about returning to your Parkinson’s UK local group or 
exercise class? 
• I feel I need to get back to the group meetings and group exercise 
sessions 
• I feel this is too risky at the moment. Perhaps it is too early 
 






25. Since the start of the COVID-19 period, have you noticed that any of the 
following Parkinson’s symptoms have got worse?  
• None of my symptoms have got worse 
• Tremor 
• Stiffness 
• Slowness of movement 
• Falls and dizziness 
• Freezing 











• Hallucinations and delusions 
• Shortness of breath 
• Other (please specify): …………………… 
 
26. If you would like to, please add any additional comments about how the 
COVID-19 period and social distancing regulations have affected your life: 
free text  
 
Thank you for taking the time to complete this questionnaire. 
If you would like to submit your answers, please click on the ‘submit’ button. 
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Appendix 25 (The invitation email that has been sent to Parkinson’s 




We have an opportunity for people with Parkinson's to take part in some research looking 
at physical activities during lockdown. 
 
Physical activity levels during COVID-19 in Parkinson's. 
 
Aseel Aburub, a PhD student and Physiotherapy lecturer at Keele University, is investigating 
how physical activity may have changed for people with Parkinson's during COVID-19 
lockdown. 
 
The aim of the research is to better understand what changes may have happened and also 
to collect what people with Parkinson's prefer as physical activities and exercises. 
 
What is involved? 
You'll be asked to complete a short online questionnaire that should take on longer than 
15minutes. 
 
For more information, please read the information sheet 
 
Who do the researchers need? 
362 people diagnosed with Parkinson's and are happy to fill in an online questionnaire. 
 
Interested in taking part? 
Please go to the online questionnaire. 
 
If you have problems accessing the questionnaire or questions about it please contact 




This opportunity is not managed by Parkinson’s UK.  
 
Maybe this research isn't for you?  
We realise that not every piece of research is right for everyone. 
 
To find more opportunities near you, use our postcode searchable Take Part Hub which is 
regularly updated with new research looking for people like you. 
 
Best wishes,  
Research Participation Lead 
 
Go to the questionnaire 
